Search Result
Results for "
Humanization
" in MedChemExpress (MCE) Product Catalog:
5
Biochemical Assay Reagents
1005
Inhibitory Antibodies
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P99888
-
|
|
EGFR
|
Others
|
|
Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .
|
-
-
- HY-P99868
-
|
MGD 011
|
CD19
CD3
|
Cancer
|
|
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .
|
-
-
- HY-P9990
-
-
-
- HY-P99026
-
|
TJ011133; TJC4
|
CD47
|
Cancer
|
|
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity .
|
-
-
- HY-P99269
-
|
BIBH 1; Anti-Human FAP Recombinant Antibody
|
FAP
|
Cancer
|
|
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
|
-
-
- HY-P99854
-
|
RC48-0
|
EGFR
ADC Antibody
|
Cancer
|
|
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
|
-
-
- HY-P99773
-
|
JS002
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .
|
-
-
- HY-P9969
-
|
EMD 72000
|
EGFR
|
Cancer
|
|
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab .
|
-
-
- HY-P9906A
-
|
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .
|
-
-
- HY-P990571
-
|
|
CD19
|
Inflammation/Immunology
|
|
Coltuximab is a CHO-expressed humanized antibody that targets CD19. Coltuximab is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Coltuximab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P99210
-
-
-
- HY-P99405
-
|
PRX 002; RG 7935; RO 7046015
|
α-synuclein
|
Neurological Disease
|
|
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
|
-
-
- HY-P990673
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 148.74 kDa. The isotype control for Vandortuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990631
-
|
|
Neuropeptide Y Receptor
|
Inflammation/Immunology
|
|
Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
-
- HY-P990651
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
PY314 is a humanized antibody expressed in CHO, targeting TREM2. PY314 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PY314 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990662
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sapelizumab is a CHO-expressed humanized antibody targeting IL-6Ra/CD126. Sapelizumab has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Sapelizumab can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
-
- HY-P990642
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Oportuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Oportuzumab contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Oportuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990318
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Alacizumab is a CHO-expressed humanized antibody that targets VEGFR2/KDR/CD309. Alacizumab contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.08 kDa. The isotype control for Alacizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990594
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
GSK-679586 is a CHO-expressed humanized antibody that targets IL-13. GSK-679586 is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GSK-679586 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990661
-
|
|
c-Met/HGFR
|
Inflammation/Immunology
|
|
SAIT-301 is a humanized antibody expressed in CHO cells, targeting HGFR/c-Met. SAIT-301 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for SAIT-301 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P99859
-
|
LY3002813
|
Amyloid-β
|
Neurological Disease
|
|
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .
|
-
-
- HY-P990312
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ABT-325 is a humanized antibody expressed in CHO that targets IL-18. ABT-325 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.28 kDa. The isotype control for ABT-325 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990678
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Vonlerizumab is a CHO-expressed humanized antibody targeting TNFRSF4/OX40/CD134. Vonlerizumab carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Vonlerizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990602
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
IMA-026 is a humanized antibody expressed in CHO cells that targets IL-13. IMA-026 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.88 kDa. The isotype control for IMA-026 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P99015
-
|
|
TNF Receptor
|
Cancer
|
|
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .
|
-
-
- HY-P9960
-
|
2H7; PRO70769; RG1594
|
CD20
|
Inflammation/Immunology
|
|
Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .
|
-
-
- HY-P99021
-
|
LY 2951742
|
CGRP Receptor
|
Neurological Disease
|
|
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
|
-
-
- HY-P99264
-
|
Humanized Anti-CD22 Recombinant Antibody
|
ADC Antibody
CD22
Apoptosis
|
Cancer
|
|
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
|
-
-
- HY-P990573
-
|
RG-7636
|
Endothelin Receptor
|
Inflammation/Immunology
|
|
DEDN6526A (RG-7636) is a humanized antibody expressed in CHO cells, targeting ETBR. DEDN6526A (RG-7636) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for DEDN6526A (RG-7636) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990356
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD59 Antibody is a CHO-expressed humanized antibody that targets CD59. The Anti-CD59 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD59 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990592
-
|
E-6071; HGS-1035
|
CCR
|
Inflammation/Immunology
|
|
GSK-3050002 (E-6071) is a CHO-expressed humanized antibody that targets CCL20. GSK-3050002 (E-6071) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GSK-3050002 (E-6071) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P99372
-
|
Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)
|
ADC Antibody
|
Cancer
|
|
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .
|
-
-
- HY-P99310
-
|
RG4934
|
Interleukin Related
|
Inflammation/Immunology
|
|
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .
|
-
-
- HY-P990613
-
|
CBA-1205
|
Notch
|
Inflammation/Immunology
|
|
LIV-1205 (CBA-1205) is a humanized antibody expressed in CHO cells that targets DLK1. LIV-1205 (CBA-1205) contains a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LIV-1205 (CBA-1205) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990612
-
|
AML-01
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
LGN-523 (AML-01) is a CHO-expressed humanized antibody that targets CD98. LGN-523 (AML-01) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for LGN-523 (AML-01) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990328
-
|
XT-M4
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990595
-
|
|
Amyloid-β
|
Inflammation/Immunology
|
|
GSK-933776 is a humanized antibody expressed in CHO, targeting Amyloid Beta/Aβ. GSK-933776 has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.34 kDa. The isotype control for GSK-933776 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P99442
-
|
Hu1D10
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
|
-
-
- HY-P9993
-
|
LY-3462817
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis. Peresolimab can be used in research of rheumatoid arthritis .
|
-
-
- HY-P99626
-
|
LY 3015014
|
PCSK9
|
Metabolic Disease
|
|
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
|
-
-
- HY-P990541
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P99010
-
|
|
FGFR
|
Cancer
|
|
Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer .
|
-
-
- HY-P9988
-
|
BA301
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .
|
-
-
- HY-P9914
-
|
Anti-Human C5, Humanized Antibody; h5G1.1
|
Complement System
|
Cardiovascular Disease
Neurological Disease
|
|
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
|
-
-
- HY-P99043
-
|
|
Notch
|
Cancer
|
|
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .
|
-
-
- HY-P99106
-
-
-
- HY-P990526
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Anti-TNFRSF21/DR6/CD358 Antibody is a CHO-expressed humanized antibody that targets TNFRSF21/DR6/CD358. The Anti-TNFRSF21/DR6/CD358 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TNFRSF21/DR6/CD358 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990363
-
|
PTA001_A4
|
Cadherin
|
Inflammation/Immunology
|
|
The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized antibody expressed in CHO cells, targeting CDH17/Cadherin-17. The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.12 kDa. The isotype control for the Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P99153
-
|
MORAb-003
|
Antibiotic
|
Cancer
|
|
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
|
-
-
- HY-P99166
-
|
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
|
-
- HY-P99118
-
|
HLX 10
|
PD-1/PD-L1
Akt
STAT
|
Cancer
|
|
Serplulimab (HLX 10) is a humanized anti-PD-1 monoclonal antibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer .
|
-
- HY-P99027
-
|
LAG525; IMP701; Hu5A8
|
LAG-3
|
Cancer
|
|
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
|
-
- HY-P991159
-
|
|
EGFR
|
Cancer
|
|
Ruzaltatug is a humanized IgG1 antibody targeting ERBB3. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990667
-
|
|
Integrin
|
Inflammation/Immunology
|
|
STX-100 is a humanized antibody expressed in HEK293 cells, targeting Integrin aVb6 (ITGAV & ITGB6). STX-100 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.12 kDa. The isotype control for STX-100 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P9950
-
|
Olizumab; rhuMab-E25; IGE25; RG-3648
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research . The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.
|
-
- HY-P99227
-
|
ALX-0681; ALX-0081
|
Integrin
Transmembrane Glycoprotein
|
Cardiovascular Disease
|
|
Caplacizumab (ALX-0681) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the binding of vWF with platelet glycoprotein (GP) Ibα. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP) .
|
-
- HY-P99313
-
|
Anti-Human IGHE Recombinant Antibody
|
Apoptosis
|
Inflammation/Immunology
|
|
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
|
-
- HY-P99507
-
|
MCLA-128; PB4188; R040517
|
EGFR
|
Cancer
|
|
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3 .
|
-
- HY-P99044
-
|
MBG453
|
Tim3
|
Inflammation/Immunology
|
|
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .
|
-
- HY-P99962
-
|
BGB-A425
|
Mucin
|
Cancer
|
|
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
|
-
- HY-P99396
-
|
BI 655130
|
Interleukin Related
|
Inflammation/Immunology
|
|
Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways .
|
-
- HY-P99656
-
|
MCDS0593A
|
ADC Antibody
|
Cancer
|
|
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
-
- HY-P991132
-
|
|
VEGFR
|
Cardiovascular Disease
Cancer
|
|
Efclarofusp alfa is a CHO-expressed humanized antibody consisting of VEGFR-1 and VEGFR-2 regions fused to human IgG1 Fc. Efclarofusp alfa is an angiogenesis inhibitor .
|
-
- HY-147407
-
|
|
EGFR
|
Cancer
|
|
Imbotolimod, immunoglobulin G1-kappa, is a humanized monoclonal antibody with anti-ERBB2 and antineoplastic activity. Imbotolimod is a derivative of telratolimod .
|
-
- HY-P9947
-
|
|
Integrin
|
Others
|
|
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .
|
-
- HY-P9945
-
|
SB 240563
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
-
- HY-P99019
-
|
TEV-48125; LBR-101; PF-04427429; RN-307
|
CGRP Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC50 values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC50 value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine .
|
-
- HY-P99329
-
|
Anti-Human CD33 Recombinant Antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .
|
-
- HY-P99854A
-
|
RC48-0 (powder)
|
EGFR
ADC Antibody
|
Cancer
|
|
Disitamab (RC48-0) (powder) is a humanized monoclonal antibody targeting HER2. Disitamab (powder) can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
|
-
- HY-P9945A
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
-
- HY-P99613
-
|
MK-4280
|
LAG-3
|
Cancer
|
|
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902). Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P99379
-
|
CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)
|
Interleukin Related
|
Cancer
|
|
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
|
-
- HY-P99045
-
|
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
|
-
- HY-P991548
-
|
|
CD20
|
Inflammation/Immunology
Cancer
|
|
BLX-301 is a humanized monoclonal antibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis .
|
-
- HY-P99315
-
|
BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99804
-
|
MK1654
|
RSV
|
Infection
|
|
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody against the protein F of respiratory syncytial virus (RSV) with an extended half-life. Clesrovimab can bind to the conserved site IV of the RSV F glycoprotein and neutralize various strains containing RSV F. Clesrovimab can be used in the research of RSV diseases .
|
-
- HY-P99374
-
|
Anti-TSPAN26/CD37 Reference Antibody (naratuximab)
|
ADC Antibody
|
Cancer
|
|
Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine .
|
-
- HY-P99264A
-
|
Humanized Anti-CD22 Recombinant Antibody (powder)
|
ADC Antibody
CD22
Apoptosis
|
Cancer
|
|
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
x
|
-
- HY-P991236
-
|
DHES0815A antibody; RG-6148 antibody
|
EGFR
DNA Alkylator/Crosslinker
|
Cancer
|
|
MHES0488A is a selective humanized antibody that targets HER2 with a KD value of 0.8 nM. MHES0488A is an antibody part of DHES0815A. MHES0488A is internalized by cells and transported to lysosomes, and then releases PBD-monoamide that enters the nucleus, alkylates DNA and induces DNA damage and apoptosis. MHES0488A is promising for research of cancers, such as HER2-positive breast cancer and gastric cancer .
|
-
- HY-P99961
-
|
JS004; Icatolimab
|
CD28
|
Cancer
|
|
Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer, such as lymphoma and non-small cell lung cancer (NSCLC) .
|
-
- HY-P990038
-
-
- HY-P99475
-
|
MSB-2311
|
PD-1/PD-L1
|
Cancer
|
|
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .
|
-
- HY-P990011
-
-
- HY-P99451
-
-
- HY-P9906
-
|
Anti-Human VEGF, Humanized Antibody
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
|
-
- HY-P99316
-
|
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
|
-
- HY-P990020
-
|
|
c-Kit
|
Others
|
|
Eglatoprutug is an humanized immunoglobulin G1-kappa, anti-c-Kit monoclonal antibody .
|
-
- HY-P990082
-
|
|
VEGFR
|
Cancer
|
|
Suvemcitug is a humanized IgG1κ antibody targeting VEGF derived from the African hare (Oryctolagus cuniculus) .
|
-
- HY-P99558
-
|
GEXMab73; GT-MAb7.3-GEX; TrastuzuMab-GEX
|
EGFR
|
Cancer
|
|
Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer .
|
-
- HY-P9910
-
|
GA101; Anti-Human CD20 type II, Humanized Antibody
|
CD20
|
Cancer
|
|
Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
|
-
- HY-P990901
-
-
- HY-P99968
-
|
|
Mucin
|
Cancer
|
|
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers .
|
-
- HY-P99295
-
|
RG 7160; RO 5083945; Anti-EGFR Recombinant Antibody
|
EGFR
|
Cancer
|
|
Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .
|
-
- HY-P9981
-
|
XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .
|
-
- HY-P990089
-
-
- HY-P991587
-
|
|
Orphan GPCR
|
Cancer
|
|
SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
|
-
- HY-P990048
-
|
|
CTLA-4
|
Cancer
|
|
Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody. Muzastotug is an immunostimulant and antineoplastic .
|
-
- HY-P9911
-
|
Anti-Human lymphocyte α4β7 integrin, Humanized Antibody; LDP-02; MLN-002
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
|
-
- HY-P99869
-
|
|
Interleukin Related
|
Others
|
|
Ebdarokimab (AK101) is a humanized IgG1-κ antibody, usually expressed in CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P99018
-
-
- HY-P99430
-
|
EM901; CC-93269
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99938
-
|
HX008
|
PD-1/PD-L1
|
Cancer
|
|
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor .
|
-
- HY-P9912
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
-
- HY-P990040
-
|
LVGN-6051
|
TNF Receptor
|
Cancer
|
|
Exlinkibart (LVGN-6051) targets TNFRSF9 and is an IgG1κ antibody humanized through complementarity-determining region (CDR) grafting technology.
|
-
- HY-P99866
-
|
MEHD-7945A; RG 7597
|
EGFR
|
Others
|
|
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody that specifically targets Her3 (ErbB3) .
|
-
- HY-P99292
-
|
HuZAF; Anti-Human IFNG Recombinant Antibody
|
IFNAR
|
Inflammation/Immunology
|
|
Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
|
-
- HY-P99796
-
|
ATN-103; PF-5230896
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis .
|
-
- HY-P9902
-
|
MK-3475; Lambrolizumab
|
PD-1/PD-L1
|
Cancer
|
|
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
|
-
- HY-P9912A
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
-
- HY-P9904
-
|
MPDL3280A; RG-7446; RO-5541267
|
PD-1/PD-L1
Apoptosis
Autophagy
|
Cancer
|
|
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
|
-
- HY-P990016
-
-
- HY-P9997
-
|
ANB030
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .
|
-
- HY-P990042
-
|
ONC-392; BNT 316
|
CTLA-4
|
Cancer
|
|
Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment .
|
-
- HY-P99317
-
|
LY-2062430
|
Amyloid-β
|
Neurological Disease
|
|
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease .
|
-
- HY-P99884
-
|
PF-06801591
|
PD-1/PD-L1
|
Others
Cancer
|
|
Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P99017
-
|
ALD-403
|
CGRP Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab can be used in the study of preventing migraines .
|
-
- HY-P99835
-
|
MABT 5102A; RG 7412
|
Amyloid-β
|
Neurological Disease
|
|
Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonal antibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research .
|
-
- HY-P9917
-
|
Anti-Human IL6R, Humanized Antibody; RG-1569; rhPM-1
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
|
-
- HY-P990092
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. Rolistobart is an immunostimulant and antineoplastic .
|
-
- HY-P99589
-
|
16B5; AB-16B5
|
Apoptosis
|
Cancer
|
|
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
|
-
- HY-P99828
-
|
PF-06523435; hu24
|
RET
|
Others
Cancer
|
|
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is usually CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P990028
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Raludotatug is a humanized anti-CDH6 IgG1 monoclonal antibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734) .
|
-
- HY-P99906
-
|
DKN-01; LY-2812176
|
β-catenin
|
Cancer
|
|
Sirexatamab (DKN-01) is a humanized IgG4 monoclonal antibody that can bind to and neutralize circulating DKK1. Sirexatamab exhibits antitumor activity in tumor models expressing DKK1 .
|
-
- HY-P99370
-
|
LY2495655; Anti-GDF8 / Myostatin Reference Antibody (landogrozumab)
|
TGF-beta/Smad
|
Inflammation/Immunology
Cancer
|
|
Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease .
|
-
- HY-P990036
-
|
PF-06823859
|
IFNAR
|
Inflammation/Immunology
|
|
Dazukibart (PF-06823859) is a potent, selective humanized IgG1 neutralizing monoclonal antibody that targets interferon β (IFNβ). Dazukibart can be used in the study of moderate to severe dermatomyositis .
|
-
- HY-P99644
-
ACT017
1 Publications Verification
|
Glycoprotein VI
|
Cardiovascular Disease
|
|
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke .
|
-
- HY-P990933
-
-
- HY-P990906
-
-
- HY-P99181
-
-
- HY-P99857
-
|
PF-06252616
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
|
-
- HY-108739
-
|
BI 655075
|
Thrombin
|
Cardiovascular Disease
|
|
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
|
-
- HY-P990077
-
|
CT-011; MDV9300
|
PD-1/PD-L1
|
Cancer
|
|
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research .
|
-
- HY-P990995
-
|
|
Tau Protein
|
Inflammation/Immunology
|
|
HY-P990995 is an MAPT-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9966
-
|
MGA271
|
CD276/B7-H3
|
Cancer
|
|
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators .
|
-
- HY-P99491
-
|
AVTX-007; CERC-007; MEDI 2338
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab specifically binds IL-18 and blocks the interaction of IL-18 with its receptor. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma .
|
-
- HY-P9952
-
|
LymphoStat B
|
TNF Receptor
CD20
|
Inflammation/Immunology
Cancer
|
|
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research . The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.
|
-
- HY-P990051
-
-
- HY-P99401
-
|
OMP-131R10
|
Wnt
|
Cancer
|
|
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors .
|
-
- HY-P991215
-
|
|
HPV
|
Infection
|
|
Anti-HPV18 L1 Antibody (H18L1-A) is a humanized antibody targeting the L1 protein of human papillomavirus type 18 (HPV18). Anti-HPV18 L1 Antibody (H18L1-A) blocks the binding of the HPV18 virus to cell surface receptors, neutralizing the virus activity, and thus inhibiting the virus from infecting cells. Anti-HPV18 L1 Antibody (H18L1-A) is promising for research of human papillomavirus-related diseases .
|
-
- HY-P990961
-
|
IMM-2510; SYN-2510
|
VEGFR
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Palverafusp alfa is an VEGFA/PDCD1-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99308
-
|
AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody
|
CD20
|
Cancer
|
|
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
|
-
- HY-P990904
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990904 is an CCR8-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991038
-
|
|
CD28
|
Inflammation/Immunology
|
|
HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990919
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P990919 is an TNFRSF4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990993
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
HY-P990993 is an GDF8-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990960
-
-
- HY-P991014
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P991014 is an TNFRSF17-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99365
-
|
ALXN1210
|
Complement System
|
Metabolic Disease
|
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
|
-
- HY-P990945
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
HY-P990945 is an CTLA4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99452
-
|
SNDX-6352
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases .
|
-
- HY-P990978
-
|
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990978 is an ERBB2-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99560
-
|
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
|
-
- HY-P990930
-
|
|
CD22
|
Inflammation/Immunology
|
|
HY-P990930 is an CD22-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990949
-
|
YYB-101; ABX101
|
c-Met/HGFR
|
Inflammation/Immunology
|
|
HY-P990949 is an HGF-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P99634
-
|
PankoMab
|
Mucin
|
Cancer
|
|
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) .
|
-
- HY-P990027
-
|
IMGC-936 antibody; MGA021
|
ADC Antibody
MMP
|
Cancer
|
|
Izeltabart (MGA021) is a humanized IgG1 monoclonal antibody targeting ADAM9, which can be used as an ADC Antibody to synthesize the ADC molecule IMGC936 (Izeltabart Tapatansine). Izeltabart can be used in the study of cancer .
|
-
- HY-P99471
-
|
UCB 0107
|
Tau Protein
|
Neurological Disease
|
|
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody. Bepranemab targets the central portion of tau, specifically amino acids 235 to 246. Bepranemab can be used for Alzheimer’s disease (AD) research .
|
-
- HY-P990962
-
|
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990962 is an EGFR/CD47-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9944
-
|
MEDI 493
|
RSV
|
Infection
Inflammation/Immunology
Cancer
|
|
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice .
|
-
- HY-P990994
-
|
HFB-200301
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P990994 is an TNFRSF1B-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99185
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .
|
-
- HY-P99250
-
|
MetMAb
|
c-Met/HGFR
|
Cancer
|
|
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .
|
-
- HY-P990667B
-
|
|
Integrin
|
Inflammation/Immunology
|
|
STX-100 (Biotinylated) is a biotin-labeled STX-100 (HY-P990667). STX-100 is a humanized antibody expressed in HEK293 cells, targeting Integrin aVb6 (ITGAV & ITGB6) .
|
-
- HY-P9907A
-
|
Anti-Human HER2, Humanized Antibody (PBS)
|
ADC Antibody
EGFR
|
Cancer
|
|
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
|
-
- HY-P991000
-
-
- HY-P990072
-
|
LZM-009
|
PD-1/PD-L1
|
Cancer
|
|
Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .
|
-
- HY-176264
-
|
|
SARS-CoV
Virus Protease
Cytochrome P450
|
Infection
|
|
DNDI-6510 (Compound (S)-x38) is a non-covalent SARS-CoV-2 MPro inhibitor with a IC50 of 0.04 μM. DNDI-6510 has a potent antiviral activity across SARS-CoV-2 and its variants as well as a weak efficacy to SARS-CoV-1. DNDI-6510 significantly improves drug exposure in metabolically humanized mice model (8HUM) .
|
-
- HY-P99363
-
|
Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609
|
Transmembrane Glycoprotein
|
Cancer
|
|
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer .
|
-
- HY-P99270
-
|
CS-1008; Anti-Human TRAIL-R2 Recombinant Antibody
|
Apoptosis
|
Cancer
|
|
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
|
-
- HY-P99439
-
|
IMA-638
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma .
|
-
- HY-P9911A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
|
-
- HY-P99476
-
|
|
VEGFR
|
Cancer
|
|
ABP 215 (Bevacizumab-awwb), a Bevacizumab (HY-P9906) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA. ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research .
|
-
- HY-P99965
-
|
SKY59; RO7112689; RG-6107
|
Complement System
|
Cardiovascular Disease
Metabolic Disease
|
|
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
|
-
- HY-P99892
-
|
PR-1594407; DC-1630423
|
EGFR
|
Others
|
|
Serclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P990070
-
|
BION-1301
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Zigakibart (BION-1301) is an IgG4-kappa, anti-TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256) humanized monoclonal antibody. Zigakibart shows anti-inflammatory activity .
|
-
- HY-P9953
-
|
Certolizumab; CDP870
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
|
-
- HY-P99904
-
|
MEDI-507
|
CD2
|
Inflammation/Immunology
Cancer
|
|
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells .
|
-
- HY-P9975
-
|
TGN1412; TAB08
|
CD28
|
Inflammation/Immunology
|
|
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .
|
-
- HY-P99539
-
|
REGN4018
|
CD3
|
Cancer
|
|
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity .
|
-
- HY-P990018
-
-
- HY-P99834
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Crefmirlimab is a humanized CD8 specific minibody. The minibody (Mb) maintains the specificity of full-length antibodies but has no immune effector functions and is biologically inert .
|
-
- HY-P991019
-
-
- HY-P990910
-
-
- HY-P99540
-
|
PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105
|
CTLA-4
|
Cancer
|
|
Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99028
-
|
TMB-355; TNX-355
|
HIV
|
Infection
|
|
Ibalizumab (TMB-355) is a humanized anti-CD4 IgG4 monoclonal antibody. Ibalizumab prevents HIV cell entry by binding to CD4 receptor. Ibalizumab can be used for the research of infection, such as HIV-1 infection .
|
-
- HY-P99858
-
|
AB154
|
Transmembrane Glycoprotein
|
Cancer
|
|
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
|
-
- HY-P990983
-
-
- HY-P99192
-
|
LY2875358
|
c-Met/HGFR
|
Cancer
|
|
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .
|
-
- HY-P99886
-
|
h5G1. 1-SC
|
Complement System
Apoptosis
|
Cardiovascular Disease
Neurological Disease
|
|
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .
|
-
- HY-P99172
-
|
|
CD47
Interleukin Related
|
Cancer
|
|
CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
|
-
- HY-P99112
-
|
RG-6168; SA-237
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Satralizumab is a humanized monoclonal antibody that targets IL-6R. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research .
|
-
- HY-P99883
-
|
SAR156597
|
Interleukin Related
|
Others
|
|
Romilkimab (SAR156597) is a chimeric humanized IG antibody that specifically targets IL-4 and IL13 .
|
-
- HY-P990764B
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Sigvotatug (Biotinylated) is a biotinylated derivative of Sigvotatug (HY-P990764). Sigvotatug (Biotinylated) is a humanized IgG1 κ monoclonal antibody inhibitor against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991050
-
|
AK-1967
|
Dipeptidyl Peptidase
|
Inflammation/Immunology
|
|
Procizumab (AK-1967) is a humanized IgG1 antibody that targets dipeptidyl peptidase 3 (DPP3). Procizumab has the potential for the study of sepsis. The isotype control for Procizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99224
-
|
IMMU-106; hA20
|
Integrin
|
Cancer
|
|
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .
|
-
- HY-P99633
-
|
BGB-A333
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
|
-
- HY-P990899
-
|
|
CD47
|
Inflammation/Immunology
|
|
HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P99368
-
|
MCS110
|
c-Fms
|
Metabolic Disease
Cancer
|
|
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
|
-
- HY-P990007
-
|
PRA023; PRA-023
|
TNF Receptor
|
Inflammation/Immunology
|
|
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis .
|
-
- HY-P991024
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P991024 is an CD274/TNFRSF9-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P99215
-
|
Anti-EGFL7; RG 7414
|
VEGFR
|
Cancer
|
|
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .
|
-
- HY-P99404
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion .
|
-
- HY-P99544
-
|
HBM-9167; KL-A167
|
PD-1/PD-L1
|
Cancer
|
|
Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) .
|
-
- HY-P990022
-
|
DS-6016A
|
TGF-β Receptor
|
Metabolic Disease
|
|
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonal antibody. Prafnosbart can be used for bone metabolism disorders research .
|
-
- HY-P990088
-
|
|
VEGFR
PD-1/PD-L1
|
Cardiovascular Disease
|
|
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker 101GGSGGSGGSGGSGGS 115 to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor .
|
-
- HY-P991432
-
|
|
TNF Receptor
NF-κB
c-Myc
|
Cancer
|
|
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
|
-
- HY-P99697
-
|
PRO 140
|
CCR
HIV
|
Infection
Cancer
|
|
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .
|
-
- HY-P990969
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990969 is an CD3E/CD4-targeting IgG1 λ1 type humanized antibody, the recommed isotype control is Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
- HY-P99576
-
|
OG1953
|
VEGFR
|
Others
|
|
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
|
-
- HY-P990049
-
|
JMT-101
|
EGFR
|
Cancer
|
|
Becotatug (JMT-101) is a humanized IgG1 antibody targeting EGFR. Becotatug can also be conjugated to Afatinib (HY-10261) and Osimertinib (HY-15772) as a synthetic ADC. Becotatug can be used for the study of EGFR-mutated advanced non-small cell lung cancer (NSCLC) .
|
-
- HY-P99162
-
|
CIM331; CD14152
|
Interleukin Related
|
Inflammation/Immunology
|
|
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
|
-
- HY-P99417
-
|
UCB4144; VR 942
|
Interleukin Related
|
Inflammation/Immunology
|
|
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma .
|
-
- HY-P99412
-
|
OSE-127
|
Interleukin Related
|
Cancer
|
|
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .
|
-
- HY-P99221
-
|
RN-624; PF 4383119
|
Trk Receptor
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia .
|
-
- HY-P99282
-
|
VB6-845; Anti-Human EpCAM Recombinant Antibody Fab Fragment, 17-1A
|
Apoptosis
|
Cancer
|
|
Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models .
|
-
- HY-P991051
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
GSK-2330811 is a humanized IgG1 antibody that targets Oncostatin M (OSM). GSK-2330811 has the potential for the study of diffuse cutaneous systemic sclerosis (dcSSc). The isotype control for GSK-2330811 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99443
-
|
HuDreg-55
|
P-selectin
|
Inflammation/Immunology
|
|
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma .
|
-
- HY-P9951A
-
|
RG-6321 (anti-VEGF)
|
VEGFR
|
Cardiovascular Disease
|
|
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
|
-
- HY-P99013
-
|
GC33; RO5137382
|
Glycoprotein VI
|
Cancer
|
|
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
|
-
- HY-P99241
-
|
PF 06946860
|
TGF-beta/Smad
|
Cancer
|
|
Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 monoclonal antibody with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers .
|
-
- HY-P991074
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
GMA-161 is a humanized IgG1 antibody that targets Fcγ receptor III (CD16). GMA-161 has the potential for the study of autoimmune disorders. The isotype control for GMA-161 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9979
-
|
UCB7665
|
TNF Receptor
|
Inflammation/Immunology
|
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
|
-
- HY-P99849
-
|
ABT-806
|
EGFR
|
Cancer
|
|
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .
|
-
- HY-P991674
-
|
BJT-778
|
HBV
|
Infection
Inflammation/Immunology
|
|
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug has significant antiviral activity, and neutralizes and removes HBV and HDV as well as depleting HBsAg-containing subviral particles. Brelovitug can be used for HDV and HBV infections, chronic hepatitis delta (CHD) and chronic hepatitis B (CHB) research .
|
-
- HY-P99371
-
|
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
-
- HY-P9968
-
|
h-R3
|
EGFR
|
Cancer
|
|
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
-
- HY-P991052
-
|
|
TNF Receptor
|
Cancer
|
|
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991066
-
|
|
nAChR
|
Neurological Disease
|
|
ARGX-119 is a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
- HY-P99345
-
|
TSR-042; ANB-011; WBP-285
|
PD-1/PD-L1
|
Cancer
|
|
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
|
-
- HY-P99767
-
|
ALXN1007; Lendalizumab
|
Complement System
|
Infection
|
|
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus .
|
-
- HY-P99778
-
|
MORAb-004
|
EGFR
|
Cancer
|
|
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer .
|
-
- HY-P99649
-
|
MEDI3902
|
Bacterial
|
Infection
|
|
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections .
|
-
- HY-P99702
-
|
BCD-089
|
Interleukin Related
|
Inflammation/Immunology
|
|
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
|
-
- HY-P99256
-
|
SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
|
-
- HY-P99161
-
|
BGB149
|
TAM Receptor
|
Cancer
|
|
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas .
|
-
- HY-P99230
-
|
|
Integrin
CD22
|
Cancer
|
|
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99032
-
|
IPH2201
|
Checkpoint Kinase (Chk)
IFNAR
|
Inflammation/Immunology
Cancer
|
|
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
|
-
- HY-P9978
-
|
JS-001
|
PD-1/PD-L1
|
Cancer
|
|
Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
|
-
- HY-P99045A
-
|
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
|
-
- HY-P99051
-
|
BAY 1834942
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system .
|
-
- HY-P99843
-
|
|
TROP2
ADC Antibody
|
Cancer
|
|
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .
|
-
- HY-P9902A
-
|
MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)
|
PD-1/PD-L1
|
Cancer
|
|
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 .
|
-
- HY-P99285
-
|
hBU 12
|
ADC Antibody
CD19
|
Cancer
|
|
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .
|
-
- HY-P990925
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990925 is an CD3E-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9907
-
Trastuzumab
Maximum Cited Publications
49 Publications Verification
Anti-Human HER2, Humanized Antibody
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
ADC Antibody
|
Cancer
|
|
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
|
-
- HY-P99302
-
|
Humanized Anti-CD28 Recombinant Antibody
|
CD28
|
Inflammation/Immunology
|
|
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft .
|
-
- HY-P99391
-
|
ABT-700
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
|
-
- HY-P990008
-
Atrosab
1 Publications Verification
|
TNF Receptor
Apoptosis
|
Inflammation/Immunology
|
|
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9949
-
|
Sch 55700; CDP-835; JES1-39D10
|
Interleukin Related
|
Inflammation/Immunology
|
|
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
|
-
- HY-NP160
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Recombinant Humanized Type I Collagen is a recombinant humanized collagen protein with has unique immunological features and plays an important role in the structure and function of skin, bones, tendons, etc .
|
-
- HY-P9972
-
|
PDR001
|
PD-1/PD-L1
|
Cancer
|
|
Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody. Spartalizumab binds to PD-1 at picomolar affinity and blocks the interactions with PD-L1 and PD-L2, thereby relieving the inhibition on T cell activity and restoring the immune system's ability to attack tumors. Spartalizumab can be used in the research of undifferentiated thyroid carcinoma (ATC) and neuroendocrine tumors (NENs) .
|
-
- HY-P991041
-
|
Anti-SEZ6 Antibody (SC17); ABBV-011 antibody; ABBV-706 antibody
|
ADC Antibody
|
Cancer
|
|
Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99731
-
|
hLL1; MEDI-115
|
CD74
|
Cancer
|
|
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death .
|
-
- HY-P99169
-
|
TJ004309
|
CD73
|
Cancer
|
|
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
|
-
- HY-P99234
-
|
|
Interleukin Related
ADC Antibody
|
Cancer
|
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
-
- HY-P990980
-
-
- HY-P10544
-
|
|
Interleukin Related
|
Others
|
|
Humanized anti-tac (HAT) binding peptide is a peptide that can specifically bind to the Fc region of HAT. HAT is a humanized monoclonal antibody against the low affinity p55 subunit of the interleukin IL-2 receptor. Humanized anti-tac (HAT) binding peptide can be used to develop affinity chromatography media to purify specific monoclonal antibodies .
|
-
- HY-P99901
-
|
VIS649
|
SARS-CoV
|
Inflammation/Immunology
Cancer
|
|
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) .
|
-
- HY-P991062
-
|
Gensci-059
|
CD47
|
Cancer
|
|
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990061
-
|
JTX 8064
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .
|
-
- HY-P99399
-
|
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
-
- HY-P99891
-
|
Hu23F2G
|
Integrin
|
Cardiovascular Disease
|
|
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .
|
-
- HY-P99737
-
|
LY3074828
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
|
-
- HY-P99252
-
|
Anti-Human CD6 Recombinant Antibody
|
CD6
|
Infection
Inflammation/Immunology
|
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
|
-
- HY-P99746
-
|
3C23K; GM102
|
TGF-β Receptor
|
Inflammation/Immunology
Cancer
|
|
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming .
|
-
- HY-P99293
-
|
IDEC 114; Anti-Human CD80 Recombinant Antibody
|
CD28
Apoptosis
|
Cancer
|
|
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
|
-
- HY-P9924
-
|
LY2439821
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
|
-
- HY-P99659
-
|
ANB 019
|
Interleukin Related
|
Inflammation/Immunology
|
|
Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases .
|
-
- HY-P9948
-
|
Campath-IH
|
Apoptosis
|
Cancer
|
|
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
|
-
- HY-P9983
-
|
SGN-33; HuM-195
|
Transmembrane Glycoprotein
Radionuclide-Drug Conjugates (RDCs)
|
Inflammation/Immunology
|
|
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .
|
-
- HY-108831
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
|
-
- HY-P99236
-
|
FP-1305
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma .
|
-
- HY-P99727
-
|
CTB012
|
RABV
|
Infection
|
|
Mazorelvimab (CTB012) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Mazorelvimab binds to highly discontinuous conserved residues that are not in or near antigenic site III. Mezagitamab has potential application in the prevention of rabies .
|
-
- HY-P99422
-
|
SHR-1316
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
|
-
- HY-P99050
-
|
BIVV009; IPN-009; TNT009
|
Complement System
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome .
|
-
- HY-NP162
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Recombinant Humanized Type XVII Collagen is a transmembrane protein that forms hemidesmosomes. Recombinant Humanized Type XVII Collagen facilitates interactions between stem cells，surrounding cells，and the extracellular matrix，thereby regulating skin homeostasis，aging，and wound healing. Recombinant Humanized Type XVII Collagen also possesses unique cell adhesion sites and signal transduction functions，which can regulate cell migration，proliferation，and differentiation .
|
-
- HY-P990025
-
|
ARGX-117
|
Complement System
|
Inflammation/Immunology
|
|
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .
|
-
- HY-P99325
-
|
IDEC-131; Anti-Human CD40 ligand Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
|
|
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
|
-
- HY-P99284
-
|
MK-0646; h7C10
|
IGF-1R
Apoptosis
|
Cancer
|
|
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .
|
-
- HY-P99639
-
|
Genolimzumab; APL-501; CBT-501; GB-226
|
PD-1/PD-L1
|
Cancer
|
|
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
|
-
- HY-P99970
-
|
|
ADC Antibody
Sodium Phosphate Cotransporter
|
Cancer
|
|
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99781
-
|
MLN-1202
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab can also improve synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-108831A
-
|
AN100226; BG00002
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab (Solution) (AN100226; BG00002) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
|
-
- HY-NP132A
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Recombinant humanized type III collagen (MW 55900) is a type III collagen with a molecular weight of 55900 Da. Recombinant humanized type III collagen has various biological functions, such as promoting skin extracellular matrix regeneration and improving the cell microenvironment. Recombinant humanized type III collagen inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen functions in cell adhesion, migration, proliferation and differentiation through its interaction with integrins .
|
-
- HY-P990071
-
|
|
EGFR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP) .
|
-
- HY-P99822
-
|
SHR-1209
|
PCSK9
LDLR
|
Metabolic Disease
|
|
Recaticimab (SHR-1209) is an orally active humanized monoclonal IgG1 antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia .
|
-
- HY-P99029
-
|
Hu5F9-G4
|
CD47
|
Cancer
|
|
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer .
|
-
- HY-P99829
-
|
PF-06647020; ABBV-647; h6M24-vc0101
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .
|
-
- HY-P99025
-
|
TNX-650; MILR1444A; RG3637
|
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases .
|
-
- HY-P99304
-
|
Anti-Human ERBB3 Recombinant Antibody
|
EGFR
PI3K
Akt
p38 MAPK
|
Cancer
|
|
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer .
|
-
- HY-P991181
-
-
- HY-126350
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
CL2-SN-38 is a cleavable linker-based agent-Linker conjugate, it can conjugate with the anti-Trop-2-humanized antibody hRS7. CL2-SN-38 can be used for the reasearch of cancer .
|
-
- HY-P990714
-
|
|
CD3
|
Inflammation/Immunology
|
|
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
|
-
- HY-P99397
-
|
ALX 0761; M 1095
|
Interleukin Related
MMP
|
Inflammation/Immunology
|
|
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis .
|
-
- HY-P99300
-
|
QGE 031; Anti-IGHE Recombinant Antibody
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .
|
-
- HY-P99361
-
|
PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)
|
TNF Receptor
|
Cancer
|
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
|
-
- HY-P99229
-
|
|
ADC Antibody
|
Cancer
|
|
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99385
-
|
ALX-0061
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
|
-
- HY-P99614
-
|
BFKB8488A; RG-7992; RO-7040551
|
FGFR
|
Metabolic Disease
|
|
Fazpilodemab (BFKB8488A) is a humanized bispecific IgG1 antibody that selectively targets and activates fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .
|
-
- HY-P991190
-
|
AV-380
|
TGF-beta/Smad
|
Cancer
|
|
Rilogrotug (AV-380) is a humanized IgG1 monoclonal antibody targeting GDF15 .
|
-
- HY-P991695
-
-
- HY-P991686
-
-
- HY-P99899
-
|
PR-1498487
|
ADC Antibody
|
Cancer
|
|
Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric antibody targeting LRRC15. Samrotamab markedly reduces bladder cancer cells viability and inhibits clonogenic growth, migratory and invasive capabilities. Samrotamab significantly increases LRRC15 mRNA level while suppressing SCG5 mRNA expression. Samrotamab can be used for synthesis of ADC ABBV-085 .
|
-
- HY-P99712
-
|
hz208F2-4
|
IGF-1R
Apoptosis
ADC Antibody
|
Cancer
|
|
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye
diseases sup>[2].
|
-
- HY-NP131
-
|
|
Discoidin Domain Receptor
Apoptosis
Autophagy
|
Cancer
|
|
Recombinant Humanized Type III Collagen 10.4kDa is a novel biomaterial that have anticancer effects. Recombinant Humanized Type III Collagen 10.4kDa activates discoidin domain receptor 1 (DDR1), and thus inhibits autophagy, proliferation, and migration of cancer cells, and induces apoptosis .
|
-
- HY-P99757
-
|
Hu3F8-BsAb
|
CD2
CD3
|
Cancer
|
|
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .
|
-
- HY-P991189
-
|
|
Mesothelin
|
Cancer
|
|
AMG-305 is a humanized IgG1 monoclonal antibody targeting CDH3/MSLN .
|
-
- HY-P9980
-
|
GSK2857914
|
ADC Antibody
TNF Receptor
|
Cancer
|
|
Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
|
-
- HY-108738
-
|
Ro 24-7375
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Daclizumab (Ro 24-7375) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector T cell activation, regulatory T cell (Treg) expansion and survival, and activation-induced T-cell apoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research .
|
-
- HY-P99682
-
|
hLIV22
|
ADC Antibody
|
Cancer
|
|
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .
|
-
- HY-P9995
-
|
JNJ-63733657
|
Tau Protein
|
Neurological Disease
|
|
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .
|
-
- HY-P99562
-
|
XmAb-18087
|
CD3
|
Cancer
|
|
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
|
-
- HY-P99489
-
|
ABBV 181; PR 1648817
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
|
-
- HY-P99033
-
|
BTCT-4465A; RG-7828; RO7030816
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
|
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
|
-
- HY-P99509
-
-
- HY-P99898
-
|
|
Bacterial
|
Others
|
|
Setoxaximab is an IgG1-κ humanized chimeric antibody targeting shiga toxin type 1 .
|
-
- HY-P991564
-
|
IBI-343 antibody
|
ADC Antibody
Claudin
|
Cancer
|
|
Arcotatug is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADC .
|
-
- HY-P991625
-
|
|
VEGFR
|
Cancer
|
|
VX70 is a humanized monoclonal antibody inhibitor targeting VEGF-A. VX70 can be used for cancers research .
|
-
- HY-P99760
-
|
BCD-145
|
CTLA-4
|
Cancer
|
|
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
|
-
- HY-P9959
-
|
CMC-544; PF-5208773; WAY-207294
|
Antibody-Drug Conjugates (ADCs)
CD22
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
Inotuzumab ozogamicin (CMC-544) is an anti-CD22 antibody-drug conjugate (ADC). Inotuzumab ozogamicin consists of a humanized IgG4 anti-CD22 mAb, covalently linked to Calicheamicin (HY-19609) via an acid-labile AcBut (HY-132261) linker. The antibody portion is Inotuzumab (HY-P99264), and the drug-linker conjugate for ADC is N-Ac-γ-Calicheamicin-AcBut-NHS ester (HY-103688). Inotuzumab ozogamicin binds to the minor groove of DNA, inducing double-strand cleavage and subsequent apoptosis. Inotuzumab ozogamicin can be used for the study of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) .
|
-
- HY-P990093
-
|
CM310
|
Interleukin Related
STAT
|
Inflammation/Immunology
|
|
Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα (KD values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively). Stapokibart effectively blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis) .
|
-
- HY-P99601
-
|
BFCR 4350A; RG 6160; RO 7187797
|
CD3
|
Neurological Disease
Cancer
|
|
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .
|
-
- HY-P991286
-
-
- HY-P99684
-
|
J2898A
|
EGFR
|
Cancer
|
|
Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289 .
|
-
- HY-P991568
-
|
|
CXCR
|
Cancer
|
|
AT009 is an anti-CXCR4 humanized monoclonal antibody. AT009 can be used for cancer research .
|
-
- HY-P991287
-
-
- HY-171572
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. Atezolizumab-MMAE is composed of a humanized anti-PD-L1 antibody (Atezolizumab) (HY-P9904), a lysosomally cleavable dipeptide linker (valine-citrulline), a tubulin inhibitor (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Atezolizumab-MMAE has a potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effect. Atezolizumab-MMAE has a significantly anti-tumor activity in MC38 xenograft PD-1-humanized immune system mice model .
|
-
- HY-158109
-
|
|
Antibody-Drug Conjugates (ADCs)
CD2
Topoisomerase
|
Cancer
|
|
M3554 is an anti-GD2 antibody-drug conjugate (ADC) based on the humanized anti-GD2 antibody. M3554 consists of the humanized monoclonal antibody Dinutuximab (HY-P9933) linked to a topoisomerase 1 inhibitor Exatecan (HY-13631) via a cleavable β-glucuronide linker. M3554 can be used for the study of neuroblastoma, osteosarcoma or glioma .
|
-
- HY-P99496
-
|
RPC 4046; ABT 308; CC-93538
|
Interleukin Related
|
Inflammation/Immunology
|
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
|
-
- HY-P991188
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
MGD007 is a humanized IgG1 monoclonal antibody targeting GPA33. MGD007 can be used for study of Metastatic Colorectal Cancer .
|
-
- HY-P991527
-
-
- HY-P991220
-
|
|
TREM receptor
|
Neurological Disease
|
|
AL002 is a humanized monoclonal immunoglobulin G1 (IgG1) antibody and a TREM2 agonist antibody for use in neurological disease research .
|
-
- HY-P991580
-
|
|
Factor XI
|
Cardiovascular Disease
|
|
REGN-7508 is a humanized monoclonal antibody inhibitor targeting FXI. REGN-7508 can be used for atherothrombosis and venous thromboembolism research .
|
-
- HY-P991683
-
|
|
Discoidin Domain Receptor
|
Cancer
|
|
Ensavatatug is a humanized monoclonal antibody inhibitor targeting discoidin domain receptor tyrosine kinase 1 (DDR1). Ensavatatug is promising for research of cancers .
|
-
- HY-P991579
-
|
|
Factor XI
|
Cardiovascular Disease
|
|
REGN-9933 is a humanized monoclonal antibody inhibitor targeting FXI. REGN-9933 can be used for atherothrombosis and venous thromboembolism research .
|
-
- HY-P991578
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
SNG-8023 is an anti-ERα humanized monoclonal antibody. SNG-8023 can be used for cancer research, such as breast cancer .
|
-
- HY-P991581
-
|
|
Factor XI
|
Cardiovascular Disease
|
|
MK-2060 is a humanized monoclonal antibody inhibitor targeting FXI. MK-2060 can be used for atherothrombosis and venous thromboembolism research .
|
-
- HY-P99762
-
|
MGD009
|
CD3
|
Cancer
|
|
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
|
-
- HY-P99515
-
-
- HY-P991643
-
-
- HY-P99395
-
|
JNJ 56022473; CSL 362
|
Interleukin Related
|
Cancer
|
|
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
|
-
- HY-P991519
-
-
- HY-P991725
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Velvakiment is a humanized VHH nanobody that targets IL-17A. Velvakiment can be used for autoimmune diseases such as multiple sclerosis and rheumatoid arthritis research .
|
-
- HY-P991575
-
-
- HY-P991267
-
-
- HY-P991259
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
MEDI-7836 is a humanized monoclonal antibody inhibitor that targets the interleukin-13 receptor. MEDI-7836 is promising for research of inflammation-related diseases .
|
-
- HY-P99296
-
|
CNTO 95; Anti-Human CD51 Recombinant Antibody
|
Integrin
|
Cancer
|
|
Intetumumab (CNTO 95) is a humanized monoclonal antibody targeting CD51/αV-integrins. Intetumumab is used in the research of pancreatic ductal adenocarcinoma (PDAC) .
|
-
- HY-P99102
-
|
10-1074
|
HIV
|
Infection
|
|
Zinlirvimab is a human IgG1-λ2, HIV neutralising antibody targeting to HIV-1 gp120 envelope glycoprotein (IIIB gp120 V3 loop) .
|
-
- HY-NP132
-
|
|
Biochemical Assay Reagents
Integrin
|
Cancer
|
|
Recombinant Humanized Type III Collagen 28.6kDa is a type III collagen 28.6kDa. Recombinant humanized type III collagen (rhCOLIII) has various biological functions, such as promoting skin extracellular matrix regeneration and improving the cell microenvironment. rhCOLIII inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen functions in cell adhesion, migration, proliferation and differentiation through its interaction with integrins .
|
-
- HY-P991645
-
|
MDX-1203 antibody; BMS-936561 antibody
|
TNF Receptor
ADC Antibody
|
Cancer
|
|
MDX-1115 is a humanized IgG1 monoclonal antibody targeting CD70. MDX-1115 can be used for synthesis of ADC BMS-936561 .
|
-
- HY-P991684
-
-
- HY-P991658
-
|
ARGX-109; GB224; RYI-008
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gerilimzumab (GB224) is a humanized monoclonal antibody inhibitor targeting interleukin-6 (IL-6). Gerilimzumab is promising for research of autoimmune diseases such as rheumatoid arthritis .
|
-
- HY-P99022
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
|
-
- HY-P991704
-
|
|
Tau Protein
|
Cancer
|
|
Moponetug is a humanized IgG1κ antibody targeting MAPT. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9994
-
|
SBT6050
|
Antibody-Drug Conjugates (ADCs)
EGFR
Toll-like Receptor (TLR)
|
Inflammation/Immunology
Cancer
|
|
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .
|
-
- HY-P991558
-
|
RG-7356
|
Transmembrane Glycoprotein
|
Cancer
|
|
RO-5429083 is a humanized monoclonal antibody inhibitor targeting CD44. RO-5429083 can be used for acute myeloid leukemia (AML) and solid tumors research .
|
-
- HY-P991714
-
|
TORL-4-500 antibody
|
Notch
|
Inflammation/Immunology
|
|
Roltotatug is a humanized IgG1κ antibody targeting DLK1. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991715
-
|
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Sanritatug is a humanized IgG1κ antibody targeting CD38. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991692
-
-
- HY-P991179
-
|
|
TNF Receptor
|
Cancer
|
|
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes .
|
-
- HY-P991093
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
NGM-707 is a humanized monoclonal antibody that blocks ILT2 and ILT4 receptors. NGM-707 has the potential for the study of advanced and metastatic solid tumors .
|
-
- HY-P991707
-
|
SHR-A2102 antibody
|
Nectin-4
|
Cancer
|
|
Notiretatug is a humanized IgG1κ antibody targeting Nectin-4. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991729
-
-
- HY-P991681
-
|
|
Claudin
CD3
|
Cancer
|
|
Emaretamig is a humanized IgG1κ monoclonal antibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research .
|
-
- HY-P991712
-
-
- HY-P991591
-
|
|
Integrin
|
Inflammation/Immunology
|
|
MOR101 is a humanized monoclonal antibody inhibitor targeting ICAM-1/CD54. MOR101 can be used to study acute and chronic inflammation, such as burns .
|
-
- HY-P990920
-
|
MK-6070; HPN328
|
CD3
|
Inflammation/Immunology
|
|
HY-P990920 is an CD3E/ALB/DLL3-targeting (scFv-heavy-lamdba)-VH-VH' type chimeric humanized antibody .
|
-
- HY-P991670
-
-
- HY-P991597
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SSGJ-608 is a humanized monoclonal antibody targeting IL-17A. SSGJ-608 can be used in the research of autoimmune and inflammatory diseases, such as moderate-to-severe plaque psoriasis .
|
-
- HY-P991687
-
|
|
Claudin
|
Cancer
|
|
Gaspantatug is a humanized IgG1κ antibody targeting CLDN18.2. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991702
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Merinetug is a humanized IgG1κ antibody targeting Amyloid beta/Aβ. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991644
-
|
|
Integrin
|
Cancer
|
|
IMGN388 Antibody is an Integrin targeting humanized monoclonal antibody. IMGN388 Antibody can be used for synthesis of ADC SGN-PDL1V (HY-171821) .
|
-
- HY-P991705
-
-
- HY-P99706
-
|
AK 117
|
CD47
Interleukin Related
|
Cancer
|
|
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
|
-
- HY-P991140
-
|
|
Claudin
|
Cancer
|
|
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
|
-
- HY-P991269
-
|
|
Interleukin Related
|
Metabolic Disease
|
|
LY2189102 is a humanized monoclonal antibody inhibitor targeting interleukin-1β (IL-1β). LY2189102 is promising for research of type 2 diabetes .
|
-
- HY-132262
-
|
IMGN-901; BB-1090
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity .
|
-
- HY-P991177
-
|
RC-108 antibody
|
c-Met/HGFR
|
Cancer
|
|
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991710
-
-
- HY-P991726
-
|
|
Orphan GPCR
|
Cancer
|
|
Vemzatatug is a humanized IgG1κ monoclonal antibody inhibitor targeting GPRC5D. Vemzatatug has an antitumor activity. Vemzatatug can be used for cancers like multiple myeloma (MM) research .
|
-
- HY-P991596
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ANB004 is a humanized monoclonal antibody inhibitor, targeting IL-17. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research .
|
-
- HY-171270
-
|
|
Antibody-Drug Conjugates (ADCs)
Mucin
|
Cancer
|
|
Clivatuzumab-MMAE is an antibody-drug conjugate (ADC) (Clivatuzumab antibody (HY-P99968), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is a humanized anti-mucin monoclonal antibody.
|
-
- HY-P991666
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
BMS-986090 is a humanized monoclonal antibody antagonist targeting CD40. BMS-986090 is promising for research of autoimmune diseases such as systemic lupus erythematosus (SLE) and focal segmental glomerulosclerosis (FSGS) .
|
-
- HY-P991721
-
|
|
PCSK9
|
Cardiovascular Disease
|
|
Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .
|
-
- HY-P99053
-
-
- HY-139441
-
-
- HY-P991222
-
|
|
Phosphatase
|
Metabolic Disease
|
|
AMG-529 is a humanized anti-ASGR1 monoclonal antibody that binds to ASGR1 and blocks ligand binding, resulting in dose-induced increases in ALP, a biomarker of ASGR1 inhibition .
|
-
- HY-P991693
-
|
|
CD47
|
Inflammation/Immunology
|
|
Ipsoprubart is a humanized IgG1κ antibody targeting SIRPa/CD172a. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99573
-
|
MGD-013
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .
|
-
- HY-P991176
-
|
RO7443904
|
CD19
CD28
|
Cancer
|
|
RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003) .
|
-
- HY-P99191
-
|
NI-0501
|
IFNAR
|
Inflammation/Immunology
|
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
|
-
- HY-163837
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-48 (compound HD10) is a potent inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.1 nM. PD-1/PD-L1-IN-48 plays an important role in cancer research .
|
-
- HY-P991552
-
|
|
CD3
|
Metabolic Disease
Inflammation/Immunology
|
|
AFM15 is a humanized monoclonal antibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD) .
|
-
- HY-148127
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
TAM558 is a payload molecule used for the synthesis of OMTX705. OMTX705 is a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470 (HY-148128), with antitumor activity .
|
-
- HY-P991603
-
|
|
Integrin
|
Inflammation/Immunology
|
|
ASP5094 is a humanized monoclonal antibody against integrin alpha-9. ASP5094 has good safety and tolerability. ASP5094 can be used in the research of diseases such as rheumatoid arthritis .
|
-
- HY-P991139
-
|
|
CTLA-4
|
Cancer
|
|
Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
|
-
- HY-P991260
-
|
|
Interleukin Related
|
Infection
|
|
CNTO-6785 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CNTO-6785 is promising for research of chronic obstructive pulmonary disease (COPD) .
|
-
- HY-P991271
-
|
NNC-114-0005
|
Interleukin Related
|
Inflammation/Immunology
|
|
NN-8828 (NNC-114-0005) is a humanized monoclonal antibody inhibitor targeting interleukin-21 (IL-21). NN-8828 is promising for research of immune system diseases .
|
-
- HY-P991263
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SCH-900117 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
|
-
- HY-P991152
-
|
QX-005N
|
Interleukin Related
|
Inflammation/Immunology
|
|
Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-141602
-
-
- HY-P991264
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ZL-1102 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). ZL-1102 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
|
-
- HY-P991718
-
|
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Tagmokitug is a humanized IgG1κ monoclonal antibody inhibitor targeting CCR8. Tagmokitug has antitumor activity. Tagmokitug can be used for tumor immunotherapy research, such as breast, colon and lung cancer .
|
-
- HY-177568
-
-
- HY-P991046
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Donanemab (Mouse IgG2a) is a chimeric antibody composed of humanized variable regions and a mouse IgG2b backbone. Donanemab (Mouse IgG2b) is an anti-amyloid inhibitor used in Alzheimer's disease research.
|
-
- HY-P99488
-
|
JSP-191; AMG-191
|
c-Kit
|
Inflammation/Immunology
Cancer
|
|
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
|
-
- HY-P991604
-
|
YFC51.1; LDP-01
|
Integrin
|
Inflammation/Immunology
|
|
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .
|
-
- HY-P991075
-
|
|
NAMPT
|
Inflammation/Immunology
|
|
ALT-100 (Human IgG1) is a humanized IgG1 monoclonal antibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991150
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-111149A
-
|
|
CXCR
|
Inflammation/Immunology
|
|
PS372424 hydrochloride, a three amino-acid fragment of CXCL10, is a specific human CXCR3 agonist with anti-inflammatory activity. PS372424 hydrochloride prevents human T-cell migration in a humanized model of arthritic inflammation .
|
-
- HY-P991281
-
-
- HY-111149
-
|
|
CXCR
|
Inflammation/Immunology
|
|
PS372424, a three amino-acid fragment of CXCL10, is a specific human CXCR3 agonist with anti-inflammatory activity. PS372424 prevents human T-cell migration in a humanized model of arthritic inflammation .
|
-
- HY-171135
-
-
- HY-P991728
-
|
TORL-3-600 antibody
|
Cadherin
|
Cancer
|
|
Zarutatug is an anti-CDH17 (cadherin 17) IgG1κ type humanized antibody with antineoplastic activity. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991699
-
|
AZD9829 antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lixarkitug is a humanized IgG1κ antibody targeting IL-3Ra/CD123. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991265
-
|
|
Interleukin Related
|
Cancer
|
|
OSE-703 is a humanized monoclonal antibody inhibitor targeting interleukin-7 receptor α subunit (IL-7Rα). OSE-703 is promising for research of tumors and respiratory diseases .
|
-
- HY-P991135
-
|
|
CCR
|
Cancer
|
|
Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
|
-
- HY-P991679
-
|
TORL-2-307 antibody
|
Claudin
|
Cancer
|
|
Elatatug is an anti-CLDN18 (claudin 18) IgG1κ type humanized antibody with antineoplastic activity. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991711
-
|
|
Trk Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Povovetug is a humanized IgG1κ chimeric monoclonal antibody inhibitor targeting NGF/bNGF. Povovetug has a significant analgesic activity. Povovetug can be used for central neuroinflammation like chronic radicular pain research .
|
-
- HY-P99462
-
|
CDX-0159; CDX-0158
|
c-Kit
|
Inflammation/Immunology
|
|
Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .
|
-
- HY-P991650
-
|
|
PSMA
|
Cancer
|
|
MDX1201 is a humanized monoclonal antibody targeting PSMA1/7. MDX1201 conjugated with a fluorescent dye AlexaTM488 can be used as a probe for near-infrared fluorescence imaging (NIRF) imaging of prostate cancer .
|
-
- HY-P991195
-
|
SIM1811-03
|
TNF Receptor
|
Cancer
|
|
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
-
- HY-P991649
-
|
SAR566658 antibody
|
Mucin
ADC Antibody
|
Cancer
|
|
Anti-CA6 Antibody (huDS6) is a Mucin 1-associated sialoglycotope (CA6) targeting humanized monoclonal antibody. Anti-CA6 Antibody (huDS6) can be used for synthesis of ADCs .
|
-
- HY-P991272
-
|
PF-05230900
|
Interleukin Related
|
Inflammation/Immunology
|
|
ATR-107 is a humanized monoclonal antibody inhibitor targeting interleukin-21 receptor (IL-21R). ATR-107 is promising for research of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus .
|
-
- HY-P991145
-
|
|
SLC39 (Zinc Transporter)
|
Cancer
|
|
Laventatug is a humanized monoclonal antibody targeting human SLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
|
-
- HY-P991690
-
|
|
RSV
|
Infection
|
|
Glarivibart is a humanized IgG1κ monoclonal antibody inhibitor targeting Respiratory syncytial virus (RSV) fusion F protein (RSV-F). Glarivibart has significant antiviral activity. Glarivibart can be used for RSV infections research .
|
-
- HY-P991175
-
-
- HY-P99581
-
|
OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01
|
Wnt
|
Cancer
|
|
Tabituximab barzuxetan (exclude Y90) is a radioimmunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan shows antineoplastic activity. Tabituximab barzuxetan can be used for synovial sarcoma research .
|
-
- HY-P99038
-
|
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
|
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
|
-
- HY-P991688
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gimvekibart is a humanized IgG4κ monoclonal antibody inhibitor targeting IL-4Ra/CD124. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research .
|
-
- HY-P99332
-
|
Anti-Human CD3E Recombinant Antibody; HuM291
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
|
-
- HY-P991266
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SM-17 is a humanized monoclonal antibody inhibitor targeting interleukin 25 (IL-25) and interleukin-17 receptor B (IL17RB). SM-17 is promising for research of immune system diseases .
|
-
- HY-P991717
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Sunakiment is a humanized IgG1λ monoclonal antibody inhibitor targeting Thymic stromal lymphopoietin (TSLP). Sunakiment can be used for inflammatory and immune system disorders like ulcerative colitis, rheumatoid arthritis and allergy and cancers research .
|
-
- HY-P991614
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
IBI356 is a humanized monoclonal antibody inhibitor targeting OX40L/CD134L/CD252. IBI356 can be used to study chronic inflammatory skin diseases, such as atopic dermatitis .
|
-
- HY-P990912
-
-
- HY-P991228
-
|
|
Galectin
|
Cancer
|
|
Lyt-200 is a humanized monoclonal antibody targeting Galectin-9. Lyt-200 exhibits potent inhibitory effects on hematological cancer cells and can also be used in combination with methotrexate (HY-14519) for research purposes .
|
-
- HY-P991696
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Lecomkafusp alfa is a fusion protein that combines human IL-2 fused via a protease cleavable peptide linker to a humanized single-domain VHH fragment anti-ALB (149-263). Lecomkafusp alfa is an immunomodulator and has antineoplastic activity .
|
-
- HY-P99334
-
|
Anti-Human CD70 Recombinant Antibody; SGN-75
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity .
|
-
- HY-P991554
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .
|
-
- HY-P991167
-
|
|
Bacterial
|
Infection
|
|
Vecantoxatug is a humanized monoclonal antibody targeting Clostridium tetani toxin (TeNT, neurotoxin). Vecantoxatug specifically binds to Clostridium tetani toxin, preventing the toxin from binding to cell receptors and thus exerting antitoxin activity. Vecantoxatug is promising for research of tetanus .
|
-
- HY-P991608
-
|
7F11C7
|
Mucin
|
Cancer
|
|
CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .
|
-
- HY-P991635
-
|
|
TNF Receptor
|
Cancer
|
|
PF-07329640 is a humanized monoclonal antibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research .
|
-
- HY-P991258
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .
|
-
- HY-P991185
-
|
|
c-Met/HGFR
|
Cancer
|
|
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991652
-
|
RG-7594
|
Integrin
|
Cancer
|
|
MINT1526A (RG-7594) is a humanized IgG1 monoclonal antibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research .
|
-
- HY-P991556
-
|
|
TNF Receptor
|
Cancer
|
|
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .
|
-
- HY-P991130
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
|
-
- HY-P99513
-
|
CTB011
|
RABV
|
Infection
|
|
Zamerovimab (CTB011) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Zamerovimab targets residues at and near antigenic site III. Zamerovimab can be used in rabies studies .
|
-
- HY-P991723
-
|
CX-2051 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Varsetatug is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug has an antitumor activity. Varsetatug can be used for cancers such as breast, prostate and ovarian cancer research .
|
-
- HY-P991526
-
|
|
CD3
|
Cancer
|
|
M701 is a humanized bispecific CD3/EpCAM T-cell engager antibody. M701 effectively kill high EpCAM expressing cancer cells. M701 can be used for the study of malignant ascites and gastric cancer .
|
-
- HY-P991285
-
-
- HY-P991155
-
|
|
CD3
TNF Receptor
|
Cancer
|
|
Ramantamig is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (tumor necrosis factor receptor superfamily member 17)。Ramantamig is promising for research of cancers, especially hematological malignancies such as multiple myeloma .
|
-
- HY-P991698
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Liscastobart is a humanized IgG4κ antibody targeting PDCD1/PD-1/CD279. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991659
-
|
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
SCH708980 is a humanized monoclonal antibody inhibitor targeting IL-10. SCH708980 has anti-immunosuppressive activity. SCH708980 can be used for visceral leishmaniasis, sepsis-associated kidney injury (SAKI) and osteoporosis research .
|
-
- HY-P991675
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Camtarkibart is an anti-IL4R IgG4κ type humanized antibody with immunomodulator activity. The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991703
-
|
GSK5733584 antibody; HS-20089 antibody; hu2F7
|
CD276/B7-H3
|
Cancer
|
|
Mocertatug is a humanized IgG1κ antibody targeting B7-H4/VTCN1. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991183
-
|
|
CD28
CD38
CD3
|
Cancer
|
|
SAR442257 is a humanized IgG4-S228P, kappa monoclonal antibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on T cells .
|
-
- HY-P991619
-
|
TF8-5G9
|
Transmembrane Glycoprotein
|
Cancer
|
|
CNTO-860 is a humanized anti-tissue factor monoclonal antibody. CNTO-860 can improve tumor control when combined with Paclitaxel (HY-B0015) in colon cancer model and significantly increase tumor-free survival .
|
-
- HY-P991536
-
|
|
Amyloid-β
|
Neurological Disease
|
|
KHK6640 is a humanized anti-amyloid beta oligomer-specific antibody. KHK6640 demonstrates high potency and efficacy for cognitive improvement in several rodent Alzheimer’s models. KHK6640 can be studied in research for neurological diseases such as Alzheimer’s disease .
|
-
- HY-P991415
-
|
AM712
|
VEGFR
Tie
|
Others
|
|
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
|
-
- HY-P991174
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody that targets TREM2. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991153
-
|
|
Virus Protease
|
Infection
|
|
Potravitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation .
|
-
- HY-P991589
-
|
NOV-1105
|
c-Met/HGFR
|
Cancer
|
|
SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. SFN68 significantly inhibits HGF/c-Met interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .
|
-
- HY-P991612
-
|
Sym024
|
CD73
|
Inflammation/Immunology
Cancer
|
|
S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
|
-
- HY-P991123
-
|
|
Adenylate Cyclase
|
Inflammation/Immunology
|
|
Bocunebart is a humanized monoclonal antibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases .
|
-
- HY-P99790
-
|
CEN 000029; cM-T412
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
|
-
- HY-P991628
-
|
|
PD-1/PD-L1
VEGFR
|
Cancer
|
|
SSGJ-707 is a bispecific, recombinant humanized IgG4 monoclonal antibody inhibitor targeting PD-1 and VEGF. SSGJ-707 can be used for cancers research, such as advanced non-small cell lung cancer (NSCLC) and recurrent endometrial cancer
|
-
- HY-P99006
-
|
MORab-009
|
Mesothelin
|
Cancer
|
|
Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium .
|
-
- HY-P991261
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways .
|
-
- HY-P990896
-
|
|
ADC Antibody
|
Cancer
|
|
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
|
-
- HY-P99117
-
|
AK104
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
|
-
- HY-P99352
-
|
Anti-MSLN Antibody
|
Mesothelin
ADC Antibody
|
Cancer
|
|
Anetumab (Anti-MSLN Antibody) is a fully humanized anti mesothelin (MSLN) IgG1 antibody. Anetumab (Anti-MSLN Antibody) can be used to synthesize the ADC molecule Anetumab ravtansine (HY-141606). Anetumab (Anti-MSLN Antibody) can be used for the research of cancer .
|
-
- HY-P991251
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
QX006N is a humanized monoclonal antibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases .
|
-
- HY-P991689
-
|
|
VEGFR
|
Cancer
|
|
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research .
|
-
- HY-P991647
-
|
|
CXCR
|
Cancer
|
|
ALX-0651 is a biparatopic humanized monoclonal antibody inhibitor targeting CXCR4. ALX-0651 inhibits hematopoietic stem cell trafficking, tumor progression and metastasis. ALX-0651 can be used for non-Hodgkin’s lymphoma and multiple myeloma research .
|
-
- HY-P991193
-
|
|
MMP
|
Cancer
|
|
NGM-438 is a humanized IgG1 monoclonal antibody targeting LAIR1. NGM438 reversed collagen-induced immune suppression in myeloid cells and promoted anti-PD1 mAb-driven T cell responses in immune cell-based functional assays .
|
-
- HY-P991719
-
|
YL201 antibody
|
CD276/B7-H3
|
Inflammation/Immunology
Cancer
|
|
Tambotatug is a humanized IgG1κ monoclonal antibody inhibitor targeting CD276/B7-H3. Tambotatug has antitumor activity. Tambotatug can be used for tumor immunotherapy like colorectal cancer (CRC) research .
|
-
- HY-P991204
-
|
ARX517 antibody
|
PSMA
|
Cancer
|
|
Anti-PSMA Antibody (ARX517 antibody) is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991187
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-164894
-
-
- HY-P991716
-
-
- HY-P991282
-
|
|
Interleukin Related
|
Cancer
|
|
KHK2823 is a humanized monoclonal anti-human CD123/IL3RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). KHK2823 can be used in research related to leukemia .
|
-
- HY-P991727
-
-
- HY-P991593
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ABT-147 is a humanized IgG1 monoclonal antibody inhibitor targeting IL-12. ABT-147 can be used to study autoimmune diseases like rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD) and other diseases like Asthma .
|
-
- HY-P991202
-
|
|
TSH Receptor
|
Endocrinology
|
|
Anti-TSHR Antibody (M22) is a humanized IgG1 monoclonal antibody that targets thyrotropin receptor (TSHR). Anti-TSHR Antibody (M22) inhibits the binding of TSH and TSHR. Recommend Isotype Controls: Human IgG1 lambda, Isotype Control (HY-P99992) .
|
-
- HY-P991113
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonal antibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers .
|
-
- HY-P99505
-
|
COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis .
|
-
- HY-P990373
-
-
- HY-P991144
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma .
|
-
- HY-P3239
-
|
GSK2857916; Belantamab mafodotin-blm
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. The antibody portion is Belantamab (HY-P9980), and the drug-linker conjugate for ADC is McMMAF (HY-15578). Belantamab mafodotin has anti-myeloma activity .
|
-
- HY-P991129
-
|
QX-002N
|
Interleukin Related
|
Inflammation/Immunology
|
|
Crusekitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
-
- HY-P990928
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990928 is an CD3E-targeting [(scFv -κ-heavy) G1-h-CH2-CH3 (scFv-heavy -κ)]2 type chimeric human and humanized antibody .
|
-
- HY-145627
-
|
BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .
|
-
- HY-P991583
-
|
|
FGFR
ERK
|
Cancer
|
|
GP369 is a humanized FGFR2-IIIb-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer .
|
-
- HY-P991657
-
|
|
Complement System
|
Cardiovascular Disease
|
|
MEDI7814 is a humanized monoclonal antibody inhibitor targeting C5a and C5adesArg. MEDI7814 binds to recombinant human C5a and serum purified human C5a with affinities of 14 pM and 8 pM, respectively. MEDI7814 is acute inflammatory diseases such as sepsis and renal ischemia-reperfusion injury .
|
-
- HY-P99016
-
|
|
ADC Antibody
Nectin-4
|
Cancer
|
|
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .
|
-
- HY-164893
-
-
- HY-P991237
-
|
|
EGFR
|
Cancer
|
|
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. HMBD-001 inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. HMBD-001 is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .
|
-
- HY-P991639
-
|
|
Apoptosis
|
Cancer
|
|
BIW-8962 is a humanized anti-ganglioside GM2 antibody. BIW-8962 exhibits ADCC/CDC activity against multiple myeloma cells. BIW-8962 demonstrates potent anti-tumor activity in mouse xenograft models. BIW-8962 is indicated for research in myeloma and other cancers .
|
-
- HY-P991257
-
|
|
Interleukin Related
|
Cancer
|
|
MK-1966 is a humanized monoclonal antibody inhibitor targeting interleukin-10 (IL-10). MK-1966 blocks the inhibitory effects of IL-10 on immune cells such as macrophages and dendritic cells to restore anti-tumor immune responses. MK-1966 is promising for research of cancers .
|
-
- HY-148178
-
|
|
Parasite
|
Infection
|
|
MMV688533 is an antimalarial agent with rapid anti-plasmodial activity and effective single-dose activity against Plasmodium falciparum infection in humanized mouse models. MMV688533 can inhibit the activity of asexual blood stage parasites with an IC50 value of 1.3 nM. MMV688533 exhibits excellent pharmacokinetic properties and safety .
|
-
- HY-P991201
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
REGN-7257 is a humanized monoclonal antibody targeting IL2RG that effectively blocks signaling of all γ-c cytokines. REGN-7257 can be used in the study of aplastic anemia. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-171734
-
-
- HY-P991588
-
|
AC101
|
EGFR
|
Cancer
|
|
HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
|
-
- HY-P99893
-
|
AMG-570
|
CD28
TNF Receptor
|
Others
|
|
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonal antibody targets ICOSL and BAFF. Prezalumab demonstrates beneficial activities on the arthritis of systemic lupus erythematosus. Prezalumab can be used for the research of sjogren's syndrome cutaneous lupus erythematosus, psoriasis and systemic lupus erythematosus (SLE) .
|
-
- HY-P991068
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
hT84.66-M5A is a humanized IgG1 antibody that targets carcinoembryonic antigen (CEA). The isotype control for hT84.66-M5A can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991665
-
|
OBT357NF; OBT357
|
Transmembrane Glycoprotein
|
Cancer
|
|
MEN1112 (OBT357NF) is a selective humanized monoclonal antibody targeting the Bst1/CD157 antigen (EC50=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML .
|
-
- HY-P991283
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
AMG 317 is a humanized monoclonal anti-CD124/IL4R/IL-4Rα antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002). AMG 317 can be used in research related to asthma .
|
-
- HY-P991708
-
|
|
PSMA
CD3
|
Cancer
|
|
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .
|
-
- HY-P991507
-
|
|
EGFR
|
Cancer
|
|
SCT200 is a fully humanized IgG1 anti-EGFR monoclonal antibody with a Kd of 0.08 nM. SCT200 can kill tumor cells by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the Fc. SCT200 can be used for the study of refractory RAS and BRAF wild-type metastatic colorectal cancer .
|
-
- HY-P99037
-
|
M281
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
|
-
- HY-P99381
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .
|
-
- HY-P990587
-
|
|
CD28
|
Inflammation/Immunology
|
|
FR104 is a humanized antibody expressed in CHO cells that targets CD28. FR104 comprises a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for FR104 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-170780
-
|
|
Parasite
Dihydroorotate Dehydrogenase
|
Infection
|
|
DSM1465 (Compound 82) is a potent, selective inhibitor of P. falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC50 value of 15 nM, inhibits P. falciparum 3D7 (Pf3D7) parasites with an EC50 value of 1.4 nM. DSM1465 shows potent in vivo activity in the humanized P. falciparum mouse model .
|
-
- HY-P991576
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-CD326/EPCAM Antibody (3622W94) is a humanized antibody expressed in CHO cells, targeting EpCAM/TROP1/CD326. Anti-CD326/EPCAM Antibody (3622W94) can be used for epithelial cancers research, such as pancreatic, prostate and breast cancer.
|
-
- HY-P99233
-
|
HuMax-TAC
|
ADC Antibody
Transmembrane Glycoprotein
Interleukin Related
|
Cancer
|
|
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99493
-
|
IMGN242; huC242-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
-
- HY-153920A
-
|
ABSK021 hydrochloride
|
c-Fms
c-Kit
PDGFR
|
Cancer
|
|
Pimicotinib (ABSK021) hydrochloride is a selective and orally active CSF1R inhibitor with an IC50 value of 19.48 nM (determined by inhibiting ADP production). Pimicotinib hydrochloride exhibits anti-tumor activity .
|
-
- HY-153920
-
|
ABSK021
|
c-Fms
c-Kit
PDGFR
|
Cancer
|
|
Pimicotinib (ABSK021) is a selective and orally active CSF1R inhibitor with an IC50 value of 19.48 nM (determined by inhibiting ADP production). Pimicotinib exhibits anti-tumor activity .
|
-
- HY-142221
-
|
|
PD-1/PD-L1
|
Cancer
|
|
ARB-272572 is an oral effective small molecule PD-L1 inhibitor, with an IC50 value of 400 pM. ARB-272572 has research significance in tumors and chronic viral infections .
|
-
- HY-172953
-
|
|
Parasite
|
Infection
|
|
Insecticidal agent 24 is an orally active pyridylspiroindoline frontrunner. Insecticidal agent 24 has antiplasmodial activity (Pf NF54 IC50: 0.08 μM). Insecticidal agent 24 inhibits hERG activity (IC50: 6.5 μM). Insecticidal agent 24 reduces parasitemia in a humanized immunodeficient NSG mouse Plasmodium falciparum infection model .
|
-
- HY-P990480
-
|
|
LDLR
|
Inflammation/Immunology
|
|
The Anti-oxLDL Antibody is a humanized antibody expressed in CHO cells that targets oxLDL. The Anti-oxLDL Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-oxLDL Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991151
-
|
|
PD-1/PD-L1
TNF Receptor
|
Cancer
|
|
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
|
-
- HY-P99239
-
|
HUJ-591; TLX591
|
PSMA
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
|
-
- HY-171265
-
|
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Others
|
|
MRG003 is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575) .
|
-
- HY-P991173
-
|
|
Notch
|
Cancer
|
|
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990669
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Torudokimab is a humanized antibody expressed in CHO, targeting IL-33. Torudokimab has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Torudokimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P991668
-
|
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
PF-06688992 is an antibody-drug conjugate (ADC) targeting the GD3 antigen, which is composed of humanized anti-GD3 huR24 linked to a chemotherapeutic agent. PF-06688992 can induce tumor cell apoptosis. PF-06688992 is promising for research of GD3-overexpressing tumors such as melanoma .
|
-
- HY-P991178
-
|
|
TNF Receptor
|
Cancer
|
|
BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
|
-
- HY-P990466
-
|
|
Mesothelin
|
Inflammation/Immunology
|
|
Anti-Mesothelin Antibody is a humanized antibody expressed in CHO that targets Mesothelin. The Anti-Mesothelin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-Mesothelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990431
-
|
|
Ser/Thr Protease
|
Inflammation/Immunology
|
|
Anti-HGFA Antibody is a humanized antibody expressed in CHO cells, targeting HGFA. The Anti-HGFA Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFA Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990564
-
|
BAY-103356; CDP-571
|
TNF Receptor
|
Inflammation/Immunology
|
|
Senlizumab is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. Senlizumab is composed of huIgG4SP heavy chains and huκ light chains, with a predicted molecular weight (MW) of 146.9 kDa. The isotype control for Senlizumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P991569
-
|
|
Wnt
|
Metabolic Disease
Endocrinology
|
|
PF-04840082 is a humanized IgG2 monoclonal antibody inhibitor targeting Dkk-1. PF-04840082 binds the physiological antagonist (Dkk-1) of the Wnt/LRP5 signal pathway and increases bone mass and bone mass density by activating osteoblasts. PF-04840082 can be used for osteoporosis research .
|
-
- HY-P991574
-
|
REG-101
|
ATGL
|
Cardiovascular Disease
|
|
MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonal antibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research .
|
-
- HY-P990552A
-
|
MNPR-101
|
Integrin
|
Cancer
|
|
huATN-658 (MNPR-101) is a humanized monoclonal antibody inhibitor targeting urokinase-type plasminogen activator receptor (uPAR). huATN-658 blocks the interaction between uPAR and integrins, inhibiting the proliferation, invasion and migration of tumor cells. huATN-658 is promising for research of breast cancer (especially triple-negative breast cancer) .
|
-
- HY-P991517
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
BI-836858 is a fully humanized IgG1 anti-CD33 monoclonal antibody. BI-836858 is Fc-engineered for increased binding to FcγRIIIa (CD16). BI-836858 has antibody-dependent cellular cytotoxicity (ADCC) activities. BI-836858 can be used for the study of acute myeloid leukemia (AML) .
|
-
- HY-P99163
-
|
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies .
|
-
- HY-48564
-
|
|
ADC Payload
|
Cancer
|
|
TAM558 intermediate-54 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .
|
-
- HY-P990675
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
VGX-100 is a humanized antibody expressed in CHO cells, targeting VEGFC. VGX-100 is composed of huIgG1 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for VGX-100 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990622
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
MB-311 is a humanized antibody expressed in CHO cells, targeting Lewis Y. MB-311 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MB-311 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-400690
-
|
|
Drug Intermediate
|
Cancer
|
|
TAM558 intermediate-4 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .
|
-
- HY-P990532
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-TPBG Antibody is a humanized antibody expressed in CHO cells, targeting TPBG. The Anti-TPBG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-TPBG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990006
-
|
TEV-48574
|
TNF Receptor
|
Inflammation/Immunology
|
|
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
|
-
- HY-P991197
-
|
LM-305 antibody; AZD-0305 antibody
|
CD3
|
Cancer
|
|
Anti-GPRC5D Antibody (LM-305 antibody) is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P9968A
-
|
|
EGFR
|
Cancer
|
|
Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody targeting EGFR with a KD value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
-
- HY-P990460
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
Anti-LAP Antibody is a humanized antibody expressed in CHO cells, targeting LAP. The Anti-LAP Antibody features a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-LAP Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-150233
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Cys-McMMAF is the released payload of AlMcMMAF, an anti-5T4 humanized A1 antibody conjugated to the microtubule disrupting MMAF (HY-15579) via a maleimidocaproyl linker. Cys-McMMAF has antitumor efficacy in two tumor mouse models (H1975 and MDA-MB-361-DYT2 models) .
|
-
- HY-P990544
-
|
AJW 200; AJvW 2
|
Integrin
|
Inflammation/Immunology
|
|
Anti-vWF Antibody is a humanized antibody expressed in CHO cells that targets vWF. The Anti-vWF Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.62 kDa. The isotype control for Anti-vWF Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-130246A
-
|
|
Succinate Receptor 1
|
Inflammation/Immunology
|
|
NF-56-EJ40 hydrochloride is a potent, high-affinity, and highly selective human SUCNR1 (GPR91) antagonist with an IC50 of 25 nM and a Ki of 33 nM, and shows almost no activity towards rat SUCNR1. NF-56-EJ40 hydrochloride has high affinity for humanized rat SUCNR1 with a Ki value of 17.4 nM .
|
-
- HY-P990591
-
|
Aletekitug
|
Interleukin Related
|
Inflammation/Immunology
|
|
GSK-1070806 is a CHO-expressed humanized antibody that targets IL-18. GSK-1070806 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 147.38 kDa. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-164153
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
-
- HY-400688
-
|
|
ADC Payload
|
Cancer
|
|
TAM558 intermediate-24 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .
|
-
- HY-P990614
-
|
|
Myosin
|
Inflammation/Immunology
|
|
LK-1 is a humanized antibody expressed in CHO that targets S100A4. LK-1 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LK-1 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990611
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
KRN-330 is a humanized antibody expressed in CHO cells, targeting GPA33. KRN-330 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for KRN-330 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99249
-
|
Pogalizumab; MOXR 0916
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .
|
-
- HY-400687
-
|
|
Drug Intermediate
|
Cancer
|
|
TAM558 intermediate-1 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .
|
-
- HY-P991244
-
|
|
EGFR
|
Cancer
|
|
REGN-1400 is a humanized monoclonal antibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .
|
-
- HY-P991246
-
|
|
Virus Protease
HIV
|
Infection
|
|
VRC01LS is a humanized monoclonal antibody inhibitor targeting the CD4-binding site of HIV-1 envelope glycoprotein (Env). VRC01LS blocks the binding of HIV-1 to host cell CD4 receptor, inhibiting viral entry. VRC01LS is promising for research of HIV-1 infection .
|
-
- HY-P990374
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CLEC7A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC7A. The predicted molecular weight (MW) of Anti-CLEC7A Antibody is 150 kDa. The isotype control for Anti-CLEC7A Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-400689
-
|
|
Drug Intermediate
|
Cancer
|
|
TAM558 intermediate-34 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .
|
-
- HY-P990467
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
The Anti-MICB Antibody is a humanized antibody expressed in CHO cells, targeting MICB. The Anti-MICB Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for the Anti-MICB Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P991653
-
|
|
CCR
HIV
|
Infection
|
|
HGS004 is a humanized IgG4 monoclonal antibody inhibitor targeting CCR5. HGS004 has potent antivival activity against a diverse panel of CCR5-tropic HIV-1 and durg (such as Maraviroc (HY-13004))-resistant strains. HGS004 can be used for HIV-1 infections research .
|
-
- HY-P990589
-
|
BXL-1H5
|
Trk Receptor
|
Inflammation/Immunology
|
|
GBR-900 is a humanized antibody expressed in CHO that targets TrkA/NTRK1. GBR-900 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GBR-900 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-130246
-
|
|
Succinate Receptor 1
|
Inflammation/Immunology
|
|
NF-56-EJ40 is a potent, high-affinity, and highly selective human SUCNR1 (GPR91) antagonist with an IC50 of 25 nM and a Ki of 33 nM, and shows almost no activity towards rat SUCNR1. NF-56-EJ40 has high affinity for humanized rat SUCNR1 with a Ki value of 17.4 nM .
|
-
- HY-P99761
-
|
XmAb5871
|
CD19
Apoptosis
|
Inflammation/Immunology
|
|
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .
|
-
- HY-P990620
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
LY3022856 is a humanized antibody expressed in CHO, targeting VEGFR3/FLT4. LY3022856 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.18 kDa. The isotype control for LY3022856 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990677
-
|
|
CCR
|
Inflammation/Immunology
|
|
VLST-002 is a humanized antibody expressed in CHO cells, targeting CCL5/RANTES. VLST-002 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99542
-
|
SAR-408701; HuMAb2-3-SPDB-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
|
-
- HY-P99101
-
|
AEX-4089; MGC026 antibody
|
ADC Antibody
|
Cancer
|
|
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
|
-
- HY-P99956
-
|
VLS-101; MK-2140
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer .
|
-
- HY-P990561
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
BT-063 is a humanized antibody expressed in CHO cells, targeting IL-10. BT-063 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for BT-063 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990474
-
|
AS2886401-00
|
Trk Receptor
|
Inflammation/Immunology
|
|
Anti-NGF/bNGF Antibody is a CHO-expressed humanized antibody that targets NGF/bNGF. Anti-NGF/bNGF Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.14 kDa. The isotype control for Anti-NGF/bNGF Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-163480
-
|
|
CXCR
|
Inflammation/Immunology
|
|
PF-06835375 is a humanized IgG1 antibody selective against CXCR5 expressed on B cells, Tfh cells, and circulating Tfh-like (cTfh) cells. PF-06835375 can be used for the study of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
-
- HY-P99464
-
|
IMMU-LL 2
|
CD22
|
Cancer
|
|
Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .
|
-
- HY-P99394
-
|
JNJ-64407564
|
CD3
|
Cancer
|
|
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .
|
-
- HY-P991655
-
|
|
IFNAR
HIV
|
Infection
Inflammation/Immunology
|
|
AGS-009 is a humanized monoclonal neutralising antibody targeting IFN-α. AGS-009 significantly reduces activated lymphocytes, such as CD4 + and CD8 + T cells as well as B cells in SIV infection rhesus macaque models. AGS-009 can be used for autoimmune diseases like systemic lupus erythematosus (SLE) and HIV infections research .
|
-
- HY-P990638
-
|
|
CXCR
|
Inflammation/Immunology
|
|
NI-0701 is a humanized antibody expressed in CHO cells that targets CCL5/RANTES. NI-0701 has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0701 can be referenced as Human IgG2 lambda, Isotype Control (HY-P991206).
|
-
- HY-P991240
-
|
|
EGFR
|
Cancer
|
|
CDX-3379 is a humanized monoclonal antibody inhibitor targeting ErbB3. CDX-3379 binds to ErbB3, blocking the dimerization of ErbB3 with other receptors, thereby inhibiting the phosphorylation of ErbB3. CDX-3379 can inhibit the growth and proliferation of tumor cells. CDX-3379 is promising for research of tumors expressing ErbB3 and NRG1, such as HNSCC .
|
-
- HY-P991651
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
MEDI4212 is a humanized IgG1λ monoclonal antibody inhibitor targeting IgE. MEDI4212 potently inhibits human IgE-mediated functional responses through its receptor FcεRI, such as calcium signaling, β-hexosaminidase release and phagocytosis. MEDI4212 prevents the binding of IgE to CD23 with an IC50 of 8 nM. MEDI4212 can be used severe asthma research .
|
-
- HY-P9918
-
|
Ticilimumab; CP-675206
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
|
-
- HY-P991149
-
|
|
TNF Receptor
|
Cancer
|
|
Nesfrotamig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2) and human tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Nesfrotamig is promising for research of cancers, especially in ERBB2-positive related tumor diseases, such as breast cancer and gastric cancer .
|
-
- HY-P991180
-
|
|
TNF Receptor
|
Cancer
|
|
TRX-518 is a humanized agonist antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR). TRX-518 specifically targets GITR⁺ Tregs and CD45RA⁻Foxp3⁺ effector Tregs (eTregs) among regulatory T cells (Tregs), reducing the number of Tregs in circulation and within tumors. TRX-518 is promising for research of cancers .
|
-
- HY-P9929
-
|
BLA761046; MBL-CDB1; MDX-1388
|
Bacterial
|
Infection
|
|
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
|
-
- HY-P99414
-
|
AMG 557
|
Transmembrane Glycoprotein
Interleukin Related
|
Inflammation/Immunology
|
|
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
|
-
- HY-P990639
-
|
|
CXCR
|
Inflammation/Immunology
|
|
NI-0801 is a humanized antibody expressed in CHO, targeting CXCL10/IP-10. NI-0801 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0801 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-164152
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-P991620
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .
|
-
- HY-P990562
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CAT-2200 is a humanized antibody expressed in CHO, targeting CTLA-8/IL-17a. CAT-2200 is equipped with huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CAT-2200 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990524
-
|
|
Ser/Thr Protease
|
Inflammation/Immunology
|
|
The Anti-TMPRSS2 Antibody is a CHO-expressed humanized antibody that targets TMPRSS2. The Anti-TMPRSS2 Antibody features a huIgG1 heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. For the isotype control of the Anti-TMPRSS2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990352
-
|
Ona36
|
Scavenger Receptor Class B type I (SR-BI）
|
Inflammation/Immunology
|
|
Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990501
-
|
|
Wnt
β-catenin
|
Inflammation/Immunology
|
|
Anti-RSPO1 Antibody is a humanized antibody expressed in CHO that targets RSPO1. The Anti-RSPO1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-RSPO1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-164152A
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-164154
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
-
- HY-P991146
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
-
- HY-P991638
-
|
|
TNF Receptor
|
Cancer
|
|
XmAb-2513 is a humanized monoclonal antibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP). XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research .
|
-
- HY-P99492
-
|
SB-408075; huC242-DM1
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1 (HY-19792)) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
-
- HY-P991534
-
|
|
Amyloid-β
|
Neurological Disease
|
|
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .
|
-
- HY-P990452
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-5 Antibody is a CHO-expressed humanized antibody that targets IL-5. The Anti-IL-5 Antibody is composed of huIgG4 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-5 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990672
-
U3-1784
2 Publications Verification
|
FGFR
|
Inflammation/Immunology
|
|
U3-1784 is a humanized antibody expressed in CHO that targets FGFR4/CD334. U3-1784 is equipped with a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for U3-1784 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990473
-
|
|
Trk Receptor
|
Inflammation/Immunology
|
|
Anti-MUSK Antibody is a humanized antibody expressed in CHO that targets MUSK. The Anti-MUSK Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 143.86 kDa. For the isotype control of Anti-MUSK Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
- HY-P991250
-
|
|
Integrin
|
Cancer
|
|
MSH-TP15e is a humanized monoclonal antibody inhibitor targeting intercellular adhesion molecule-1 (ICAM-1). MSH-TP15e recruits natural killer cells and significantly triggers antibody-dependent cell-mediated cytotoxicity (ADCC) to inhibit tumor cell growth. MSH-TP15e is promising for research of multiple myeloma (MM) .
|
-
- HY-P990645
-
|
|
Cadherin
|
Inflammation/Immunology
|
|
PF-03732010 is a humanized antibody expressed in CHO, targeting CDH3/P-cadherin. PF-03732010 has a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 142.7 kDa. The isotype control for PF-03732010 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-132260
-
|
IMGN529; Debio 1562
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Naratuximab emtansine (IMGN529) is a CD37-targeted ADC consisting of a humanized IgG1 mAb coupled to the microtubule disruptor DM1. Naratuximab emtansine has high affinity and specificity for CD37, allowing ADC internalization, processing and intracellular release of DM1. Due to its ability to disrupt microtubule assembly, DM1 can subsequently induce cell cycle arrest and apoptosis .
|
-
- HY-P990523
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-TMEFF2 Antibody is a humanized antibody expressed in CHO cells, targeting TMEFF2. The Anti-TMEFF2 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TMEFF2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990349
-
|
|
CD19
|
Inflammation/Immunology
|
|
The Anti-CD19 Antibody is a humanized antibody expressed in CHO cells, targeting CD19. The Anti-CD19 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990547
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
APX-007 is a CHO-expressed humanized antibody that targets IL-6Ra/CD126. APX-007 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for APX-007 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990434
-
|
|
Histone Methyltransferase
|
Inflammation/Immunology
|
|
The Anti-Histone H3 Antibody is a CHO-expressed humanized antibody that targets Histone H3. The Anti-Histone H3 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-Histone H3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99009
-
|
RVT-1401; HBM9161; IMVT-1401
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
|
-
- HY-P990647
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
PF-06342674 is a CHO-expressed humanized antibody that targets IL-7Ra/CD127. PF-06342674 carries a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.14 kDa. The isotype control for PF-06342674 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990419
-
|
|
Amino Acid Decarboxylase
|
Inflammation/Immunology
|
|
Anti-GAD65 Antibody is a humanized antibody expressed in CHO cells that targets GAD65. The Anti-GAD65 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.48 kDa. The isotype control for Anti-GAD65 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990478
-
|
|
CRAC Channel
|
Inflammation/Immunology
|
|
Anti-Orai1 Antibody is a humanized antibody expressed in CHO cells that targets Orai1. The Anti-Orai1 Antibody has a huIgG2 heavy chain and a huλ light chain, with an predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Orai1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P99391A
-
|
ABT-700 (powder)
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
|
-
- HY-P990439
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
The Anti-IFNAR1 Antibody is a humanized antibody expressed in CHO cells, targeting IFNAR1. The Anti-IFNAR1 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.92 kDa. The isotype control for the Anti-IFNAR1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990360
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
The Anti-CD9 Antibody is a humanized antibody expressed in CHO, targeting CD9. The Anti-CD9 Antibody is equipped with huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990559
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
BMS-986178 is a humanized antibody expressed in CHO, targeting TNFRSF4/OX40/CD134. BMS-986178 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for BMS-986178 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990676
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
VIB-9600 is a humanized antibody expressed in CHO cells, targeting FcgR2a/CD32a. VIB-9600 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VIB-9600 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990517
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
Anti-TGFb1 Antibody is a humanized antibody expressed in CHO cells that targets TGFb1. The Anti-TGFb1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TGFb1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990372
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
|
|
The Anti-CLEC14A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC14A. The Anti-CLEC14A Antibody contains an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CLEC14A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-132253
-
|
|
Antibody-Drug Conjugates (ADCs)
Transmembrane Glycoprotein
|
Cancer
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-164763
-
|
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
SHR-A1201 is a HER2-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody (HY-P9907), a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer .
|
-
- HY-P99115
-
|
ASC 22; KN 035
|
PD-1/PD-L1
|
Cancer
|
|
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .
|
-
- HY-P990344
-
|
|
Bcl-2 Family
|
Inflammation/Immunology
|
|
The Anti-Bcl-2 Antibody is a humanized antibody expressed in CHO cells, targeting Bcl-2. The Anti-Bcl-2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Bcl-2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-109539
-
|
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). The antibody portion is Gemtuzumab (HY-P99971), and the drug-linker conjugate for ADC is N-Ac-γ-Calicheamicin-AcBut-NHS ester (HY-103688). Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML) .
|
-
- HY-P99683
-
|
SGN-LIV1A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .
|
-
- HY-P991654
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD of 0.43 nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research .
|
-
- HY-P990649
-
|
TRU-015
|
CD20
|
Inflammation/Immunology
|
|
PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 (TRU-015) is a single-chain Fv antibody, and its predicted molecular weight (MW) is 54.6 kDa. The isotype control for PF-5212374 (TRU-015) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-132253A
-
|
|
Antibody-Drug Conjugates (ADCs)
Transmembrane Glycoprotein
|
Cancer
|
|
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-164762
-
|
SHR-A1811
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .
|
-
- HY-164992
-
|
MRG002; Trastuzumab MMAE
|
Antibody-Drug Conjugates (ADCs)
EGFR
Microtubule/Tubulin
|
Cancer
|
|
Trastuzumab vedotin (MRG002) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab vedotin is composed of a humanized anti-HER2 antibody Trastuzumab (HY-P9907), an enzymatically cleavable peptide-linker Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE; HY-15162). Trastuzumab vedotin can be used for the research of HER2-positive breast cancer .
|
-
- HY-P990317
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
AGS-67E is a humanized antibody expressed by CHO, targeting TSPAN26/CD37. AGS-67E has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.44 kDa. The isotype control for AGS-67E can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990555
-
|
OSE-172
|
CD47
|
Inflammation/Immunology
|
|
BI-765063 (OSE-172) is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4-type heavy chain and a huκ-type light chain, with a predicted molecular weight (MW) of 146.3 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P991633
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
TQC2938 is a humanized IgG2 monoclonal antibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research .
|
-
- HY-P990643
-
|
|
Integrin
|
Inflammation/Immunology
|
|
OS-2966 is a humanized antibody expressed in CHO cells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-171683
-
|
|
Antibody-Drug Conjugates (ADCs)
CCR
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Anti-CCL2 (Carlumab)-VcMMAE is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with valine-citrulline (vc) and the tubulin inhibitor MMAE (HY-15162). The ADC toxic molecule and linker part are McMMAE (HY-15575). Anti-CCL2 (Carlumab)-VcMMAE induces apoptosis and can be used in cancer research .
|
-
- HY-P99705
-
|
RG-7599; DNIB-0600A; NaPi2b-ADC
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Lifastuzumab vedotin (RG-7599; DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research .
|
-
- HY-P990332
-
|
CNTO 2125
|
Amyloid-β
|
Inflammation/Immunology
|
|
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHO cells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991609
-
|
|
MMP
|
Cancer
|
|
ABX-MA1 is a humanized IgG2 monoclonal antibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research .
|
-
- HY-P991555
-
|
|
TNF Receptor
Apoptosis
|
Cancer
|
|
XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonal antibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .
|
-
- HY-P991572
-
|
|
EGFR
|
Cancer
|
|
MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .
|
-
- HY-P99242
-
|
|
CD276/B7-H3
|
Cancer
|
|
Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .
|
-
- HY-P991720
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research .
|
-
- HY-171682
-
|
|
Antibody-Drug Conjugates (ADCs)
CCR
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Anti-CCL2 (Carlumab)-McMMAF is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated to the protective group maleimidocaproyl and the tubulin inhibitor MMAF (HY-15579). The ADC toxic molecule and linker part are McMMAF (HY-15578). Anti-CCL2 (Carlumab)-McMMAF induces apoptosis and can be used in cancer research .
|
-
- HY-P990353
-
|
TRX1
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD4 Antibody (TRX1) is a humanized antibody expressed in CHO cells that targets CD4. Anti-CD4 Antibody (TRX1) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD4 Antibody (TRX1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990403
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
The Anti-DSG3 Antibody is a humanized antibody expressed in CHO cells, targeting DSG3. The Anti-DSG3 Antibody has a huIgG1 type heavy chain and a huκ type light chain, and its predicted molecular weight (MW) is 146.54 kDa. The isotype control for the Anti-DSG3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990378
-
|
|
Complement System
|
Inflammation/Immunology
|
|
Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990321
-
|
MEDI 8968
|
Interleukin Related
|
Inflammation/Immunology
|
|
AMG-108 is a humanized antibody expressed in CHO cells, targeting IL-1R1/CD121a. AMG-108 is composed of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.62 kDa. The isotype control for AMG-108 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P991646
-
|
heMab
|
Transmembrane Glycoprotein
|
Cancer
|
|
ING-1 (heMab) is a high-affinity humanized monoclonal antibody against epithelial cell adhesion molecule (Ep-CAM). ING-1 is a transmembrane glycoprotein mediating Ca 2+. ING-1 binds to Ep-CAM on tumor cells and exhibits potent in vitro activity, targeting and inhibiting tumor growth and metastasis in mouse cancer models. ING-1 is useful in the research of breast, colorectal, and lung cancers, among other cancers .
|
-
- HY-P991611
-
|
|
iGluR
|
Inflammation/Immunology
|
|
ART5803 is a humanized IgG1 monoclonal antibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis .
|
-
- HY-155740
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-32 (compound A56) is a potent PD-1/PD-L1 inhibitor (IC50=2.4 nM), with anticancer activity. PD-1/PD-L1-IN-32 significantly inhibits tumor growth in hPD-L1 MC38 humanized mouse model, without obvious toxicity against mouse normal ability .
|
-
- HY-P991082
-
|
SAR-428926 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonal antibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. Antibody Anti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990579
-
|
|
HCV
|
Inflammation/Immunology
|
|
Anti-CLDN6 Antibody (DS-9606A antibody) is a humanized antibody expressed in CHO cells, targeting CLDN6. Anti-CLDN6 Antibody features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for Anti-CLDN6 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990398
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Anti-DC-SIGN/CD209 Antibody is a CHO-expressed humanized antibody that targets DC-SIGN/CD209. Anti-DC-SIGN/CD209 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DC-SIGN/CD209 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991706
-
|
|
Phosphodiesterase (PDE)
CD3
|
Cancer
|
|
Nelvutamig is a humanized immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3) antibody targeting ENPP3/CD203c and CD3E. The corresponding isotype control is: Human immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3) .
|
-
- HY-P99612
-
|
MORAb-202
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
|
-
- HY-P990417
-
|
|
Antifolate
|
Inflammation/Immunology
|
|
Anti-FOLR1/FRA Antibody is a humanized antibody expressed in CHO cells, targeting FOLR1/FRA. The Anti-FOLR1/FRA Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.46 kDa. The isotype control for the Anti-FOLR1/FRA Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990426
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
The Anti-GREM1/Gremlin Antibody is a humanized antibody expressed in CHO that targets GREM1/Gremlin. The Anti-GREM1/Gremlin Antibody has a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GREM1/Gremlin Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990664
-
|
SC-005 antibody
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Melanotransferrin/CD228 Antibody (SC-005 antibody) is a humanized antibody expressed in CHO cells, targeting Melanotransferrin/CD228. Anti-Melanotransferrin/CD228 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.16 kDa. The isotype control for Anti-Melanotransferrin/CD228 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991582
-
|
|
Fc Receptor (FcR)
|
Cancer
|
|
BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
|
-
- HY-P991570
-
|
AD5-10
|
TNF Receptor
Apoptosis
Caspase
Atg8/LC3
Akt
Beclin1
JNK
|
Cancer
|
|
Zaptuzumab (AD5-10) is a DR5-specific humanized monoclonal antibody that selectively binds to DR5 with high affinity. Zaptuzumab specifically induces cancer cell death by both caspase-apoptosis and autophagic cell death (ACD). Zaptuzumab activates both ADCC and CDC. Zaptuzumab induces ROS generation and GSH level reduction. Zaptuzumab shows a significant suppression of the tumor growth and good safety in various xenografts mice tumor models .
|
-
- HY-132258A
-
|
IMGN853 (solution)
|
Antibody-Drug Conjugates (ADCs)
Antifolate
|
Cancer
|
|
Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .
|
-
- HY-P99199
-
|
NI-0401
|
CD3
|
Inflammation/Immunology
|
|
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
|
-
- HY-163378
-
|
|
Complement System
|
Inflammation/Immunology
|
|
C5aR1 antagonist 1 (Compound 7e) is an orally active C5a receptor 1 (C5aR1) antagonist. C5aR1 antagonist 1 is active in DISCO and migration assays, with IC50 values of 38 nM and 17 nM, respectively. C5aR1 antagonist 1 can be used for the research of acute and chronic inflammatory diseases .
|
-
- HY-P991610
-
|
Sym025
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
|
-
- HY-P990387
-
|
|
Ser/Thr Protease
|
Inflammation/Immunology
|
|
The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized antibody expressed in CHO cells, targeting CTSS/Cathepsin S. The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTSS/Cathepsin S Antibody (Fsn0503h) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990369
-
|
AB3-7
|
HCV
|
Inflammation/Immunology
|
|
Anti-CLDN6 Antibody (AB3-7) is a humanized antibody expressed in CHO targeting CLDN6. Anti-CLDN6 Antibody (AB3-7) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 78.02 kDa. The isotype control for Anti-CLDN6 Antibody (AB3-7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991511
-
|
|
PACAP Receptor
|
Neurological Disease
|
|
ALD1910 is a humanized monoclonal antibody against PACAP38 and PACAP27. ALD1910 blocks PACAP signaling through the pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a nonlinear epitope within PACAP and blocks its binding to the cell surface. ALD1910 can be used for the study of PACAP-mediated migraine .
|
-
- HY-143880
-
|
|
Mas-related G-protein-coupled Receptor (MRGPR)
|
Neurological Disease
|
|
MRGPRX1 agonist 4 (compound 1t) is a potent and orally active Mas-related G protein-coupled receptor X1 (MRGPRX1) positive allosteric modulator with an EC50 value of 0.1 μM. MRGPRX1 agonist 4 has good metabolic stability and oral bioavailability. MRGPRX1 agonist 4 can reduce behavioral heat hypersensitivity in a neuropathic pain model humanized MRGPRX1 mice. MRGPRX1 agonist 4 can be used for researching neuropathic pain .
|
-
- HY-138298
-
|
DS-8201 (solution); DS-8201a (solution)
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
|
-
- HY-P990319
-
|
|
NAMPT
|
Inflammation/Immunology
|
|
ALT-100 (Human IgG4) is a humanized antibody expressed in CHO, targeting NAMPT. ALT-100 (Human IgG4) consists of a huIgG1/huIgG4 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For inflammatory or fibrotic diseases, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-138298A
-
|
DS-8201; DS-8201a
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
|
-
- HY-171737
-
|
|
Antibody-Drug Conjugates (ADCs)
Sodium Channel
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Anti-SLC34A2 (Lifastuzumab)-McMMAF is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the protective group maleimidocaproyl and the tubulin inhibitor MMAF (HY-15579). The ADC toxic molecule and linker part McMMAF (HY-15578). Anti-SLC34A2 (Lifastuzumab)-McMMAF induces apoptosis and can be used in cancer research .
|
-
- HY-P991671
-
|
|
CD3
CD20
Transmembrane Glycoprotein
|
Cancer
|
|
Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research .
|
-
- HY-12927
-
|
|
CXCR
|
Inflammation/Immunology
|
|
SX-517 is a dual CXCR2/1 antagonist, containing boronic acid. SX-517 inhibits CXCL1-induced Ca 2+ flux (IC50=38 nM), and antagonizes CXCL8-induced [(35)S]GTPγS binding (IC50=60 nM) and ERK1/2 phosphorylation. SX-517 has significant ability for inflammation suppression, in both humanized polymorphonuclear (PMN) cells and in murine model .
|
-
- HY-111817A
-
|
|
Parasite
|
Infection
|
|
(Rac)-ACT-451840 is an isomer of ACT-451840 that exhibits significant antimalarial effects. (Rac)-ACT-451840 exhibits significant antimalarial activity against P. berghei-infected mice at a dose of 20 mg/kg (ED90=13 mg/kg), and has an inhibitory effect at a dose of 300 mg/kg. The ED90 of (Rac)-ACT-451840 in the P. falciparum humanized immunodeficient mouse model is 3.7 mg/kg. (Rac)-ACT-451840 is similar to artemisinin, with a rapid onset of action but requires repeated high doses.
|
-
- HY-P991542
-
|
|
CD19
|
Cancer
|
|
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .
|
-
- HY-P991621
-
|
EOS-215
|
TREM receptor
|
Cancer
|
|
EOS006215 is a humanized monoclonal antibody inhibitor targeting TREM-2. EOS006215 reprograms TREM2 + macrophages, significantly blocks their pleiotropic pro-tumoral functions and overcomes resistance. EOS215 decreases metastasis burden in orthotopic 4T1 triple negative breast cancer mice model and significantly inhibits tumor growth in anti-PD-1 resistant mice model. EOS006215 can be used to study advanced malignant solid neoplasm, such as triple negative breast cancer (TNBC) .
|
-
- HY-P991515
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonal antibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) .
|
-
- HY-P99263
-
|
Anti-Human selectin P Recombinant Antibody
|
P-selectin
|
Cardiovascular Disease
|
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
|
-
- HY-P991599
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990531
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
The Anti-TNFSF9/4-1BBL Antibody is a CHO-expressed humanized antibody that targets TNFSF9/4-1BBL. The Anti-TNFSF9/4-1BBL Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-TNFSF9/4-1BBL Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990627
-
|
MEDI-547 antibody
|
Ephrin Receptor
|
Inflammation/Immunology
|
|
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is a humanized antibody expressed in CHO cells, targeting EphA2. Anti-EphA2 Antibody (1C1) contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 146.68 kDa. The isotype control for Anti-EphA2 Antibody (1C1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990415
-
|
|
FGFR
|
Inflammation/Immunology
|
|
The Anti-FGFR1/CD331 Antibody is a humanized antibody expressed in CHO cells, targeting FGFR1/CD331. The Anti-FGFR1/CD331 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FGFR1/CD331 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990542
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Anti-VEGFR2/KDR/CD309 Antibody is a humanized antibody expressed in CHO, targeting VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody is equipped with muIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-VEGFR2/KDR/CD309 Antibody, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991217
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
EU-103 is a humanized monoclonal antibody targeting V-Set And Immunoglobulin Domain Containing 4 (VSIG4) with a KD value ranging from 10 −7 and 10 −9. EU-103 blocks the interaction between VSIG4 and CD8+ T cells, promotes the conversion of M2 macrophages into M1 macrophages, induces the proliferation of CD8+ T cells and the secretion of pro-inflammatory cytokines, thereby inhibiting tumor growth. EU-103 is promising for research of cancers, such as bladder cancer, breast cancer, and colon cancer .
|
-
- HY-P991565
-
|
|
c-Met/HGFR
|
Cancer
|
|
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
|
-
- HY-171685
-
-
- HY-P991551
-
|
|
Dipeptidyl Peptidase
p38 MAPK
ERK
|
Infection
Cancer
|
|
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for researches on cancer or infection such as Malignant Mesothelioma and MERS .
|
-
- HY-171681
-
|
|
Antibody-Drug Conjugates (ADCs)
CCR
Microtubule/Tubulin
|
Cancer
|
|
Anti-CCL2 (Carlumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with the linker SPDB (HY-12448) and the tubulin inhibitor DM4 (HY-12454). The ADC toxic molecule and linker part are sulfo-SPDB-DM4 (HY-101141). Anti-CCL2 (Carlumab)-SPDB-DM4 can be used in cancer research .
|
-
- HY-P99016A
-
|
|
Antibody-Drug Conjugates (ADCs)
Nectin-4
|
Cancer
|
|
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
|
-
- HY-P991294
-
|
|
ADC Antibody
|
Cancer
|
|
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
|
-
- HY-P991598
-
|
MOR12743; MOR03207
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .
|
-
- HY-P991047
-
|
JR-141 antibody (uncoupled from iduronate 2-sulfatase)
|
Transferrin Receptor
|
Neurological Disease
Cancer
|
|
Anti-CD71/TfR1 Antibody (JR-141 antibody (uncoupled from iduronate 2-sulfatase)) is a humanized anti-human transferrin receptor (CD71; TfR) antibody. Anti-CD71/TfR1 Antibody is the antibody part of the fusion protein Pabinafusp alfa (HY-P99797). The recommend isotype control of Anti-CD71/TfR1 Antibody: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991561
-
|
|
CD47
|
Cancer
|
|
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
|
-
- HY-P990397
-
|
FA19-1
|
VEGFR
|
Inflammation/Immunology
|
|
The Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized antibody expressed in CHO cells that targets DCBLD2/ESDN. The Anti-DCBLD2/ESDN Antibody (FA19-1) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-DCBLD2/ESDN Antibody (FA19-1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99016B
-
|
|
Antibody-Drug Conjugates (ADCs)
Nectin-4
|
Cancer
|
|
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
|
-
- HY-171680
-
|
|
Antibody-Drug Conjugates (ADCs)
CCR
Microtubule/Tubulin
|
Cancer
|
|
Anti-CCL2 (Carlumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated to the linker SMCC (HY-42360) and the cytotoxic microtubule inhibitor DM1 (HY-19792). The ADC toxic molecule and linker part are SMCC-DM1 (HY-101070). Anti-CCL2 (Carlumab)-SMCC-DM1 can be used in the research of cancer, especially prostate cancer .
|
-
- HY-P991613
-
|
|
Orexin Receptor (OX Receptor)
NF-κB
|
Cancer
|
|
BGB-A445 is a humanized non-ligand-blocking agonistic OX40 monoclonal antibody with high affinity to OX40. BGB-A445 activates downstream NF-κB pathway to induce immune cell activation, proliferation, and survival. BGB-A445 dose-dependently and significantly depletes regulatory T cells via antibody-dependent cellular cytotoxicity (ADCC). BGB-A445 demonstrates robust and dose-dependent antitumor efficacy in the MC38 mice models. BGB-A445 can be used for the researches of cancer, such as colon adenocarcinoma .
|
-
- HY-171684
-
|
|
Antibody-Drug Conjugates (ADCs)
CCR
Topoisomerase
|
Cancer
|
|
Anti-CCL2 (Carlumab)-MC-Vc-PAB-SN38 is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated to the linker Mc-VC-PAB and the topoisomerase I inhibitor SN38 (HY-13704). The ADC toxic molecule and linker part are Mc-VC-PAB-SN38 (HY-131057). Anti-CCL2 (Carlumab)-MC-Vc-PAB-SN38 can be used in cancer research .
|
-
- HY-P99744
-
|
TAK-573
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
|
-
- HY-P99555
-
|
OPN-305
|
Toll-like Receptor (TLR)
MyD88
NOD-like Receptor (NLR)
Tau Protein
Interleukin Related
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
|
-
- HY-P990472
-
|
H5B14
|
c-Met/HGFR
|
Inflammation/Immunology
|
|
Anti-MSPR/RON/CD136 Antibody (H5B14) is a humanized antibody expressed in CHO cells, targeting MSPR/RON/CD136. Anti-MSPR/RON/CD136 Antibody (H5B14) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 156.7 kDa. The isotype control for Anti-MSPR/RON/CD136 Antibody (H5B14) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99048
-
|
IBI308
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
- HY-P991634
-
|
|
CD73
TNF Receptor
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research .
|
-
- HY-P991566
-
|
|
CTLA-4
|
Cancer
|
|
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
|
-
- HY-P99056
-
|
PF 05082566
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
|
-
- HY-P990362
-
|
|
Cadherin
|
Inflammation/Immunology
|
|
Anti-CDH1/E-cadherin/CD324 Antibody is a humanized antibody expressed in CHO, targeting CDH1/E-cadherin/CD324. The Anti-CDH1/E-cadherin/CD324 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-CDH1/E-cadherin/CD324 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991656
-
|
|
CXCR
Apoptosis
p38 MAPK
Akt
|
Cancer
|
|
LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .
|
-
- HY-P991270
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy .
|
-
- HY-P991198
-
|
|
Tim3
|
Cancer
|
|
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
|
-
- HY-P991567
-
|
VX5/5261
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
VX5 is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration (EC50s for 105 and 253 nM for human tonsillar and pre-B-697-hCXCR5 cells, respectively). VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .
|
-
- HY-P991595
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-177414
-
|
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Inflammation/Immunology
Cancer
|
|
BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). BB-1701 is composed of a humanized anti-HER2 antibody (Trastuzumab) (HY-P9907), a linker (Mal-PEG2-VCP), a microtubule inhibitor (Eribulin) (HY-13442), and the drug-linker conjugate for ADC is Mal-PEG2-VCP-Eribulin (HY-128870). BB-1701 has a potent cytotoxicity and bystander effects on tumors with heterogeneous target expression. BB-1701 significantly induces immunogenic cell death and the activation of the immune .
|
-
- HY-P990543
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-171735
-
|
|
Antibody-Drug Conjugates (ADCs)
Sodium Channel
Microtubule/Tubulin
|
Cancer
|
|
Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the linker SMCC (HY-42360) and the the cytotoxic microtubule inhibitor DM1 (HY-19792). The ADC toxic molecule and linker part are SMCC-DM1 (HY-101070). Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 can be used in the research of cancer .
|
-
- HY-145774
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice .
|
-
- HY-171736
-
|
|
Antibody-Drug Conjugates (ADCs)
Sodium Channel
Microtubule/Tubulin
|
Cancer
|
|
Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated with the linker SPDB (HY-12448) and the tubulin inhibitor DM4 (HY-12454). The ADC toxic molecule and linker part are sulfo-SPDB-DM4 (HY-101141). Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 can be used in cancer research .
|
-
- HY-P991584
-
|
|
FGFR
|
Cancer
|
|
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .
|
-
- HY-P990091
-
|
SAR 445088
|
Complement System
|
Inflammation/Immunology
|
|
Riliprubart (SAR 445088) is an anti-C1s humanized IgG4 monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a. Riliprubart can be used to study complement-mediated diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-171738
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
Sodium Channel
|
Cancer
|
|
Anti-SLC34A2 (Lifastuzumab)-MC-Vc-PAB-SN38 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the linker Mc-VC-PAB and the topoisomerase I inhibitor SN38 (HY-13704). The ADC toxic molecule and linker part are Mc-VC-PAB-SN38 (HY-131057). Anti-SLC34A2 (Lifastuzumab)-MC-Vc-PAB-SN38 can be used in cancer research .
|
-
- HY-P99157
-
|
|
CD276/B7-H3
|
Cancer
|
|
Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
|
-
- HY-P990486
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Anti-PDCD1/PD-1/CD279 Antibody is a CHO-expressed humanized antibody that targets PDCD1/PD-1/CD279. Anti-PDCD1/PD-1/CD279 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PDCD1/PD-1/CD279 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-153360
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .
|
-
- HY-P11084
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .
|
-
- HY-P99048A
-
|
IBI308 (Anti-PD-1)
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
- HY-P991223
-
|
|
Transmembrane Glycoprotein
TNF Receptor
|
Cancer
|
|
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
|
-
- HY-175370
-
|
|
PROTACs
RIP kinase
|
Cancer
|
|
PROTAC RIPK1 Degrader-1 is a selective RIPK1 PROTAC degrader. PROTAC RIPK1 Degrader-1 degrades RIPK1 in multiple cancer cell lines (e.g., A375, B16F10 cells). PROTAC RIPK1 Degrader-1 enhances the anti-cancer effect of radiotherapy in syngeneic and humanized mouse models. PROTAC RIPK1 Degrader-1 can be used to study cancers such as melanoma. (Pink: RIPK1-ligand-2: HY-175371, Blue: (S,R,S)-AHPC-Me: HY-112078, Pink + Black: RIPK1 ligand-Linker Conjugate-1: HY-175374, Black: Bispiperidin-piperazin-acetater: HY-175373) .
|
-
- HY-171945
-
|
ABBV-400; Temab-A
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
c-Met/HGFR
|
Cancer
|
|
Telisotuzumab Adizutecan (ABBV-400) is an anti- c-Met antibody-drug conjugate (ADC). Telisotuzumab Adizutecan consists of a humanized anti-c-Met antibody Telisotuzumab (HY-P99391), a stable and cleavable linker (TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane), a topoisomerase 1 inhibitor (7-MAD-MDCPT) (HY-132162), and the drug-linker conjugate for ADC is TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (HY-171946). Telisotuzumab Adizutecan has a significant anti-tumor activity in advanced solid tumors, such as colorectal, gastric and non-small cell lung cancer .
|
-
- HY-P99929
-
|
HFB-30132A
|
SARS-CoV
|
Inflammation/Immunology
|
|
Enuzovimab (HFB-30132A) is a mAb against SARS-COV-2 Omicron. Enuzovimab binds to spike (S) protein with high affinity .
|
-
- HY-P99821
-
-
- HY-P99346
-
|
CT-P59
|
SARS-CoV
Angiotensin-converting Enzyme (ACE)
|
Infection
|
|
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
|
-
- HY-P99193
-
|
MEDI-528
|
Interleukin Related
|
Inflammation/Immunology
|
|
Enokizumab (MEDI-528) is a monoclonal antibody targeting to interleukin (IL)-9. IL-9 regulates the development of airway inflammation, mucus production, airway hyperresponsiveness, and airway fibrosis largely by increasing mast cell numbers and activity in the airways .
|
-
- HY-P9923
-
|
MEDI-563; BIW-8405; KHK4563
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
|
-
- HY-P99724
-
-
- HY-P99113
-
|
MEDI-551
|
ADC Antibody
CD19
|
Inflammation/Immunology
|
|
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .
|
-
- HY-P99816
-
|
|
PCSK9
|
Metabolic Disease
|
|
Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke .
|
-
- HY-P9991
-
|
TST001
|
Gap Junction Protein
|
Cancer
|
|
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
|
-
- HY-P99872
-
|
CSJ-117; NVP-CSJ117
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin (TSLP). Ecleralimab significantly attenuates allergen-induced airway responses and inflammation. Ecleralimab can be used for the study of inhaled asthma .
|
-
- HY-P990041
-
|
ADG-116
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer .
|
-
- HY-P99768
-
|
TTAC-0001
|
VEGFR
|
Cancer
|
|
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
|
-
- HY-P99954
-
|
|
Bacterial
|
Infection
|
|
Rivabazumab pegol is a PcrV protein antibody that can be used to study the phase II pegylated Fab of chronic Pseudomonas aeruginosa infection .
|
-
- HY-P99209
-
|
MEDI-524
|
RSV
|
Infection
|
|
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
|
-
- HY-P99842A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus .
|
-
- HY-P991063
-
|
BNT-313; Tixestobart
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
GEN-1053 (BNT-313) is a fully human IgG1 antibody that targets CD27. GEN-1053 binds to CD27 and forms a hexamer upon binding. The isotype control for GEN-1053 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
- HY-P99591
-
|
AS1402; huHMFG-1
|
Mucin
|
Cancer
|
|
Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer .
|
-
- HY-P9923A
-
|
MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
|
|
Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA)) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .
|
-
- HY-P99337
-
|
Ansuvimab-zyk; mAb114
|
Filovirus
|
Infection
|
|
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
|
-
- HY-P99788
-
|
|
ADC Antibody
ALCAM/CD166
|
Cancer
|
|
Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers .
|
-
- HY-P99160
-
|
hMN14
|
Transmembrane Glycoprotein
|
Cancer
|
|
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .
|
-
- HY-P99245
-
|
RG 7155; RO 5509554
|
c-Fms
|
Cancer
|
|
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .
|
-
- HY-P99756
-
|
MEDI8897
|
RSV
|
Infection
|
|
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
|
-
- HY-P990726
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99222
-
|
MGA-031; PRV-031
|
CD3
|
Metabolic Disease
|
|
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
|
-
- HY-P990686
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ispectamab is an anti-TNFRSF17 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P9965
-
|
HuLuc 63; PDL 063; BMS 901608
|
Transmembrane Glycoprotein
|
Cancer
|
|
Elotuzumab (HuLuc 63) is an IgG1 monoclonal antibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating natural killer cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide (HY-A0003), Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma .
|
-
- HY-P99808
-
|
|
VEGFR
|
Cancer
|
|
Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers .
|
-
- HY-P99631
-
|
CSL312
|
Factor Xa
|
Cardiovascular Disease
|
|
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
|
-
- HY-P990030
-
-
- HY-P99953
-
|
KB001
|
Bacterial
|
Infection
|
|
Rivabazumab is a recombinant antibody against Pseudomonas aeruginosa pcrV .
|
-
- HY-P99490
-
|
hzVSF-v13
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies .
|
-
- HY-P99550
-
|
MEDI-3506
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
|
-
- HY-P990697
-
|
ARX-788
|
EGFR
|
Inflammation/Immunology
|
|
Anvatabart is an anti-ERBB2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99693
-
|
GC1102
|
HBV
|
Infection
|
|
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection .
|
-
- HY-P99216
-
|
PF-04360365; RN 1219
|
EGFR
|
Neurological Disease
|
|
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease .
|
-
- HY-P99052
-
|
BGB-A317
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
|
-
- HY-P99042
-
|
|
Transmembrane Glycoprotein
ADC Antibody
|
Cancer
|
|
Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity .
|
-
- HY-P9971
-
|
SHR-1210; INCSHR1210
|
PD-1/PD-L1
|
Cancer
|
|
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
|
-
- HY-P990737
-
|
LY-3041658
|
CXCR
|
Inflammation/Immunology
|
|
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99253
-
|
KW-0761
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .
|
-
- HY-P99248
-
|
Risankizumab rzaa; BI 655066; ABBV-066
|
Interleukin Related
|
Inflammation/Immunology
|
|
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
|
-
- HY-P990046
-
|
Incagn-02385
|
LAG-3
|
Inflammation/Immunology
|
|
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .
|
-
- HY-P9984
-
|
rhuMAb Beta7; RG7413; PRO145223
|
Integrin
|
Cancer
|
|
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
|
-
- HY-P990764
-
|
SGN-B6A antibody
|
Integrin
|
Inflammation/Immunology
|
|
Sigvotatug is an anti-ITGB6 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990761
-
-
- HY-P99291
-
|
LM609; MEDI-522
|
Integrin
Apoptosis
Akt
|
Cancer
|
|
Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99730
-
|
TAK-079
|
CD38
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
|
-
- HY-P990981
-
|
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Clesitamig is a DLL3/CD3/CD137 trispecific T cell engager, consisting of two CD3/CD137 dual-specific antigen-binding fragments (Fabs) and one additional DLL3 antigen-binding fragment (Fab). Clesitamig exhibits potent antitumor activity and can be used in research on tumors such as small cell lung cancer .
|
-
- HY-P99049
-
|
APX005M; APX005M; EPI-0050
|
TNF Receptor
|
Inflammation/Immunology
|
|
Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .
|
-
- HY-P99356
-
|
BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)
|
α-synuclein
|
Neurological Disease
|
|
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease .
|
-
- HY-P990698
-
-
- HY-145645
-
|
NI-0101
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
Paridiprubart (NI-0101) is a humanised anti-TLR4 monoclonal antibody. Paridiprubar inhibits the production of pro-inflammatory cytokines by monocytes from rheumatoid arthritis specimen induced by rheumatoid arthritis synovial fluid (RASF). Paridiprubart can be used for the study of rheumatoid arthritis .
|
-
- HY-P990691
-
-
- HY-P99251
-
|
|
PCSK9
|
Others
|
|
Lodelcizumab is a monoclonal antibody targeting PCSK9. Lodelcizumab can be used for the research of hypercholesterolemia .
|
-
- HY-P9962
-
|
|
Fungal
|
Infection
|
|
Efungumab is a monoclonal antibody with antifungal activity. Efungumab binds to HSP 90, preventing a conformational change needed for fungal viability. Efungumab can be used for research on invasive candidiasis (IC) .
|
-
- HY-P99632
-
|
REGN 2477
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
|
-
- HY-P99183
-
|
EMD 525797; DI17E6
|
Integrin
|
Cancer
|
|
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .
|
-
- HY-P990055
-
|
|
EGFR
|
Cancer
|
|
Nezutatug is an anti-HER3 antibody, and used for cancer research .
|
-
- HY-P99259
-
|
FPA 008; Anti-Human CSF1R Recombinant Antibody
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
|
-
- HY-P990753
-
-
- HY-P991042
-
|
|
IGF-1R
|
Cancer
|
|
Anti-IGFBP2 Antibody (M14) is an human anti-IGFBP2 monoclonal inhibitory antibody, which binds IGFBP2 with high affinity and blocks its binding with IGF1. Anti-IGFBP2 Antibody (M14) inhibits human endothelial cell recruitment, thus blocks the tumor progression of human metastatic cancer .
|
-
- HY-P99289
-
|
Antibody hLL 2; AMG-412
|
CD22
|
Inflammation/Immunology
Cancer
|
|
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
|
-
- HY-P990057
-
-
- HY-P99785
-
|
HLX20; HLX43 antibody
|
PD-1/PD-L1
|
Cancer
|
|
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
|
-
- HY-P99616
-
|
MOR-202
|
CD38
|
Cancer
|
|
Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research .
|
-
- HY-P990747
-
|
|
CD38
|
Inflammation/Immunology
|
|
Lumrotatug is an anti-CD38 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99850
-
-
- HY-P990702
-
|
LVGN-3616
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Pradusinstobart is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99967
-
|
|
ADC Antibody
|
Cancer
|
|
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .
|
-
- HY-P990739
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99113A
-
|
|
CD19
|
Inflammation/Immunology
|
|
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica .
|
-
- HY-P99831
-
|
GB-221
|
EGFR
|
Others
Cancer
|
|
Coprelotamab (GB-221) is an IgG-κ monoclonal antibody targeting EGFR2. The commonly used expression system for Coprelotamab is CHO DG44 (Chinese Hamster Ovary) cells .
|
-
- HY-P990746
-
-
- HY-P990771
-
|
|
CD73
|
Inflammation/Immunology
|
|
Uprevstobart is an anti-NT5E human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99014
-
|
ARGX-110
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .
|
-
- HY-P990751
-
-
- HY-P99629
-
|
FHTR 2163; RG 6147; RO 7171009
|
Ser/Thr Protease
|
Neurological Disease
|
|
Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular degeneration (AMD) research .
|
-
- HY-P99258
-
|
OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody
|
Notch
|
Cancer
|
|
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .
|
-
- HY-P99171
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II) .
|
-
- HY-P99506
-
|
SC-003 mAb; SC-Mab003; SC34.28ss1
|
ADC Antibody
|
Cancer
|
|
Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research .
|
-
- HY-P99758
-
|
CS1003
|
PD-1/PD-L1
|
Cancer
|
|
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research .
|
-
- HY-P99367
-
-
- HY-P99701
-
|
BMS-986004
|
TNF Receptor
|
Inflammation/Immunology
|
|
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time .
|
-
- HY-P99246
-
|
MABp1
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Bermekimab (MABp1) is a human monoclonal antibody targeting interleukin-1α(IL-1α) . Bermekimab can prevent tumor-related inflammation. Bermekimab can be used in the research of atopic dermatitis .
|
-
- HY-P99498
-
|
CEA-IL2v; RG 7813; RO 6895882
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Cergutuzumab amunaleukin (CEA-IL2v) is a monomeric carcinoembryonic antigen (CEA)-targeted IL-2 variant-based immunocytokine. Cergutuzumab amunaleukin has immunostimulating and antineoplastic activities .
|
-
- HY-P990749
-
-
- HY-P99495
-
|
RWJ 49004
|
HIV
|
Inflammation/Immunology
|
|
Cedelizumab (RWJ 49004) is a IgG4 monoclonal antibody targeting CD4. Cedelizumab has immunosuppressant properties .
|
-
- HY-P99809
-
|
MK-1308
|
CTLA-4
|
Cancer
|
|
Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody .
|
-
- HY-P99865
-
|
AK-119
|
CD73
|
Others
|
|
Dresbuxelimab (AK-119) is an IgG-κ monoclonal antibody targeting CD73. The expression system is usually CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P99673
-
|
REGN-3500; SAR-440340
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
|
-
- HY-P99594
-
|
ZKAB001; STI-1014; STI-A1014
|
PD-1/PD-L1
|
Cancer
|
|
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .
|
-
- HY-P99827
-
|
TSR-022; GSK4069889
|
Tim3
|
Cancer
|
|
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) .
|
-
- HY-P99010A
-
|
|
Interleukin Related
FGFR
|
Cancer
|
|
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
|
-
- HY-P99610
-
|
BI-754091
|
PD-1/PD-L1
|
Cancer
|
|
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .
|
-
- HY-P9973
-
|
DLX1008; ESBA 1008; RTH258
|
VEGFR
|
Cancer
|
|
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer .
|
-
- HY-P99280
-
|
Anti-Human IL17A/IL-17F Recombinant Antibody; CDP4940; UCB-4940
|
Interleukin Related
|
Inflammation/Immunology
|
|
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
|
-
- HY-P990767
-
-
- HY-P99378
-
|
ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab)
|
Apoptosis
|
Inflammation/Immunology
|
|
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .
|
-
- HY-P99969
-
|
CMAB-302; Cipterbin
|
EGFR
|
Cancer
|
|
Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities .
|
-
- HY-P990715
-
-
- HY-P99584
-
|
KD-247
|
HIV
|
Infection
|
|
Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection .
|
-
- HY-P99704
-
|
OCS-02
|
TNF Receptor
|
Inflammation/Immunology
|
|
Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation .
|
-
- HY-P99283
-
|
NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody
|
Factor Xa
|
Others
|
|
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .
|
-
- HY-P99196
-
|
|
c-Met/HGFR
|
Cancer
|
|
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
|
-
- HY-P99971
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990712
-
|
RZ-358; XOMA 358
|
Insulin Receptor
|
Inflammation/Immunology
|
|
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P99812
-
|
INCAGN-1876
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab binds to and activates GITR on T cells, which stimulates the immune system to enhance its anti-tumor activity. Ragifilimab can be used for advanced or metastatic solid tumors research .
|
-
- HY-P99733
-
|
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .
|
-
- HY-P99012
-
|
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .
|
-
- HY-P99922
-
|
|
LAG-3
|
Cancer
|
|
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .
|
-
- HY-P99261
-
|
OMP 21M18
|
Notch
|
Cancer
|
|
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .
|
-
- HY-P990735
-
-
- HY-P99779
-
-
- HY-P99187
-
|
PF-04950615; RN316
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .
|
-
- HY-P9987
-
|
hSel001; SEG101
|
P-selectin
|
Cardiovascular Disease
|
|
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease .
|
-
- HY-P990026
-
-
- HY-P99742
-
|
ADC-1013; JNJ-64457107
|
TNF Receptor
|
Cancer
|
|
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .
|
-
- HY-P99564
-
-
- HY-P99328
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
|
-
- HY-P99465
-
-
- HY-P990773
-
|
LY-3361237
|
CD28
|
Inflammation/Immunology
|
|
Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99963
-
|
HS636
|
PD-1/PD-L1
|
Cancer
|
|
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .
|
-
- HY-P99047
-
|
AB 0024; GS 6624
|
Monoamine Oxidase
|
Inflammation/Immunology
Cancer
|
|
Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab can be used for the research of primary sclerosing cholangitis (PSC) .
|
-
- HY-P990775
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Vilastobart is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990324
-
|
3F6-9G5
|
Adenosine Receptor
|
Inflammation/Immunology
|
|
Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) is a humanized antibody expressed in CHO cells, targeting AA2AR/Adenosine A2aR. Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.66 kDa. The isotype control for Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-177442
-
|
DS-3939
|
Antibody-Drug Conjugates (ADCs)
Mucin
Topoisomerase
Apoptosis
|
Cancer
|
|
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Exatecan (HY-13631). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .
|
-
- HY-P99714
-
|
MGD019
|
PD-1/PD-L1
CTLA-4
|
Cancer
|
|
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-P99740
-
|
|
CD276/B7-H3
ADC Antibody
|
Cancer
|
|
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
|
-
- HY-P99419
-
|
GEN1046
|
PD-1/PD-L1
|
Cancer
|
|
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer .
|
-
- HY-P99959
-
|
MT-3921; rH116A3
|
TGF-β Receptor
|
Neurological Disease
|
|
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .
|
-
- HY-P990716
-
-
- HY-P990013
-
|
Glutazumab; GMA-102; GMA-105
|
GCGR
|
Metabolic Disease
|
|
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .
|
-
- HY-P99330
-
|
Anti-Human VEGFA Recombinant Antibody; RO5520985
|
VEGFR
Tie
|
Cancer
|
|
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
|
-
- HY-P990012
-
|
EBI-031
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vamikibart (RG6179) is a monoclonal antibody targeting IL-6 that can be used to inhibit uveal macular edema (UME) and reduce retinal leakage. Vamikibart can reduce anterior chamber (AC) cell density, indicating a reduction in intraocular inflammation. Vamikibart can also be used to assess the leakage dynamics of ultra-wide-angle fluorescein angiography (UWFA) in the UME model to quantify changes in retinal leakage reflecting the effect of UME inhibition .
|
-
- HY-P99635
-
|
GZ-402668
|
NF-κB
|
Cancer
|
|
Gatralimab (GZ-402668) is an IgG1 anti-CD52 monoclonal antibody .
|
-
- HY-P99563
-
|
LY 3090106
|
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
|
|
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research .
|
-
- HY-P99437
-
|
KN-026
|
EGFR
|
Cancer
|
|
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .
|
-
- HY-P99852
-
|
ABT165; PR1283233
|
VEGFR
|
Cancer
|
|
Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.. Dilpacimab can be used in research of cancer .
|
-
- HY-P99715
-
|
|
EGFR
|
Cancer
|
|
Losatuxizumab is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .
|
-
- HY-P99619
-
|
SCT-I10A
|
PD-1/PD-L1
|
Cancer
|
|
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .
|
-
- HY-P99736
-
|
BI-754111
|
LAG-3
|
Cancer
|
|
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .
|
-
- HY-P99668
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
|
-
- HY-P99108
-
-
- HY-P99674
-
|
GEN-3009
|
Transmembrane Glycoprotein
|
Cancer
|
|
Ivicentamab (GEN-3009) is an IgG1κ-type bispecific antibody targeting different epitopes of CD37. Ivicentamab can be used for cancer research .
|
-
- HY-P9992
-
|
BAY-2315497; PSMA-TTC
|
PSMA
|
Inflammation/Immunology
|
|
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research .
|
-
- HY-P99393
-
|
MEDI 0562; Tavolimab
|
TNF Receptor
|
Cancer
|
|
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
|
-
- HY-P99618
-
|
IBI-315; BH2950
|
EGFR
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .
|
-
- HY-P9999
-
|
RG6102; RO-7126209
|
Amyloid-β
|
Neurological Disease
|
|
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .
|
-
- HY-P99454
-
|
ABBV-838
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .
|
-
- HY-P99453
-
|
|
ADC Antibody
|
Cancer
|
|
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
|
-
- HY-P99339
-
|
IMCgp100
|
Interleukin Related
TNF Receptor
|
Cancer
|
|
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .
|
-
- HY-P99011
-
|
|
CD3
|
Cancer
|
|
Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .
|
-
- HY-P99116
-
|
RG7716; RO-6867461
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
|
-
- HY-P99572
-
|
BNT-312; DuoBody-CD40x-4-1BB; GEN1042
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity .
|
-
- HY-P99694
-
|
JR-171
|
Transferrin Receptor
|
Neurological Disease
|
|
Lepunafusp alfa (JR-171) is a BBB-penetrable fusion protein consisting of J-Brain Cargo and IDUA (a lysosomal enzyme, α-L-iduronidase). Lepunafusp alfa can reduce concentration of heparan sulfate (HS) and dermatan sulfate (DS). Lepunafusp alfa can be used for research of mucopolysaccharidosis type I .
|
-
- HY-P99380
-
|
ZW 25
|
EGFR
|
Cancer
|
|
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .
|
-
- HY-P99623
-
|
MGD006; S80880
|
CD3
|
Cancer
|
|
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
|
-
- HY-P99470
-
|
GEN1029
|
TNF Receptor
Apoptosis
|
Cancer
|
|
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .
|
-
- HY-P99652
-
|
AK 111
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
|
-
- HY-P990722
-
-
- HY-P99455
-
|
EMB-01
|
EGFR
c-Met/HGFR
|
Cancer
|
|
Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity .
|
-
- HY-P99721
-
|
ABT-981
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis .
|
-
- HY-P99855
-
|
BCD-132
|
CD20
|
Inflammation/Immunology
|
|
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research .
|
-
- HY-P99671
-
|
M-6495
|
ADAMTS
|
Inflammation/Immunology
|
|
Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .
|
-
- HY-P99481
-
|
NEOD001
|
Amyloid-β
|
Neurological Disease
|
|
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
|
-
- HY-P99024
-
|
RO7082859; RG-6026
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
|
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .
|
-
- HY-P99941
-
|
INCMGA-00012; MGA-012
|
PD-1/PD-L1
|
Cancer
|
|
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
|
-
- HY-P99211
-
|
ChAglyCD3; TRX 4
|
CD3
|
Metabolic Disease
|
|
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .
|
-
- HY-P9940
-
|
ACE-910; RG6013
|
Factor VIII
|
Cardiovascular Disease
|
|
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .
|
-
- HY-P99903
-
|
IBI-322
|
PD-1/PD-L1
CD47
|
Inflammation/Immunology
Cancer
|
|
Simridarlimab (IBI-322) is a bispecific antibody targeting PD-L1 and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .
|
-
- HY-145626
-
|
BA302
|
ADC Antibody
ROR
|
Cancer
|
|
Ozuriftamab is a human IgG1 kappa antibody of ROR2. Ozuriftamab can be used to synthesize ADC such as Ozuriftamab vedotin (HY-145627). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99177
-
|
|
SARS-CoV
|
Infection
Cardiovascular Disease
|
|
Enibarcimab is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody, could be used for acute heart failure, COVID-19 infections and septic shock research .
|
-
- HY-P99708
-
|
ABBV-151; ARGX-115
|
TGF-beta/Smad
|
Cancer
|
|
Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors .
|
-
- HY-P990104
-
|
|
Notch
|
Inflammation/Immunology
Cancer
|
|
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.
|
-
- HY-P99803
-
|
VAL-1221
|
Glycosidase
|
Others
|
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
-
- HY-P99034
-
-
- HY-P99298
-
|
RG 7417; TNX 234; Anti-CFD Recombinant Antibody
|
Complement System
|
Inflammation/Immunology
|
|
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .
|
-
- HY-P99679
-
-
- HY-P99798
-
|
AMG 420; BI-836909
|
CD3
|
Cancer
|
|
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
|
-
- HY-P99676
-
|
SI-B001
|
EGFR
|
Cancer
|
|
Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
|
-
- HY-P99354
-
|
Anti-Human CTLA4xLAG3
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
|
-
- HY-P99896
-
|
BTRC-4017A; RG-6194
|
EGFR
CD3
|
Cancer
|
|
Runimotamab (RG-6194) is a HER2 and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99776
-
|
XmAb-13676
|
CD20
CD3
|
Cancer
|
|
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
|
-
- HY-P99575
-
|
AMG-757
|
Notch
|
Inflammation/Immunology
Cancer
|
|
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
|
-
- HY-P99675
-
|
AK112
|
PD-1/PD-L1
VEGFR
|
Cancer
|
|
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .
|
-
- HY-P99802
-
|
BAY 2010112; AMG 212; MT112
|
CD3
|
Cancer
|
|
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-P99814
-
|
AMG-701
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
|
-
- HY-P99523
-
|
AMG 199
|
CD3
|
Cancer
|
|
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-171135
-
|
|
Chromogenic Assays
|
|
Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonal antibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity .
|
-
- HY-164153
-
|
|
Chromogenic Assays
|
|
ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
-
- HY-164152
-
|
|
Chromogenic Assays
|
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-164152A
-
|
|
Chromogenic Assays
|
|
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-132253
-
|
|
Chromogenic Assays
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-132253A
-
|
|
Chromogenic Assays
|
|
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-164762
-
|
SHR-A1811
|
Chromogenic Assays
|
|
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .
|
-
- HY-138298A
-
|
DS-8201; DS-8201a
|
Chromogenic Assays
|
|
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
|
-
- HY-P99016A
-
|
|
Chromogenic Assays
|
|
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
|
-
- HY-P9994
-
|
SBT6050
|
Chromogenic Assays
Humanized Antibody
|
|
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .
|
-
- HY-P99016B
-
|
|
Chromogenic Assays
|
|
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
|
| Cat. No. |
Product Name |
Type |
-
- HY-NP160
-
|
|
Native Proteins
|
|
Recombinant Humanized Type I Collagen is a recombinant humanized collagen protein with has unique immunological features and plays an important role in the structure and function of skin, bones, tendons, etc .
|
-
- HY-NP162
-
|
|
Native Proteins
|
|
Recombinant Humanized Type XVII Collagen is a transmembrane protein that forms hemidesmosomes. Recombinant Humanized Type XVII Collagen facilitates interactions between stem cells，surrounding cells，and the extracellular matrix，thereby regulating skin homeostasis，aging，and wound healing. Recombinant Humanized Type XVII Collagen also possesses unique cell adhesion sites and signal transduction functions，which can regulate cell migration，proliferation，and differentiation .
|
-
- HY-NP132A
-
|
|
Native Proteins
|
|
Recombinant humanized type III collagen (MW 55900) is a type III collagen with a molecular weight of 55900 Da. Recombinant humanized type III collagen has various biological functions, such as promoting skin extracellular matrix regeneration and improving the cell microenvironment. Recombinant humanized type III collagen inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen functions in cell adhesion, migration, proliferation and differentiation through its interaction with integrins .
|
-
- HY-NP131
-
|
|
Native Proteins
|
|
Recombinant Humanized Type III Collagen 10.4kDa is a novel biomaterial that have anticancer effects. Recombinant Humanized Type III Collagen 10.4kDa activates discoidin domain receptor 1 (DDR1), and thus inhibits autophagy, proliferation, and migration of cancer cells, and induces apoptosis .
|
-
- HY-NP132
-
|
|
Native Proteins
|
|
Recombinant Humanized Type III Collagen 28.6kDa is a type III collagen 28.6kDa. Recombinant humanized type III collagen (rhCOLIII) has various biological functions, such as promoting skin extracellular matrix regeneration and improving the cell microenvironment. rhCOLIII inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen functions in cell adhesion, migration, proliferation and differentiation through its interaction with integrins .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10544
-
|
|
Interleukin Related
|
Others
|
|
Humanized anti-tac (HAT) binding peptide is a peptide that can specifically bind to the Fc region of HAT. HAT is a humanized monoclonal antibody against the low affinity p55 subunit of the interleukin IL-2 receptor. Humanized anti-tac (HAT) binding peptide can be used to develop affinity chromatography media to purify specific monoclonal antibodies .
|
-
- HY-P11084
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99888
-
|
|
EGFR
|
Others
|
|
Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .
|
-
- HY-P99868
-
|
MGD 011
|
CD19
CD3
|
Cancer
|
|
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .
|
-
- HY-P99212
-
|
TRU-016
|
Inhibitory Antibodies
|
Cancer
|
|
Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research .
|
-
- HY-P99267
-
|
RhuMab IFNalpha; Anti-Human IFN alpha Recombinant Antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Rontalizumab is a humanized IgG1 monoclonal antibody targets IFN-α. Rontalizumab can be used for the research of systemic lupus erythematosus[1].
|
-
- HY-P9990
-
-
- HY-P99026
-
|
TJ011133; TJC4
|
CD47
|
Cancer
|
|
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity .
|
-
- HY-P99269
-
|
BIBH 1; Anti-Human FAP Recombinant Antibody
|
FAP
|
Cancer
|
|
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
|
-
- HY-P99854
-
|
RC48-0
|
EGFR
ADC Antibody
|
Cancer
|
|
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
|
-
- HY-P99773
-
|
JS002
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .
|
-
- HY-P9969
-
|
EMD 72000
|
EGFR
|
Cancer
|
|
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab .
|
-
- HY-P9906A
-
|
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .
|
-
- HY-P990554
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
BHQ-880 is a humanized antibody expressed in CHO cells, targeting DKK1. The predicted molecular weight (MW) of BHQ-880 is 142.96 kDa. The isotype control for BHQ-880 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990571
-
|
|
CD19
|
Inflammation/Immunology
|
|
Coltuximab is a CHO-expressed humanized antibody that targets CD19. Coltuximab is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Coltuximab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99210
-
-
- HY-P99405
-
|
PRX 002; RG 7935; RO 7046015
|
α-synuclein
|
Neurological Disease
|
|
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
|
-
- HY-P990569
-
|
MK-6018
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
CM-24 is a humanized antibody expressed in CHO cells, targeting CEACAM1/CD66a. The predicted molecular weight (MW) of CM-24 is 145 kDa. The isotype control for CM-24 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990673
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 148.74 kDa. The isotype control for Vandortuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990631
-
|
|
Neuropeptide Y Receptor
|
Inflammation/Immunology
|
|
Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990651
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
PY314 is a humanized antibody expressed in CHO, targeting TREM2. PY314 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PY314 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990662
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sapelizumab is a CHO-expressed humanized antibody targeting IL-6Ra/CD126. Sapelizumab has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Sapelizumab can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990642
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Oportuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Oportuzumab contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Oportuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990318
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Alacizumab is a CHO-expressed humanized antibody that targets VEGFR2/KDR/CD309. Alacizumab contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.08 kDa. The isotype control for Alacizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990594
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
GSK-679586 is a CHO-expressed humanized antibody that targets IL-13. GSK-679586 is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GSK-679586 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990606
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
IMMU-114 is a CHO expressed humanized antibody that targets HLA-DR. IMMU-114 is composed of huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.1 kDa. The isotype control for IMMU-114 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990661
-
|
|
c-Met/HGFR
|
Inflammation/Immunology
|
|
SAIT-301 is a humanized antibody expressed in CHO cells, targeting HGFR/c-Met. SAIT-301 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for SAIT-301 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990628
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
MEDI-570 is a humanized antibody expressed in CHO that targets ICOS/CD278. MEDI-570 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for MEDI-570 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99859
-
|
LY3002813
|
Amyloid-β
|
Neurological Disease
|
|
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .
|
-
- HY-P990312
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ABT-325 is a humanized antibody expressed in CHO that targets IL-18. ABT-325 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.28 kDa. The isotype control for ABT-325 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990678
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Vonlerizumab is a CHO-expressed humanized antibody targeting TNFRSF4/OX40/CD134. Vonlerizumab carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Vonlerizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990650
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
PY159 is a humanized antibody expressed in CHO cells, targeting TREM1/CD354. PY159 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for PY159 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990602
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
IMA-026 is a humanized antibody expressed in CHO cells that targets IL-13. IMA-026 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.88 kDa. The isotype control for IMA-026 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990567
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Citatuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Citatuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.4 kDa. The isotype control for Citatuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990644
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
PDL-241 is a humanized antibody expressed in CHO that targets SLAMF7/CS1. PDL-241 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.38 kDa. The isotype control for PDL-241 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990590
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
GFB-024 is a CHO-expressed humanized antibody that targets CB1/CNR1. GFB-024 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GFB-024 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99015
-
|
|
TNF Receptor
|
Cancer
|
|
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .
|
-
- HY-P9960
-
|
2H7; PRO70769; RG1594
|
CD20
|
Inflammation/Immunology
|
|
Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .
|
-
- HY-P99021
-
|
LY 2951742
|
CGRP Receptor
|
Neurological Disease
|
|
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
|
-
- HY-P99264
-
|
Humanized Anti-CD22 Recombinant Antibody
|
ADC Antibody
CD22
Apoptosis
|
Cancer
|
|
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
|
-
- HY-P990656
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
RG-6125 is a humanized antibody expressed in CHO, targeting CDH11/Cadherin-11. RG-6125 has a huIgG2 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for RG-6125 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990573
-
|
RG-7636
|
Endothelin Receptor
|
Inflammation/Immunology
|
|
DEDN6526A (RG-7636) is a humanized antibody expressed in CHO cells, targeting ETBR. DEDN6526A (RG-7636) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for DEDN6526A (RG-7636) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990356
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD59 Antibody is a CHO-expressed humanized antibody that targets CD59. The Anti-CD59 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD59 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990634
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
NEO-201 is a humanized antibody expressed in CHO cells that targets CEACAM6/CD66c. NEO-201 features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.48 kDa. The isotype control for NEO-201 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990592
-
|
E-6071; HGS-1035
|
CCR
|
Inflammation/Immunology
|
|
GSK-3050002 (E-6071) is a CHO-expressed humanized antibody that targets CCL20. GSK-3050002 (E-6071) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GSK-3050002 (E-6071) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990311
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
AB-25E9 is a humanized antibody expressed in CHO, targeting Siglec-15/CD33L3. The predicted molecular weight (MW) of AB-25E9 is 150 kDa. The isotype control for AB-25E9 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99358
-
|
GSK 2398852; Anti-Serum Amyloid P/SAP Reference Antibody (dezamizumab)
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab triggers immunotherapeutic clearance of amyloid. Dezamizumab can be used in research of Amyloid light-chain (AL) amyloidosis .
|
-
- HY-P99372
-
|
Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)
|
ADC Antibody
|
Cancer
|
|
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .
|
-
- HY-P99310
-
|
RG4934
|
Interleukin Related
|
Inflammation/Immunology
|
|
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .
|
-
- HY-P990414
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-FGF19 Antibody (1A6) is a CHO-expressed humanized antibody that targets FGF19. Anti-FGF19 Antibody (1A6) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-FGF19 Antibody (1A6) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990613
-
|
CBA-1205
|
Notch
|
Inflammation/Immunology
|
|
LIV-1205 (CBA-1205) is a humanized antibody expressed in CHO cells that targets DLK1. LIV-1205 (CBA-1205) contains a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LIV-1205 (CBA-1205) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990612
-
|
AML-01
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
LGN-523 (AML-01) is a CHO-expressed humanized antibody that targets CD98. LGN-523 (AML-01) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for LGN-523 (AML-01) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990328
-
|
XT-M4
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99946
-
|
rhuMAb
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Erlizumab is a CHO-expressed humanized antibody that targets Integrin b2/ITGB2/CD18. Erlizumab is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Erlizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990595
-
|
|
Amyloid-β
|
Inflammation/Immunology
|
|
GSK-933776 is a humanized antibody expressed in CHO, targeting Amyloid Beta/Aβ. GSK-933776 has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.34 kDa. The isotype control for GSK-933776 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99442
-
|
Hu1D10
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
|
- HY-P9993
-
|
LY-3462817
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis. Peresolimab can be used in research of rheumatoid arthritis .
|
- HY-P99626
-
|
LY 3015014
|
PCSK9
|
Metabolic Disease
|
|
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
|
- HY-P990541
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99010
-
|
|
FGFR
|
Cancer
|
|
Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer .
|
- HY-P9988
-
|
BA301
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .
|
- HY-P9914
-
|
Anti-Human C5, Humanized Antibody; h5G1.1
|
Complement System
|
Cardiovascular Disease
Neurological Disease
|
|
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
|
- HY-P990596
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Hersintuzumab is a CHO-expressed humanized antibody targeting ERBB2/HER2/CD340. Hersintuzumab is equipped with a huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Hersintuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99043
-
|
|
Notch
|
Cancer
|
|
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .
|
- HY-P99106
-
- HY-P990526
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Anti-TNFRSF21/DR6/CD358 Antibody is a CHO-expressed humanized antibody that targets TNFRSF21/DR6/CD358. The Anti-TNFRSF21/DR6/CD358 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TNFRSF21/DR6/CD358 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99400
-
|
ALXN 6000
|
Inhibitory Antibodies
|
Cancer
|
|
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research .
|
- HY-P990363
-
|
PTA001_A4
|
Cadherin
|
Inflammation/Immunology
|
|
The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized antibody expressed in CHO cells, targeting CDH17/Cadherin-17. The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.12 kDa. The isotype control for the Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99153
-
|
MORAb-003
|
Antibiotic
|
Cancer
|
|
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
|
- HY-P990320
-
|
TNX-832
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
ALT-836 (TNX-832) is a humanized antibody expressed in CHO cells, targeting F3/Factor III/Tissue Factor/CD142. ALT-836 (TNX-832) has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for ALT-836 (TNX-832) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P99166
-
|
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
|
- HY-P99118
-
|
HLX 10
|
PD-1/PD-L1
Akt
STAT
|
Cancer
|
|
Serplulimab (HLX 10) is a humanized anti-PD-1 monoclonal antibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer .
|
- HY-P99027
-
|
LAG525; IMP701; Hu5A8
|
LAG-3
|
Cancer
|
|
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
|
- HY-P991159
-
|
|
EGFR
|
Cancer
|
|
Ruzaltatug is a humanized IgG1 antibody targeting ERBB3. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990667
-
|
|
Integrin
|
Inflammation/Immunology
|
|
STX-100 is a humanized antibody expressed in HEK293 cells, targeting Integrin aVb6 (ITGAV & ITGB6). STX-100 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.12 kDa. The isotype control for STX-100 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P9950
-
|
Olizumab; rhuMab-E25; IGE25; RG-3648
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research . The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.
|
- HY-P99227
-
|
ALX-0681; ALX-0081
|
Integrin
Transmembrane Glycoprotein
|
Cardiovascular Disease
|
|
Caplacizumab (ALX-0681) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the binding of vWF with platelet glycoprotein (GP) Ibα. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP) .
|
- HY-P99313
-
|
Anti-Human IGHE Recombinant Antibody
|
Apoptosis
|
Inflammation/Immunology
|
|
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
|
- HY-P99507
-
|
MCLA-128; PB4188; R040517
|
EGFR
|
Cancer
|
|
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3 .
|
- HY-P99044
-
|
MBG453
|
Tim3
|
Inflammation/Immunology
|
|
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .
|
- HY-P99962
-
|
BGB-A425
|
Mucin
|
Cancer
|
|
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
|
- HY-P99396
-
|
BI 655130
|
Interleukin Related
|
Inflammation/Immunology
|
|
Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways .
|
- HY-P99656
-
|
MCDS0593A
|
ADC Antibody
|
Cancer
|
|
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
- HY-P991132
-
|
|
VEGFR
|
Cardiovascular Disease
Cancer
|
|
Efclarofusp alfa is a CHO-expressed humanized antibody consisting of VEGFR-1 and VEGFR-2 regions fused to human IgG1 Fc. Efclarofusp alfa is an angiogenesis inhibitor .
|
- HY-P9947
-
|
|
Integrin
|
Others
|
|
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .
|
- HY-P9945
-
|
SB 240563
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
- HY-P99403
-
|
GSK249320
|
Inhibitory Antibodies
|
Neurological Disease
|
|
Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke .
|
- HY-P99019
-
|
TEV-48125; LBR-101; PF-04427429; RN-307
|
CGRP Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC50 values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC50 value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine .
|
- HY-P99329
-
|
Anti-Human CD33 Recombinant Antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .
|
- HY-P99854A
-
|
RC48-0 (powder)
|
EGFR
ADC Antibody
|
Cancer
|
|
Disitamab (RC48-0) (powder) is a humanized monoclonal antibody targeting HER2. Disitamab (powder) can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
|
- HY-P9945A
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
- HY-P99613
-
|
MK-4280
|
LAG-3
|
Cancer
|
|
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902). Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P991131
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Daretabart is a humanized IgG1K antibody targeting GD2, which can be used for anti-tumor research. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .
|
- HY-P99379
-
|
CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)
|
Interleukin Related
|
Cancer
|
|
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
|
- HY-P99045
-
|
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
|
- HY-P991548
-
|
|
CD20
|
Inflammation/Immunology
Cancer
|
|
BLX-301 is a humanized monoclonal antibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis .
|
- HY-P99315
-
|
BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99804
-
|
MK1654
|
RSV
|
Infection
|
|
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody against the protein F of respiratory syncytial virus (RSV) with an extended half-life. Clesrovimab can bind to the conserved site IV of the RSV F glycoprotein and neutralize various strains containing RSV F. Clesrovimab can be used in the research of RSV diseases .
|
- HY-P99374
-
|
Anti-TSPAN26/CD37 Reference Antibody (naratuximab)
|
ADC Antibody
|
Cancer
|
|
Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine .
|
- HY-P99264A
-
|
Humanized Anti-CD22 Recombinant Antibody (powder)
|
ADC Antibody
CD22
Apoptosis
|
Cancer
|
|
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
x
|
- HY-P991236
-
|
DHES0815A antibody; RG-6148 antibody
|
EGFR
DNA Alkylator/Crosslinker
|
Cancer
|
|
MHES0488A is a selective humanized antibody that targets HER2 with a KD value of 0.8 nM. MHES0488A is an antibody part of DHES0815A. MHES0488A is internalized by cells and transported to lysosomes, and then releases PBD-monoamide that enters the nucleus, alkylates DNA and induces DNA damage and apoptosis. MHES0488A is promising for research of cancers, such as HER2-positive breast cancer and gastric cancer .
|
- HY-P99961
-
|
JS004; Icatolimab
|
CD28
|
Cancer
|
|
Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer, such as lymphoma and non-small cell lung cancer (NSCLC) .
|
- HY-P990038
-
- HY-P99319
-
- HY-P99475
-
|
MSB-2311
|
PD-1/PD-L1
|
Cancer
|
|
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .
|
- HY-P99206
-
|
Naxitamab-gqgk; Humanized 3F8; Hu3F8
|
Inhibitory Antibodies
|
Cancer
|
|
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers .
|
- HY-P990011
-
- HY-P99451
-
- HY-P9906
-
|
Anti-Human VEGF, Humanized Antibody
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
|
- HY-P99316
-
|
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
|
- HY-P990020
-
|
|
c-Kit
|
Others
|
|
Eglatoprutug is an humanized immunoglobulin G1-kappa, anti-c-Kit monoclonal antibody .
|
- HY-P990045
-
- HY-P990082
-
|
|
VEGFR
|
Cancer
|
|
Suvemcitug is a humanized IgG1κ antibody targeting VEGF derived from the African hare (Oryctolagus cuniculus) .
|
- HY-P99558
-
|
GEXMab73; GT-MAb7.3-GEX; TrastuzuMab-GEX
|
EGFR
|
Cancer
|
|
Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer .
|
- HY-P990039
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Falbikitug is a humanized immunoglobulin G1-kappa, anti-LIF monoclonal antibody. Falbikitug is an antineoplastic .
|
- HY-P9910
-
|
GA101; Anti-Human CD20 type II, Humanized Antibody
|
CD20
|
Cancer
|
|
Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
|
- HY-P990901
-
- HY-P99968
-
|
|
Mucin
|
Cancer
|
|
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers .
|
- HY-P99295
-
|
RG 7160; RO 5083945; Anti-EGFR Recombinant Antibody
|
EGFR
|
Cancer
|
|
Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .
|
- HY-P9981
-
|
XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .
|
- HY-P99801
-
- HY-P990089
-
- HY-P991587
-
|
|
Orphan GPCR
|
Cancer
|
|
SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
|
- HY-P990048
-
|
|
CTLA-4
|
Cancer
|
|
Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody. Muzastotug is an immunostimulant and antineoplastic .
|
- HY-P9911
-
|
Anti-Human lymphocyte α4β7 integrin, Humanized Antibody; LDP-02; MLN-002
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
|
- HY-P99869
-
|
|
Interleukin Related
|
Others
|
|
Ebdarokimab (AK101) is a humanized IgG1-κ antibody, usually expressed in CHO (Chinese Hamster Ovary) cells .
|
- HY-P99018
-
- HY-P99430
-
|
EM901; CC-93269
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99938
-
|
HX008
|
PD-1/PD-L1
|
Cancer
|
|
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor .
|
- HY-P9912
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
- HY-P990040
-
|
LVGN-6051
|
TNF Receptor
|
Cancer
|
|
Exlinkibart (LVGN-6051) targets TNFRSF9 and is an IgG1κ antibody humanized through complementarity-determining region (CDR) grafting technology.
|
- HY-P99866
-
|
MEHD-7945A; RG 7597
|
EGFR
|
Others
|
|
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody that specifically targets Her3 (ErbB3) .
|
- HY-P99292
-
|
HuZAF; Anti-Human IFNG Recombinant Antibody
|
IFNAR
|
Inflammation/Immunology
|
|
Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
|
- HY-P99796
-
|
ATN-103; PF-5230896
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis .
|
- HY-P9902
-
|
MK-3475; Lambrolizumab
|
PD-1/PD-L1
|
Cancer
|
|
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
|
- HY-P99658
-
|
PRX-003
|
Inhibitory Antibodies
|
Cancer
|
|
Imaprelimab (PRX-003) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody. Imaprelimab is an antineoplastic agent .
|
- HY-P9912A
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
- HY-P9904
-
|
MPDL3280A; RG-7446; RO-5541267
|
PD-1/PD-L1
Apoptosis
Autophagy
|
Cancer
|
|
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
|
- HY-P990016
-
- HY-P9982
-
|
AMG-785; CDP-7851
|
Inhibitory Antibodies
|
Endocrinology
Cancer
|
|
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis .
|
- HY-P9997
-
|
ANB030
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .
|
- HY-P990081
-
|
TB-006
|
Inhibitory Antibodies
|
Neurological Disease
|
|
Oloctinebart is a humanized immunoglobulin G4-kappa, anti-LGALS3 monoclonal antibody. Oloctinebart is used for reduction of amyloid beta oligomers formation .
|
- HY-P99570
-
|
GBR-830
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Telazorlimab (GBR-830) is a humanized monoclonal antibody against OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for the research of autoimmune diseases .
|
- HY-P990042
-
|
ONC-392; BNT 316
|
CTLA-4
|
Cancer
|
|
Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment .
|
- HY-P99317
-
|
LY-2062430
|
Amyloid-β
|
Neurological Disease
|
|
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease .
|
- HY-P99884
-
|
PF-06801591
|
PD-1/PD-L1
|
Others
Cancer
|
|
Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells .
|
- HY-P99017
-
|
ALD-403
|
CGRP Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab can be used in the study of preventing migraines .
|
- HY-P99835
-
|
MABT 5102A; RG 7412
|
Amyloid-β
|
Neurological Disease
|
|
Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonal antibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research .
|
- HY-P9917
-
|
Anti-Human IL6R, Humanized Antibody; RG-1569; rhPM-1
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
|
- HY-P990092
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. Rolistobart is an immunostimulant and antineoplastic .
|
- HY-P99571
-
|
INH-H 2002
|
Inhibitory Antibodies
|
Infection
|
|
Tefibazumab is a humanized IgG1κ monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A. Tefibazumab can be used for the research of serious Staphylococcus aureus infections .
|
- HY-P99589
-
|
16B5; AB-16B5
|
Apoptosis
|
Cancer
|
|
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
|
- HY-P99828
-
|
PF-06523435; hu24
|
RET
|
Others
Cancer
|
|
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is usually CHO (Chinese Hamster Ovary) cells .
|
- HY-P990028
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Raludotatug is a humanized anti-CDH6 IgG1 monoclonal antibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734) .
|
- HY-P99906
-
|
DKN-01; LY-2812176
|
β-catenin
|
Cancer
|
|
Sirexatamab (DKN-01) is a humanized IgG4 monoclonal antibody that can bind to and neutralize circulating DKK1. Sirexatamab exhibits antitumor activity in tumor models expressing DKK1 .
|
- HY-P99370
-
|
LY2495655; Anti-GDF8 / Myostatin Reference Antibody (landogrozumab)
|
TGF-beta/Smad
|
Inflammation/Immunology
Cancer
|
|
Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease .
|
- HY-P990036
-
|
PF-06823859
|
IFNAR
|
Inflammation/Immunology
|
|
Dazukibart (PF-06823859) is a potent, selective humanized IgG1 neutralizing monoclonal antibody that targets interferon β (IFNβ). Dazukibart can be used in the study of moderate to severe dermatomyositis .
|
- HY-P99644
-
ACT017
1 Publications Verification
|
Glycoprotein VI
|
Cardiovascular Disease
|
|
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke .
|
- HY-P990933
-
- HY-P990926
-
- HY-P990906
-
- HY-P99181
-
- HY-P99857
-
|
PF-06252616
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
|
- HY-108739
-
|
BI 655075
|
Thrombin
|
Cardiovascular Disease
|
|
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
|
- HY-P990077
-
|
CT-011; MDV9300
|
PD-1/PD-L1
|
Cancer
|
|
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research .
|
- HY-P990936
-
- HY-P990995
-
|
|
Tau Protein
|
Inflammation/Immunology
|
|
HY-P990995 is an MAPT-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9966
-
|
MGA271
|
CD276/B7-H3
|
Cancer
|
|
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators .
|
- HY-P99003
-
- HY-P99491
-
|
AVTX-007; CERC-007; MEDI 2338
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab specifically binds IL-18 and blocks the interaction of IL-18 with its receptor. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma .
|
- HY-P9952
-
|
LymphoStat B
|
TNF Receptor
CD20
|
Inflammation/Immunology
Cancer
|
|
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research . The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.
|
- HY-P990051
-
- HY-P99401
-
|
OMP-131R10
|
Wnt
|
Cancer
|
|
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors .
|
- HY-P991215
-
|
|
HPV
|
Infection
|
|
Anti-HPV18 L1 Antibody (H18L1-A) is a humanized antibody targeting the L1 protein of human papillomavirus type 18 (HPV18). Anti-HPV18 L1 Antibody (H18L1-A) blocks the binding of the HPV18 virus to cell surface receptors, neutralizing the virus activity, and thus inhibiting the virus from infecting cells. Anti-HPV18 L1 Antibody (H18L1-A) is promising for research of human papillomavirus-related diseases .
|
- HY-P99949
-
|
OMP-313M32
|
Inhibitory Antibodies
|
Cancer
|
|
Etigilimab (OMP-313M32), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (CD155; poliovirus receptor) and inhibits downstream signalling with target cell killing .
|
- HY-P990034
-
|
MLTA3698A; RG7415; PRO283698
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Pateclizumab (MLTA3698A) is a humanized antibody against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis .
|
- HY-P990961
-
|
IMM-2510; SYN-2510
|
VEGFR
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Palverafusp alfa is an VEGFA/PDCD1-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99308
-
|
AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody
|
CD20
|
Cancer
|
|
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
|
- HY-P991013
-
- HY-P990979
-
- HY-P990904
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990904 is an CCR8-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990984
-
- HY-P991038
-
|
|
CD28
|
Inflammation/Immunology
|
|
HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990919
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P990919 is an TNFRSF4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990993
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
HY-P990993 is an GDF8-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990960
-
- HY-P990931
-
- HY-P991014
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P991014 is an TNFRSF17-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990946
-
- HY-P99365
-
|
ALXN1210
|
Complement System
|
Metabolic Disease
|
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
|
- HY-P990945
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
HY-P990945 is an CTLA4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99452
-
|
SNDX-6352
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases .
|
- HY-P990978
-
|
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990978 is an ERBB2-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99560
-
|
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
|
- HY-P991026
-
- HY-P990930
-
|
|
CD22
|
Inflammation/Immunology
|
|
HY-P990930 is an CD22-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990949
-
|
YYB-101; ABX101
|
c-Met/HGFR
|
Inflammation/Immunology
|
|
HY-P990949 is an HGF-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P99634
-
|
PankoMab
|
Mucin
|
Cancer
|
|
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) .
|
- HY-P990027
-
|
IMGC-936 antibody; MGA021
|
ADC Antibody
MMP
|
Cancer
|
|
Izeltabart (MGA021) is a humanized IgG1 monoclonal antibody targeting ADAM9, which can be used as an ADC Antibody to synthesize the ADC molecule IMGC936 (Izeltabart Tapatansine). Izeltabart can be used in the study of cancer .
|
- HY-P99471
-
|
UCB 0107
|
Tau Protein
|
Neurological Disease
|
|
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody. Bepranemab targets the central portion of tau, specifically amino acids 235 to 246. Bepranemab can be used for Alzheimer’s disease (AD) research .
|
- HY-P990962
-
|
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990962 is an EGFR/CD47-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9944
-
|
MEDI 493
|
RSV
|
Infection
Inflammation/Immunology
Cancer
|
|
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice .
|
- HY-P990994
-
|
HFB-200301
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P990994 is an TNFRSF1B-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99185
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .
|
- HY-P99250
-
|
MetMAb
|
c-Met/HGFR
|
Cancer
|
|
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .
|
- HY-P990667B
-
|
|
Integrin
|
Inflammation/Immunology
|
|
STX-100 (Biotinylated) is a biotin-labeled STX-100 (HY-P990667). STX-100 is a humanized antibody expressed in HEK293 cells, targeting Integrin aVb6 (ITGAV & ITGB6) .
|
- HY-P9907A
-
|
Anti-Human HER2, Humanized Antibody (PBS)
|
ADC Antibody
EGFR
|
Cancer
|
|
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
|
- HY-P991000
-
- HY-P991001
-
- HY-P990072
-
|
LZM-009
|
PD-1/PD-L1
|
Cancer
|
|
Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .
|
- HY-P991029
-
- HY-P99363
-
|
Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609
|
Transmembrane Glycoprotein
|
Cancer
|
|
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer .
|
- HY-P99270
-
|
CS-1008; Anti-Human TRAIL-R2 Recombinant Antibody
|
Apoptosis
|
Cancer
|
|
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
|
- HY-P99439
-
|
IMA-638
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma .
|
- HY-P99281
-
|
BIWA 4; Anti-CD44 Recombinant Antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells .
|
- HY-P9911A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
|
- HY-P99476
-
|
|
VEGFR
|
Cancer
|
|
ABP 215 (Bevacizumab-awwb), a Bevacizumab (HY-P9906) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA. ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research .
|
- HY-P99965
-
|
SKY59; RO7112689; RG-6107
|
Complement System
|
Cardiovascular Disease
Metabolic Disease
|
|
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
|
- HY-P99892
-
|
PR-1594407; DC-1630423
|
EGFR
|
Others
|
|
Serclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells .
|
- HY-P990019
-
- HY-P990070
-
|
BION-1301
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Zigakibart (BION-1301) is an IgG4-kappa, anti-TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256) humanized monoclonal antibody. Zigakibart shows anti-inflammatory activity .
|
- HY-P9953
-
|
Certolizumab; CDP870
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
|
- HY-P99904
-
|
MEDI-507
|
CD2
|
Inflammation/Immunology
Cancer
|
|
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells .
|
- HY-P9975
-
|
TGN1412; TAB08
|
CD28
|
Inflammation/Immunology
|
|
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .
|
- HY-P99539
-
|
REGN4018
|
CD3
|
Cancer
|
|
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity .
|
- HY-P990018
-
- HY-P99834
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Crefmirlimab is a humanized CD8 specific minibody. The minibody (Mb) maintains the specificity of full-length antibodies but has no immune effector functions and is biologically inert .
|
- HY-P991019
-
- HY-P990910
-
- HY-P99540
-
|
PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105
|
CTLA-4
|
Cancer
|
|
Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99028
-
|
TMB-355; TNX-355
|
HIV
|
Infection
|
|
Ibalizumab (TMB-355) is a humanized anti-CD4 IgG4 monoclonal antibody. Ibalizumab prevents HIV cell entry by binding to CD4 receptor. Ibalizumab can be used for the research of infection, such as HIV-1 infection .
|
- HY-P99858
-
|
AB154
|
Transmembrane Glycoprotein
|
Cancer
|
|
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
|
- HY-P990983
-
- HY-P99192
-
|
LY2875358
|
c-Met/HGFR
|
Cancer
|
|
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .
|
- HY-P99886
-
|
h5G1. 1-SC
|
Complement System
Apoptosis
|
Cardiovascular Disease
Neurological Disease
|
|
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .
|
- HY-P99172
-
|
|
CD47
Interleukin Related
|
Cancer
|
|
CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
|
- HY-P990956
-
- HY-P99112
-
|
RG-6168; SA-237
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Satralizumab is a humanized monoclonal antibody that targets IL-6R. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research .
|
- HY-P99883
-
|
SAR156597
|
Interleukin Related
|
Others
|
|
Romilkimab (SAR156597) is a chimeric humanized IG antibody that specifically targets IL-4 and IL13 .
|
- HY-P990764B
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Sigvotatug (Biotinylated) is a biotinylated derivative of Sigvotatug (HY-P990764). Sigvotatug (Biotinylated) is a humanized IgG1 κ monoclonal antibody inhibitor against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991050
-
|
AK-1967
|
Dipeptidyl Peptidase
|
Inflammation/Immunology
|
|
Procizumab (AK-1967) is a humanized IgG1 antibody that targets dipeptidyl peptidase 3 (DPP3). Procizumab has the potential for the study of sepsis. The isotype control for Procizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99327
-
|
BT-061
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies .
|
- HY-P99224
-
|
IMMU-106; hA20
|
Integrin
|
Cancer
|
|
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .
|
- HY-P99633
-
|
BGB-A333
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
|
- HY-P990899
-
|
|
CD47
|
Inflammation/Immunology
|
|
HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
- HY-P99368
-
|
MCS110
|
c-Fms
|
Metabolic Disease
Cancer
|
|
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
|
- HY-P990007
-
|
PRA023; PRA-023
|
TNF Receptor
|
Inflammation/Immunology
|
|
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis .
|
- HY-P991024
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P991024 is an CD274/TNFRSF9-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P99215
-
|
Anti-EGFL7; RG 7414
|
VEGFR
|
Cancer
|
|
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .
|
- HY-P99763
-
|
BGB-A1217
|
Inhibitory Antibodies
|
Cancer
|
|
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer .
|
- HY-P99404
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion .
|
- HY-P99544
-
|
HBM-9167; KL-A167
|
PD-1/PD-L1
|
Cancer
|
|
Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) .
|
- HY-P990022
-
|
DS-6016A
|
TGF-β Receptor
|
Metabolic Disease
|
|
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonal antibody. Prafnosbart can be used for bone metabolism disorders research .
|
- HY-P990088
-
|
|
VEGFR
PD-1/PD-L1
|
Cardiovascular Disease
|
|
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker 101GGSGGSGGSGGSGGS 115 to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor .
|
- HY-P991432
-
|
|
TNF Receptor
NF-κB
c-Myc
|
Cancer
|
|
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
|
- HY-P99697
-
|
PRO 140
|
CCR
HIV
|
Infection
Cancer
|
|
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .
|
- HY-P990969
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990969 is an CD3E/CD4-targeting IgG1 λ1 type humanized antibody, the recommed isotype control is Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
- HY-P99576
-
|
OG1953
|
VEGFR
|
Others
|
|
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
|
- HY-P990049
-
|
JMT-101
|
EGFR
|
Cancer
|
|
Becotatug (JMT-101) is a humanized IgG1 antibody targeting EGFR. Becotatug can also be conjugated to Afatinib (HY-10261) and Osimertinib (HY-15772) as a synthetic ADC. Becotatug can be used for the study of EGFR-mutated advanced non-small cell lung cancer (NSCLC) .
|
- HY-P99162
-
|
CIM331; CD14152
|
Interleukin Related
|
Inflammation/Immunology
|
|
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
|
- HY-P99417
-
|
UCB4144; VR 942
|
Interleukin Related
|
Inflammation/Immunology
|
|
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma .
|
- HY-P99412
-
|
OSE-127
|
Interleukin Related
|
Cancer
|
|
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .
|
- HY-P99221
-
|
RN-624; PF 4383119
|
Trk Receptor
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia .
|
- HY-P99282
-
|
VB6-845; Anti-Human EpCAM Recombinant Antibody Fab Fragment, 17-1A
|
Apoptosis
|
Cancer
|
|
Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models .
|
- HY-P991051
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
GSK-2330811 is a humanized IgG1 antibody that targets Oncostatin M (OSM). GSK-2330811 has the potential for the study of diffuse cutaneous systemic sclerosis (dcSSc). The isotype control for GSK-2330811 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99443
-
|
HuDreg-55
|
P-selectin
|
Inflammation/Immunology
|
|
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma .
|
- HY-P9951A
-
|
RG-6321 (anti-VEGF)
|
VEGFR
|
Cardiovascular Disease
|
|
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
|
- HY-P99013
-
|
GC33; RO5137382
|
Glycoprotein VI
|
Cancer
|
|
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
|
- HY-P99241
-
|
PF 06946860
|
TGF-beta/Smad
|
Cancer
|
|
Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 monoclonal antibody with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers .
|
- HY-P991074
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
GMA-161 is a humanized IgG1 antibody that targets Fcγ receptor III (CD16). GMA-161 has the potential for the study of autoimmune disorders. The isotype control for GMA-161 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9979
-
|
UCB7665
|
TNF Receptor
|
Inflammation/Immunology
|
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
|
- HY-P99849
-
|
ABT-806
|
EGFR
|
Cancer
|
|
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .
|
- HY-P991674
-
|
BJT-778
|
HBV
|
Infection
Inflammation/Immunology
|
|
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug has significant antiviral activity, and neutralizes and removes HBV and HDV as well as depleting HBsAg-containing subviral particles. Brelovitug can be used for HDV and HBV infections, chronic hepatitis delta (CHD) and chronic hepatitis B (CHB) research .
|
- HY-P99371
-
|
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
- HY-P9968
-
|
h-R3
|
EGFR
|
Cancer
|
|
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
- HY-P991052
-
|
|
TNF Receptor
|
Cancer
|
|
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991066
-
|
|
nAChR
|
Neurological Disease
|
|
ARGX-119 is a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
- HY-P99345
-
|
TSR-042; ANB-011; WBP-285
|
PD-1/PD-L1
|
Cancer
|
|
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
|
- HY-P99767
-
|
ALXN1007; Lendalizumab
|
Complement System
|
Infection
|
|
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus .
|
- HY-P99778
-
|
MORAb-004
|
EGFR
|
Cancer
|
|
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer .
|
- HY-P99649
-
|
MEDI3902
|
Bacterial
|
Infection
|
|
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections .
|
- HY-P99702
-
|
BCD-089
|
Interleukin Related
|
Inflammation/Immunology
|
|
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
|
- HY-P99256
-
|
SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
|
- HY-P99161
-
|
BGB149
|
TAM Receptor
|
Cancer
|
|
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas .
|
- HY-P99230
-
|
|
Integrin
CD22
|
Cancer
|
|
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99032
-
|
IPH2201
|
Checkpoint Kinase (Chk)
IFNAR
|
Inflammation/Immunology
Cancer
|
|
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
|
- HY-P990958
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
HY-P990958 is an T cell receptor germline-encoded variable chain Vβ6/β10-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9978
-
|
JS-001
|
PD-1/PD-L1
|
Cancer
|
|
Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
|
- HY-P99045A
-
|
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
|
- HY-P99051
-
|
BAY 1834942
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system .
|
- HY-P99843
-
|
|
TROP2
ADC Antibody
|
Cancer
|
|
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .
|
- HY-P990902
-
|
BMS-986012
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
HY-P990902 is an Fucosyl ganglioside GM1 (fuc-GM1)-targeting IgG1κ type humanized antibody. Atigotatug can induce immune-mediated tumor cell death, such as small cell lung cancer . The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001)
|
- HY-P9902A
-
|
MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)
|
PD-1/PD-L1
|
Cancer
|
|
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 .
|
- HY-P99285
-
|
hBU 12
|
ADC Antibody
CD19
|
Cancer
|
|
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .
|
- HY-P990925
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990925 is an CD3E-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9907
-
Trastuzumab
Maximum Cited Publications
49 Publications Verification
Anti-Human HER2, Humanized Antibody
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
ADC Antibody
|
Cancer
|
|
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
|
- HY-P99302
-
|
Humanized Anti-CD28 Recombinant Antibody
|
CD28
|
Inflammation/Immunology
|
|
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft .
|
- HY-P99391
-
|
ABT-700
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
|
- HY-P990008
-
Atrosab
1 Publications Verification
|
TNF Receptor
Apoptosis
|
Inflammation/Immunology
|
|
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9949
-
|
Sch 55700; CDP-835; JES1-39D10
|
Interleukin Related
|
Inflammation/Immunology
|
|
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
|
- HY-P9972
-
|
PDR001
|
PD-1/PD-L1
|
Cancer
|
|
Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody. Spartalizumab binds to PD-1 at picomolar affinity and blocks the interactions with PD-L1 and PD-L2, thereby relieving the inhibition on T cell activity and restoring the immune system's ability to attack tumors. Spartalizumab can be used in the research of undifferentiated thyroid carcinoma (ATC) and neuroendocrine tumors (NENs) .
|
- HY-P991041
-
|
Anti-SEZ6 Antibody (SC17); ABBV-011 antibody; ABBV-706 antibody
|
ADC Antibody
|
Cancer
|
|
Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99731
-
|
hLL1; MEDI-115
|
CD74
|
Cancer
|
|
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death .
|
- HY-P99169
-
|
TJ004309
|
CD73
|
Cancer
|
|
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
|
- HY-P99234
-
|
|
Interleukin Related
ADC Antibody
|
Cancer
|
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
- HY-P990980
-
- HY-P99901
-
|
VIS649
|
SARS-CoV
|
Inflammation/Immunology
Cancer
|
|
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) .
|
- HY-P991062
-
|
Gensci-059
|
CD47
|
Cancer
|
|
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990061
-
|
JTX 8064
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .
|
- HY-P99399
-
|
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
- HY-P99891
-
|
Hu23F2G
|
Integrin
|
Cardiovascular Disease
|
|
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .
|
- HY-P99737
-
|
LY3074828
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
|
- HY-P99252
-
|
Anti-Human CD6 Recombinant Antibody
|
CD6
|
Infection
Inflammation/Immunology
|
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
|
- HY-P99746
-
|
3C23K; GM102
|
TGF-β Receptor
|
Inflammation/Immunology
Cancer
|
|
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming .
|
- HY-P99293
-
|
IDEC 114; Anti-Human CD80 Recombinant Antibody
|
CD28
Apoptosis
|
Cancer
|
|
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
|
- HY-P9924
-
|
LY2439821
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
|
- HY-P99659
-
|
ANB 019
|
Interleukin Related
|
Inflammation/Immunology
|
|
Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases .
|
- HY-P9948
-
|
Campath-IH
|
Apoptosis
|
Cancer
|
|
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
|
- HY-P9983
-
|
SGN-33; HuM-195
|
Transmembrane Glycoprotein
Radionuclide-Drug Conjugates (RDCs)
|
Inflammation/Immunology
|
|
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .
|
- HY-108831
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
|
- HY-P99236
-
|
FP-1305
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma .
|
- HY-P99727
-
|
CTB012
|
RABV
|
Infection
|
|
Mazorelvimab (CTB012) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Mazorelvimab binds to highly discontinuous conserved residues that are not in or near antigenic site III. Mezagitamab has potential application in the prevention of rabies .
|
- HY-P99422
-
|
SHR-1316
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
|
- HY-P99369
-
|
IPH 4102; Anti-KIR3DL2/CD158k Reference Antibody (lacutamab)
|
Inhibitory Antibodies
|
Cancer
|
|
Lacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma .
|
- HY-P99050
-
|
BIVV009; IPN-009; TNT009
|
Complement System
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome .
|
- HY-P990025
-
|
ARGX-117
|
Complement System
|
Inflammation/Immunology
|
|
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .
|
- HY-P99325
-
|
IDEC-131; Anti-Human CD40 ligand Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
|
|
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
|
- HY-P99284
-
|
MK-0646; h7C10
|
IGF-1R
Apoptosis
|
Cancer
|
|
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .
|
- HY-P99639
-
|
Genolimzumab; APL-501; CBT-501; GB-226
|
PD-1/PD-L1
|
Cancer
|
|
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
|
- HY-P99970
-
|
|
ADC Antibody
Sodium Phosphate Cotransporter
|
Cancer
|
|
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99781
-
|
MLN-1202
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab can also improve synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-108831A
-
|
AN100226; BG00002
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab (Solution) (AN100226; BG00002) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
|
- HY-P99875
-
|
BIVV-001; Altuvoct
|
Inhibitory Antibodies
|
Cardiovascular Disease
|
|
Efanesoctocog alfa is a B domain-deleted single-chain Factor VIII (FVIII) connected to D'D3 domain of von Willebrand Factor (vWF). Efanesoctocog alfa has an extended half-life. Efanesoctocog alfa can be used for the study of inherited hemophilia A .
|
- HY-P99877
-
|
AMG592
|
Inhibitory Antibodies
|
Others
|
|
Efavaleukin alfa (AMG592) is a human monoclonal antibody. Efavaleukin alfa is composed of the IGHG1 Fc fragment fused to IL-2. The expression system of Efavaleukin alfa is usually CHO (Chinese Hamster Ovary) cells .
|
- HY-P991230
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
MK-4830 is a fully humanized monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to ILT4 and blocks its interaction with HLA-G and other ligands. MK-4830 inhibits tumor growth in humanized mouse cancer models .
|
- HY-P990071
-
|
|
EGFR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP) .
|
- HY-P99822
-
|
SHR-1209
|
PCSK9
LDLR
|
Metabolic Disease
|
|
Recaticimab (SHR-1209) is an orally active humanized monoclonal IgG1 antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia .
|
- HY-P99029
-
|
Hu5F9-G4
|
CD47
|
Cancer
|
|
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer .
|
- HY-P99829
-
|
PF-06647020; ABBV-647; h6M24-vc0101
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .
|
- HY-P99025
-
|
TNX-650; MILR1444A; RG3637
|
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases .
|
- HY-P99176
-
ATG-031
3 Publications Verification
|
Inhibitory Antibodies
|
Cancer
|
|
ATG-031 is a humanized anti-CD24 monoclonal antibody with high affinity and specificity. ATG-031 interacts with Siglec-10 expressed by tumor-associated macrophages. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the anti-phagocytic surface proteins. ATG-031 can be used in the study of haematological malignancies as well as solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P99304
-
|
Anti-Human ERBB3 Recombinant Antibody
|
EGFR
PI3K
Akt
p38 MAPK
|
Cancer
|
|
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer .
|
- HY-P991181
-
- HY-P990714
-
|
|
CD3
|
Inflammation/Immunology
|
|
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
|
- HY-P99397
-
|
ALX 0761; M 1095
|
Interleukin Related
MMP
|
Inflammation/Immunology
|
|
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis .
|
- HY-P99300
-
|
QGE 031; Anti-IGHE Recombinant Antibody
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .
|
- HY-P99361
-
|
PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)
|
TNF Receptor
|
Cancer
|
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
|
- HY-P99229
-
|
|
ADC Antibody
|
Cancer
|
|
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99385
-
|
ALX-0061
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
|
- HY-P99614
-
|
BFKB8488A; RG-7992; RO-7040551
|
FGFR
|
Metabolic Disease
|
|
Fazpilodemab (BFKB8488A) is a humanized bispecific IgG1 antibody that selectively targets and activates fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .
|
- HY-P991190
-
|
AV-380
|
TGF-beta/Smad
|
Cancer
|
|
Rilogrotug (AV-380) is a humanized IgG1 monoclonal antibody targeting GDF15 .
|
- HY-P991695
-
- HY-P991686
-
- HY-P99899
-
|
PR-1498487
|
ADC Antibody
|
Cancer
|
|
Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric antibody targeting LRRC15. Samrotamab markedly reduces bladder cancer cells viability and inhibits clonogenic growth, migratory and invasive capabilities. Samrotamab significantly increases LRRC15 mRNA level while suppressing SCG5 mRNA expression. Samrotamab can be used for synthesis of ADC ABBV-085 .
|
- HY-P991040
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
hu14.18 (K322A) is a humanized anti-disialoganglioside GD2 monoclonal antibody that contains fully human amino acid sequences for immunoglobulin G1 heavy and kappa light chains. hu14.18 (K322A) has antibody-dependent cellular cytotoxicity (ADCC). hu14.18 (K322A) can be used for the study of high-risk neuroblastoma .
|
- HY-P99712
-
|
hz208F2-4
|
IGF-1R
Apoptosis
ADC Antibody
|
Cancer
|
|
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye
diseases sup>[2].
|
- HY-P99757
-
|
Hu3F8-BsAb
|
CD2
CD3
|
Cancer
|
|
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .
|
- HY-P99582
-
|
ONC-005, OTSA101
|
Inhibitory Antibodies
|
Cancer
|
|
Tabituximab (OTSA101) is a humanized monoclonal antibody against frizzled class receptor 10 (FZD10) .
|
- HY-P991189
-
|
|
Mesothelin
|
Cancer
|
|
AMG-305 is a humanized IgG1 monoclonal antibody targeting CDH3/MSLN .
|
- HY-P9980
-
|
GSK2857914
|
ADC Antibody
TNF Receptor
|
Cancer
|
|
Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
|
- HY-108738
-
|
Ro 24-7375
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Daclizumab (Ro 24-7375) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector T cell activation, regulatory T cell (Treg) expansion and survival, and activation-induced T-cell apoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research .
|
- HY-P99682
-
|
hLIV22
|
ADC Antibody
|
Cancer
|
|
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .
|
- HY-P9995
-
|
JNJ-63733657
|
Tau Protein
|
Neurological Disease
|
|
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .
|
- HY-P99562
-
|
XmAb-18087
|
CD3
|
Cancer
|
|
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
|
- HY-P99489
-
|
ABBV 181; PR 1648817
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
|
- HY-P99033
-
|
BTCT-4465A; RG-7828; RO7030816
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
|
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
|
- HY-P99509
-
- HY-P99898
-
|
|
Bacterial
|
Others
|
|
Setoxaximab is an IgG1-κ humanized chimeric antibody targeting shiga toxin type 1 .
|
- HY-P991564
-
|
IBI-343 antibody
|
ADC Antibody
Claudin
|
Cancer
|
|
Arcotatug is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADC .
|
- HY-P991625
-
|
|
VEGFR
|
Cancer
|
|
VX70 is a humanized monoclonal antibody inhibitor targeting VEGF-A. VX70 can be used for cancers research .
|
- HY-P991207
-
- HY-P99760
-
|
BCD-145
|
CTLA-4
|
Cancer
|
|
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
|
- HY-P99001
-
- HY-P991206
-
- HY-P99002
-
- HY-P9959
-
|
CMC-544; PF-5208773; WAY-207294
|
Antibody-Drug Conjugates (ADCs)
CD22
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
Inotuzumab ozogamicin (CMC-544) is an anti-CD22 antibody-drug conjugate (ADC). Inotuzumab ozogamicin consists of a humanized IgG4 anti-CD22 mAb, covalently linked to Calicheamicin (HY-19609) via an acid-labile AcBut (HY-132261) linker. The antibody portion is Inotuzumab (HY-P99264), and the drug-linker conjugate for ADC is N-Ac-γ-Calicheamicin-AcBut-NHS ester (HY-103688). Inotuzumab ozogamicin binds to the minor groove of DNA, inducing double-strand cleavage and subsequent apoptosis. Inotuzumab ozogamicin can be used for the study of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) .
|
- HY-P990093
-
|
CM310
|
Interleukin Related
STAT
|
Inflammation/Immunology
|
|
Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα (KD values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively). Stapokibart effectively blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis) .
|
- HY-P99601
-
|
BFCR 4350A; RG 6160; RO 7187797
|
CD3
|
Neurological Disease
Cancer
|
|
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .
|
- HY-P991286
-
- HY-P99684
-
|
J2898A
|
EGFR
|
Cancer
|
|
Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289 .
|
- HY-P991568
-
|
|
CXCR
|
Cancer
|
|
AT009 is an anti-CXCR4 humanized monoclonal antibody. AT009 can be used for cancer research .
|
- HY-P991667
-
- HY-P991287
-
- HY-P99496
-
|
RPC 4046; ABT 308; CC-93538
|
Interleukin Related
|
Inflammation/Immunology
|
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
|
- HY-P991188
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
MGD007 is a humanized IgG1 monoclonal antibody targeting GPA33. MGD007 can be used for study of Metastatic Colorectal Cancer .
|
- HY-P991527
-
- HY-P991220
-
|
|
TREM receptor
|
Neurological Disease
|
|
AL002 is a humanized monoclonal immunoglobulin G1 (IgG1) antibody and a TREM2 agonist antibody for use in neurological disease research .
|
- HY-P990654
-
- HY-P991580
-
|
|
Factor XI
|
Cardiovascular Disease
|
|
REGN-7508 is a humanized monoclonal antibody inhibitor targeting FXI. REGN-7508 can be used for atherothrombosis and venous thromboembolism research .
|
- HY-P991683
-
|
|
Discoidin Domain Receptor
|
Cancer
|
|
Ensavatatug is a humanized monoclonal antibody inhibitor targeting discoidin domain receptor tyrosine kinase 1 (DDR1). Ensavatatug is promising for research of cancers .
|
- HY-P991579
-
|
|
Factor XI
|
Cardiovascular Disease
|
|
REGN-9933 is a humanized monoclonal antibody inhibitor targeting FXI. REGN-9933 can be used for atherothrombosis and venous thromboembolism research .
|
- HY-P991578
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
SNG-8023 is an anti-ERα humanized monoclonal antibody. SNG-8023 can be used for cancer research, such as breast cancer .
|
- HY-P991581
-
|
|
Factor XI
|
Cardiovascular Disease
|
|
MK-2060 is a humanized monoclonal antibody inhibitor targeting FXI. MK-2060 can be used for atherothrombosis and venous thromboembolism research .
|
- HY-P99762
-
|
MGD009
|
CD3
|
Cancer
|
|
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
|
- HY-P99515
-
- HY-P991643
-
- HY-P99395
-
|
JNJ 56022473; CSL 362
|
Interleukin Related
|
Cancer
|
|
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
|
- HY-P991519
-
- HY-P991725
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Velvakiment is a humanized VHH nanobody that targets IL-17A. Velvakiment can be used for autoimmune diseases such as multiple sclerosis and rheumatoid arthritis research .
|
- HY-P991575
-
- HY-P991267
-
- HY-P991259
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
MEDI-7836 is a humanized monoclonal antibody inhibitor that targets the interleukin-13 receptor. MEDI-7836 is promising for research of inflammation-related diseases .
|
- HY-P99296
-
|
CNTO 95; Anti-Human CD51 Recombinant Antibody
|
Integrin
|
Cancer
|
|
Intetumumab (CNTO 95) is a humanized monoclonal antibody targeting CD51/αV-integrins. Intetumumab is used in the research of pancreatic ductal adenocarcinoma (PDAC) .
|
- HY-P99102
-
|
10-1074
|
HIV
|
Infection
|
|
Zinlirvimab is a human IgG1-λ2, HIV neutralising antibody targeting to HIV-1 gp120 envelope glycoprotein (IIIB gp120 V3 loop) .
|
- HY-P991645
-
|
MDX-1203 antibody; BMS-936561 antibody
|
TNF Receptor
ADC Antibody
|
Cancer
|
|
MDX-1115 is a humanized IgG1 monoclonal antibody targeting CD70. MDX-1115 can be used for synthesis of ADC BMS-936561 .
|
- HY-P991684
-
- HY-P991658
-
|
ARGX-109; GB224; RYI-008
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gerilimzumab (GB224) is a humanized monoclonal antibody inhibitor targeting interleukin-6 (IL-6). Gerilimzumab is promising for research of autoimmune diseases such as rheumatoid arthritis .
|
- HY-P99022
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
|
- HY-P991704
-
|
|
Tau Protein
|
Cancer
|
|
Moponetug is a humanized IgG1κ antibody targeting MAPT. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9994
-
|
SBT6050
|
Antibody-Drug Conjugates (ADCs)
EGFR
Toll-like Receptor (TLR)
|
Inflammation/Immunology
Cancer
|
|
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .
|
- HY-P991558
-
|
RG-7356
|
Transmembrane Glycoprotein
|
Cancer
|
|
RO-5429083 is a humanized monoclonal antibody inhibitor targeting CD44. RO-5429083 can be used for acute myeloid leukemia (AML) and solid tumors research .
|
- HY-P991714
-
|
TORL-4-500 antibody
|
Notch
|
Inflammation/Immunology
|
|
Roltotatug is a humanized IgG1κ antibody targeting DLK1. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991715
-
|
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Sanritatug is a humanized IgG1κ antibody targeting CD38. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991692
-
- HY-P991179
-
|
|
TNF Receptor
|
Cancer
|
|
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes .
|
- HY-P991093
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
NGM-707 is a humanized monoclonal antibody that blocks ILT2 and ILT4 receptors. NGM-707 has the potential for the study of advanced and metastatic solid tumors .
|
- HY-P991707
-
|
SHR-A2102 antibody
|
Nectin-4
|
Cancer
|
|
Notiretatug is a humanized IgG1κ antibody targeting Nectin-4. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991729
-
- HY-P991681
-
|
|
Claudin
CD3
|
Cancer
|
|
Emaretamig is a humanized IgG1κ monoclonal antibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research .
|
- HY-P991712
-
- HY-P991591
-
|
|
Integrin
|
Inflammation/Immunology
|
|
MOR101 is a humanized monoclonal antibody inhibitor targeting ICAM-1/CD54. MOR101 can be used to study acute and chronic inflammation, such as burns .
|
- HY-P990920
-
|
MK-6070; HPN328
|
CD3
|
Inflammation/Immunology
|
|
HY-P990920 is an CD3E/ALB/DLL3-targeting (scFv-heavy-lamdba)-VH-VH' type chimeric humanized antibody .
|
- HY-P991670
-
- HY-P991597
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SSGJ-608 is a humanized monoclonal antibody targeting IL-17A. SSGJ-608 can be used in the research of autoimmune and inflammatory diseases, such as moderate-to-severe plaque psoriasis .
|
- HY-P991687
-
|
|
Claudin
|
Cancer
|
|
Gaspantatug is a humanized IgG1κ antibody targeting CLDN18.2. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991702
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Merinetug is a humanized IgG1κ antibody targeting Amyloid beta/Aβ. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991644
-
|
|
Integrin
|
Cancer
|
|
IMGN388 Antibody is an Integrin targeting humanized monoclonal antibody. IMGN388 Antibody can be used for synthesis of ADC SGN-PDL1V (HY-171821) .
|
- HY-P991705
-
- HY-P99706
-
|
AK 117
|
CD47
Interleukin Related
|
Cancer
|
|
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
|
- HY-P991140
-
|
|
Claudin
|
Cancer
|
|
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
|
- HY-P991269
-
|
|
Interleukin Related
|
Metabolic Disease
|
|
LY2189102 is a humanized monoclonal antibody inhibitor targeting interleukin-1β (IL-1β). LY2189102 is promising for research of type 2 diabetes .
|
- HY-P991177
-
|
RC-108 antibody
|
c-Met/HGFR
|
Cancer
|
|
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991710
-
- HY-P991726
-
|
|
Orphan GPCR
|
Cancer
|
|
Vemzatatug is a humanized IgG1κ monoclonal antibody inhibitor targeting GPRC5D. Vemzatatug has an antitumor activity. Vemzatatug can be used for cancers like multiple myeloma (MM) research .
|
- HY-P991596
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ANB004 is a humanized monoclonal antibody inhibitor, targeting IL-17. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research .
|
- HY-P991694
-
- HY-P991666
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
BMS-986090 is a humanized monoclonal antibody antagonist targeting CD40. BMS-986090 is promising for research of autoimmune diseases such as systemic lupus erythematosus (SLE) and focal segmental glomerulosclerosis (FSGS) .
|
- HY-P991721
-
|
|
PCSK9
|
Cardiovascular Disease
|
|
Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .
|
- HY-P99053
-
- HY-P991222
-
|
|
Phosphatase
|
Metabolic Disease
|
|
AMG-529 is a humanized anti-ASGR1 monoclonal antibody that binds to ASGR1 and blocks ligand binding, resulting in dose-induced increases in ALP, a biomarker of ASGR1 inhibition .
|
- HY-P991693
-
|
|
CD47
|
Inflammation/Immunology
|
|
Ipsoprubart is a humanized IgG1κ antibody targeting SIRPa/CD172a. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99573
-
|
MGD-013
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .
|
- HY-P991176
-
|
RO7443904
|
CD19
CD28
|
Cancer
|
|
RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003) .
|
- HY-P99191
-
|
NI-0501
|
IFNAR
|
Inflammation/Immunology
|
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
|
- HY-P991552
-
|
|
CD3
|
Metabolic Disease
Inflammation/Immunology
|
|
AFM15 is a humanized monoclonal antibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD) .
|
- HY-P991603
-
|
|
Integrin
|
Inflammation/Immunology
|
|
ASP5094 is a humanized monoclonal antibody against integrin alpha-9. ASP5094 has good safety and tolerability. ASP5094 can be used in the research of diseases such as rheumatoid arthritis .
|
- HY-P991691
-
- HY-P991139
-
|
|
CTLA-4
|
Cancer
|
|
Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
|
- HY-P991260
-
|
|
Interleukin Related
|
Infection
|
|
CNTO-6785 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CNTO-6785 is promising for research of chronic obstructive pulmonary disease (COPD) .
|
- HY-P991271
-
|
NNC-114-0005
|
Interleukin Related
|
Inflammation/Immunology
|
|
NN-8828 (NNC-114-0005) is a humanized monoclonal antibody inhibitor targeting interleukin-21 (IL-21). NN-8828 is promising for research of immune system diseases .
|
- HY-P991263
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SCH-900117 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
|
- HY-P991152
-
|
QX-005N
|
Interleukin Related
|
Inflammation/Immunology
|
|
Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
|
- HY-P991264
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ZL-1102 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). ZL-1102 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
|
- HY-P991718
-
|
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Tagmokitug is a humanized IgG1κ monoclonal antibody inhibitor targeting CCR8. Tagmokitug has antitumor activity. Tagmokitug can be used for tumor immunotherapy research, such as breast, colon and lung cancer .
|
- HY-P991046
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Donanemab (Mouse IgG2a) is a chimeric antibody composed of humanized variable regions and a mouse IgG2b backbone. Donanemab (Mouse IgG2b) is an anti-amyloid inhibitor used in Alzheimer's disease research.
|
- HY-P99488
-
|
JSP-191; AMG-191
|
c-Kit
|
Inflammation/Immunology
Cancer
|
|
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
|
- HY-P991604
-
|
YFC51.1; LDP-01
|
Integrin
|
Inflammation/Immunology
|
|
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .
|
- HY-P991075
-
|
|
NAMPT
|
Inflammation/Immunology
|
|
ALT-100 (Human IgG1) is a humanized IgG1 monoclonal antibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991150
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
|
- HY-P991281
-
- HY-P991728
-
|
TORL-3-600 antibody
|
Cadherin
|
Cancer
|
|
Zarutatug is an anti-CDH17 (cadherin 17) IgG1κ type humanized antibody with antineoplastic activity. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991699
-
|
AZD9829 antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lixarkitug is a humanized IgG1κ antibody targeting IL-3Ra/CD123. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991265
-
|
|
Interleukin Related
|
Cancer
|
|
OSE-703 is a humanized monoclonal antibody inhibitor targeting interleukin-7 receptor α subunit (IL-7Rα). OSE-703 is promising for research of tumors and respiratory diseases .
|
- HY-P991135
-
|
|
CCR
|
Cancer
|
|
Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
|
- HY-P991679
-
|
TORL-2-307 antibody
|
Claudin
|
Cancer
|
|
Elatatug is an anti-CLDN18 (claudin 18) IgG1κ type humanized antibody with antineoplastic activity. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991711
-
|
|
Trk Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Povovetug is a humanized IgG1κ chimeric monoclonal antibody inhibitor targeting NGF/bNGF. Povovetug has a significant analgesic activity. Povovetug can be used for central neuroinflammation like chronic radicular pain research .
|
- HY-P991586
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
KB002 is a humanized monoclonal antibody inhibitor targeting GM-CSF. KB002 has significant immune activity and can be used for asthma, rheumatoid arthritis and chronic Idiopathic thrombocytopenia purpura (ITP) research .
|
- HY-P99462
-
|
CDX-0159; CDX-0158
|
c-Kit
|
Inflammation/Immunology
|
|
Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .
|
- HY-P991650
-
|
|
PSMA
|
Cancer
|
|
MDX1201 is a humanized monoclonal antibody targeting PSMA1/7. MDX1201 conjugated with a fluorescent dye AlexaTM488 can be used as a probe for near-infrared fluorescence imaging (NIRF) imaging of prostate cancer .
|
- HY-P991195
-
|
SIM1811-03
|
TNF Receptor
|
Cancer
|
|
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
- HY-P991649
-
|
SAR566658 antibody
|
Mucin
ADC Antibody
|
Cancer
|
|
Anti-CA6 Antibody (huDS6) is a Mucin 1-associated sialoglycotope (CA6) targeting humanized monoclonal antibody. Anti-CA6 Antibody (huDS6) can be used for synthesis of ADCs .
|
- HY-P991272
-
|
PF-05230900
|
Interleukin Related
|
Inflammation/Immunology
|
|
ATR-107 is a humanized monoclonal antibody inhibitor targeting interleukin-21 receptor (IL-21R). ATR-107 is promising for research of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus .
|
- HY-P991145
-
|
|
SLC39 (Zinc Transporter)
|
Cancer
|
|
Laventatug is a humanized monoclonal antibody targeting human SLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
|
- HY-P991690
-
|
|
RSV
|
Infection
|
|
Glarivibart is a humanized IgG1κ monoclonal antibody inhibitor targeting Respiratory syncytial virus (RSV) fusion F protein (RSV-F). Glarivibart has significant antiviral activity. Glarivibart can be used for RSV infections research .
|
- HY-P991175
-
- HY-P990934
-
- HY-P99581
-
|
OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01
|
Wnt
|
Cancer
|
|
Tabituximab barzuxetan (exclude Y90) is a radioimmunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan shows antineoplastic activity. Tabituximab barzuxetan can be used for synovial sarcoma research .
|
- HY-P990448
-
- HY-P99038
-
|
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
|
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
|
- HY-P991688
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gimvekibart is a humanized IgG4κ monoclonal antibody inhibitor targeting IL-4Ra/CD124. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research .
|
- HY-P99332
-
|
Anti-Human CD3E Recombinant Antibody; HuM291
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
|
- HY-P991266
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SM-17 is a humanized monoclonal antibody inhibitor targeting interleukin 25 (IL-25) and interleukin-17 receptor B (IL17RB). SM-17 is promising for research of immune system diseases .
|
- HY-P991717
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Sunakiment is a humanized IgG1λ monoclonal antibody inhibitor targeting Thymic stromal lymphopoietin (TSLP). Sunakiment can be used for inflammatory and immune system disorders like ulcerative colitis, rheumatoid arthritis and allergy and cancers research .
|
- HY-P991614
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
IBI356 is a humanized monoclonal antibody inhibitor targeting OX40L/CD134L/CD252. IBI356 can be used to study chronic inflammatory skin diseases, such as atopic dermatitis .
|
- HY-P990912
-
- HY-P991228
-
|
|
Galectin
|
Cancer
|
|
Lyt-200 is a humanized monoclonal antibody targeting Galectin-9. Lyt-200 exhibits potent inhibitory effects on hematological cancer cells and can also be used in combination with methotrexate (HY-14519) for research purposes .
|
- HY-P990916
-
- HY-P991696
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Lecomkafusp alfa is a fusion protein that combines human IL-2 fused via a protease cleavable peptide linker to a humanized single-domain VHH fragment anti-ALB (149-263). Lecomkafusp alfa is an immunomodulator and has antineoplastic activity .
|
- HY-P99334
-
|
Anti-Human CD70 Recombinant Antibody; SGN-75
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity .
|
- HY-P991554
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .
|
- HY-P991167
-
|
|
Bacterial
|
Infection
|
|
Vecantoxatug is a humanized monoclonal antibody targeting Clostridium tetani toxin (TeNT, neurotoxin). Vecantoxatug specifically binds to Clostridium tetani toxin, preventing the toxin from binding to cell receptors and thus exerting antitoxin activity. Vecantoxatug is promising for research of tetanus .
|
- HY-P991608
-
|
7F11C7
|
Mucin
|
Cancer
|
|
CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .
|
- HY-P991635
-
|
|
TNF Receptor
|
Cancer
|
|
PF-07329640 is a humanized monoclonal antibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research .
|
- HY-P991258
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .
|
- HY-P991185
-
|
|
c-Met/HGFR
|
Cancer
|
|
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991652
-
|
RG-7594
|
Integrin
|
Cancer
|
|
MINT1526A (RG-7594) is a humanized IgG1 monoclonal antibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research .
|
- HY-P991556
-
|
|
TNF Receptor
|
Cancer
|
|
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .
|
- HY-P991130
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
|
- HY-P99513
-
|
CTB011
|
RABV
|
Infection
|
|
Zamerovimab (CTB011) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Zamerovimab targets residues at and near antigenic site III. Zamerovimab can be used in rabies studies .
|
- HY-P991723
-
|
CX-2051 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Varsetatug is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug has an antitumor activity. Varsetatug can be used for cancers such as breast, prostate and ovarian cancer research .
|
- HY-P991526
-
|
|
CD3
|
Cancer
|
|
M701 is a humanized bispecific CD3/EpCAM T-cell engager antibody. M701 effectively kill high EpCAM expressing cancer cells. M701 can be used for the study of malignant ascites and gastric cancer .
|
- HY-P991285
-
- HY-P991155
-
|
|
CD3
TNF Receptor
|
Cancer
|
|
Ramantamig is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (tumor necrosis factor receptor superfamily member 17)。Ramantamig is promising for research of cancers, especially hematological malignancies such as multiple myeloma .
|
- HY-P991698
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Liscastobart is a humanized IgG4κ antibody targeting PDCD1/PD-1/CD279. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P991659
-
|
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
SCH708980 is a humanized monoclonal antibody inhibitor targeting IL-10. SCH708980 has anti-immunosuppressive activity. SCH708980 can be used for visceral leishmaniasis, sepsis-associated kidney injury (SAKI) and osteoporosis research .
|
- HY-P991675
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Camtarkibart is an anti-IL4R IgG4κ type humanized antibody with immunomodulator activity. The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P991703
-
|
GSK5733584 antibody; HS-20089 antibody; hu2F7
|
CD276/B7-H3
|
Cancer
|
|
Mocertatug is a humanized IgG1κ antibody targeting B7-H4/VTCN1. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991183
-
|
|
CD28
CD38
CD3
|
Cancer
|
|
SAR442257 is a humanized IgG4-S228P, kappa monoclonal antibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on T cells .
|
- HY-P991619
-
|
TF8-5G9
|
Transmembrane Glycoprotein
|
Cancer
|
|
CNTO-860 is a humanized anti-tissue factor monoclonal antibody. CNTO-860 can improve tumor control when combined with Paclitaxel (HY-B0015) in colon cancer model and significantly increase tumor-free survival .
|
- HY-P991536
-
|
|
Amyloid-β
|
Neurological Disease
|
|
KHK6640 is a humanized anti-amyloid beta oligomer-specific antibody. KHK6640 demonstrates high potency and efficacy for cognitive improvement in several rodent Alzheimer’s models. KHK6640 can be studied in research for neurological diseases such as Alzheimer’s disease .
|
- HY-P991415
-
|
AM712
|
VEGFR
Tie
|
Others
|
|
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
|
- HY-P991174
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody that targets TREM2. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991153
-
|
|
Virus Protease
|
Infection
|
|
Potravitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation .
|
- HY-P990952
-
- HY-P991589
-
|
NOV-1105
|
c-Met/HGFR
|
Cancer
|
|
SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. SFN68 significantly inhibits HGF/c-Met interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .
|
- HY-P991612
-
|
Sym024
|
CD73
|
Inflammation/Immunology
Cancer
|
|
S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
|
- HY-P991123
-
|
|
Adenylate Cyclase
|
Inflammation/Immunology
|
|
Bocunebart is a humanized monoclonal antibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases .
|
- HY-P99790
-
|
CEN 000029; cM-T412
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
|
- HY-P991628
-
|
|
PD-1/PD-L1
VEGFR
|
Cancer
|
|
SSGJ-707 is a bispecific, recombinant humanized IgG4 monoclonal antibody inhibitor targeting PD-1 and VEGF. SSGJ-707 can be used for cancers research, such as advanced non-small cell lung cancer (NSCLC) and recurrent endometrial cancer
|
- HY-P990948
-
- HY-P99006
-
|
MORab-009
|
Mesothelin
|
Cancer
|
|
Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium .
|
- HY-P991261
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways .
|
- HY-P990896
-
|
|
ADC Antibody
|
Cancer
|
|
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
|
- HY-P99117
-
|
AK104
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
|
- HY-P990407
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-EPOR Antibody is a humanized antibody expressed in CHO, targeting EPOR. The predicted molecular weight (MW) of Anti-EPOR Antibody is 150 kDa. The isotype control for Anti-EPOR Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P99352
-
|
Anti-MSLN Antibody
|
Mesothelin
ADC Antibody
|
Cancer
|
|
Anetumab (Anti-MSLN Antibody) is a fully humanized anti mesothelin (MSLN) IgG1 antibody. Anetumab (Anti-MSLN Antibody) can be used to synthesize the ADC molecule Anetumab ravtansine (HY-141606). Anetumab (Anti-MSLN Antibody) can be used for the research of cancer .
|
- HY-P991251
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
QX006N is a humanized monoclonal antibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases .
|
- HY-P991689
-
|
|
VEGFR
|
Cancer
|
|
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research .
|
- HY-P991647
-
|
|
CXCR
|
Cancer
|
|
ALX-0651 is a biparatopic humanized monoclonal antibody inhibitor targeting CXCR4. ALX-0651 inhibits hematopoietic stem cell trafficking, tumor progression and metastasis. ALX-0651 can be used for non-Hodgkin’s lymphoma and multiple myeloma research .
|
- HY-P991193
-
|
|
MMP
|
Cancer
|
|
NGM-438 is a humanized IgG1 monoclonal antibody targeting LAIR1. NGM438 reversed collagen-induced immune suppression in myeloid cells and promoted anti-PD1 mAb-driven T cell responses in immune cell-based functional assays .
|
- HY-P991719
-
|
YL201 antibody
|
CD276/B7-H3
|
Inflammation/Immunology
Cancer
|
|
Tambotatug is a humanized IgG1κ monoclonal antibody inhibitor targeting CD276/B7-H3. Tambotatug has antitumor activity. Tambotatug can be used for tumor immunotherapy like colorectal cancer (CRC) research .
|
- HY-P991204
-
|
ARX517 antibody
|
PSMA
|
Cancer
|
|
Anti-PSMA Antibody (ARX517 antibody) is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991187
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991716
-
- HY-P991282
-
|
|
Interleukin Related
|
Cancer
|
|
KHK2823 is a humanized monoclonal anti-human CD123/IL3RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). KHK2823 can be used in research related to leukemia .
|
- HY-P991727
-
- HY-P991593
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ABT-147 is a humanized IgG1 monoclonal antibody inhibitor targeting IL-12. ABT-147 can be used to study autoimmune diseases like rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD) and other diseases like Asthma .
|
- HY-P991202
-
|
|
TSH Receptor
|
Endocrinology
|
|
Anti-TSHR Antibody (M22) is a humanized IgG1 monoclonal antibody that targets thyrotropin receptor (TSHR). Anti-TSHR Antibody (M22) inhibits the binding of TSH and TSHR. Recommend Isotype Controls: Human IgG1 lambda, Isotype Control (HY-P99992) .
|
- HY-P991113
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonal antibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers .
|
- HY-P991184
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Anti-LY6G6D Antibody (1G4) is a humanized IgG1 monoclonal antibody that targets LY6G6D. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99505
-
|
COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis .
|
- HY-P990373
-
- HY-P991144
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma .
|
- HY-P3239
-
|
GSK2857916; Belantamab mafodotin-blm
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. The antibody portion is Belantamab (HY-P9980), and the drug-linker conjugate for ADC is McMMAF (HY-15578). Belantamab mafodotin has anti-myeloma activity .
|
- HY-P991129
-
|
QX-002N
|
Interleukin Related
|
Inflammation/Immunology
|
|
Crusekitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
- HY-P990928
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990928 is an CD3E-targeting [(scFv -κ-heavy) G1-h-CH2-CH3 (scFv-heavy -κ)]2 type chimeric human and humanized antibody .
|
- HY-145627
-
|
BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .
|
- HY-P991583
-
|
|
FGFR
ERK
|
Cancer
|
|
GP369 is a humanized FGFR2-IIIb-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer .
|
- HY-P991657
-
|
|
Complement System
|
Cardiovascular Disease
|
|
MEDI7814 is a humanized monoclonal antibody inhibitor targeting C5a and C5adesArg. MEDI7814 binds to recombinant human C5a and serum purified human C5a with affinities of 14 pM and 8 pM, respectively. MEDI7814 is acute inflammatory diseases such as sepsis and renal ischemia-reperfusion injury .
|
- HY-P99016
-
|
|
ADC Antibody
Nectin-4
|
Cancer
|
|
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .
|
- HY-P9939
-
|
KRN23; N5KG1_C10_LH; UX-023
|
Inhibitory Antibodies
|
Metabolic Disease
Cancer
|
|
Burosumab (KRN23) is a humanized FGF23-neutralizing antibody. By neutralizing FGF23, Burosumab blocks its inhibitory effect on renal phosphate reabsorption, thereby increasing serum phosphate levels and improving abnormal bone mineralization. Burosumab can be used in the research of diseases such as X-linked hypophosphatemia (XLH) and osteomalacia .
|
- HY-P991237
-
|
|
EGFR
|
Cancer
|
|
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. HMBD-001 inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. HMBD-001 is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .
|
- HY-P991639
-
|
|
Apoptosis
|
Cancer
|
|
BIW-8962 is a humanized anti-ganglioside GM2 antibody. BIW-8962 exhibits ADCC/CDC activity against multiple myeloma cells. BIW-8962 demonstrates potent anti-tumor activity in mouse xenograft models. BIW-8962 is indicated for research in myeloma and other cancers .
|
- HY-P991257
-
|
|
Interleukin Related
|
Cancer
|
|
MK-1966 is a humanized monoclonal antibody inhibitor targeting interleukin-10 (IL-10). MK-1966 blocks the inhibitory effects of IL-10 on immune cells such as macrophages and dendritic cells to restore anti-tumor immune responses. MK-1966 is promising for research of cancers .
|
- HY-P991201
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
REGN-7257 is a humanized monoclonal antibody targeting IL2RG that effectively blocks signaling of all γ-c cytokines. REGN-7257 can be used in the study of aplastic anemia. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P99791
-
|
SYNT001; ALXN1830
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity .
|
- HY-P991588
-
|
AC101
|
EGFR
|
Cancer
|
|
HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
|
- HY-P99893
-
|
AMG-570
|
CD28
TNF Receptor
|
Others
|
|
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonal antibody targets ICOSL and BAFF. Prezalumab demonstrates beneficial activities on the arthritis of systemic lupus erythematosus. Prezalumab can be used for the research of sjogren's syndrome cutaneous lupus erythematosus, psoriasis and systemic lupus erythematosus (SLE) .
|
- HY-P991068
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
hT84.66-M5A is a humanized IgG1 antibody that targets carcinoembryonic antigen (CEA). The isotype control for hT84.66-M5A can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991665
-
|
OBT357NF; OBT357
|
Transmembrane Glycoprotein
|
Cancer
|
|
MEN1112 (OBT357NF) is a selective humanized monoclonal antibody targeting the Bst1/CD157 antigen (EC50=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML .
|
- HY-P991283
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
AMG 317 is a humanized monoclonal anti-CD124/IL4R/IL-4Rα antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002). AMG 317 can be used in research related to asthma .
|
- HY-P991708
-
|
|
PSMA
CD3
|
Cancer
|
|
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .
|
- HY-P991507
-
|
|
EGFR
|
Cancer
|
|
SCT200 is a fully humanized IgG1 anti-EGFR monoclonal antibody with a Kd of 0.08 nM. SCT200 can kill tumor cells by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the Fc. SCT200 can be used for the study of refractory RAS and BRAF wild-type metastatic colorectal cancer .
|
- HY-P99037
-
|
M281
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
|
- HY-P99381
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .
|
- HY-P990587
-
|
|
CD28
|
Inflammation/Immunology
|
|
FR104 is a humanized antibody expressed in CHO cells that targets CD28. FR104 comprises a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for FR104 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P991186
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
IMM-20059 is humanized IgG1 monoclonal antibody targeting EPN1. IMM-20059 in combination with Atezolizumab (HY-P9904) significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy .
|
- HY-P990401
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-DLL3 Antibody is a humanized antibody expressed in CHO, targeting DLL3. The predicted molecular weight (MW) of the Anti-DLL3 Antibody is 146.36 kDa. The isotype control for the Anti-DLL3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991636
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
AK006 is a humanized IgG1 monoclonal antibody agonist targeting Sialic acid-binding immunoglobulin-like lectin6 (Siglec-6). AK006 potently inhibits IgE-mediated human mast cell activation. AK006 can be used for inflammatory diseases like chronic urticaria (CU) and asthma research .
|
- HY-P991576
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-CD326/EPCAM Antibody (3622W94) is a humanized antibody expressed in CHO cells, targeting EpCAM/TROP1/CD326. Anti-CD326/EPCAM Antibody (3622W94) can be used for epithelial cancers research, such as pancreatic, prostate and breast cancer.
|
- HY-P99233
-
|
HuMax-TAC
|
ADC Antibody
Transmembrane Glycoprotein
Interleukin Related
|
Cancer
|
|
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99493
-
|
IMGN242; huC242-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
- HY-P990616
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
LY2525623 is a humanized antibody expressed in CHO targeting IL-23. LY2525623 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for LY2525623 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990480
-
|
|
LDLR
|
Inflammation/Immunology
|
|
The Anti-oxLDL Antibody is a humanized antibody expressed in CHO cells that targets oxLDL. The Anti-oxLDL Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-oxLDL Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991151
-
|
|
PD-1/PD-L1
TNF Receptor
|
Cancer
|
|
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
|
- HY-P99239
-
|
HUJ-591; TLX591
|
PSMA
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
|
- HY-P991173
-
|
|
Notch
|
Cancer
|
|
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990669
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Torudokimab is a humanized antibody expressed in CHO, targeting IL-33. Torudokimab has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Torudokimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P991668
-
|
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
PF-06688992 is an antibody-drug conjugate (ADC) targeting the GD3 antigen, which is composed of humanized anti-GD3 huR24 linked to a chemotherapeutic agent. PF-06688992 can induce tumor cell apoptosis. PF-06688992 is promising for research of GD3-overexpressing tumors such as melanoma .
|
- HY-P990427
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Haptoglobin Antibody is a humanized antibody expressed in CHO cells that targets Haptoglobin. The Anti-Haptoglobin Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Haptoglobin Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990410
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-ERG Antibody is a humanized antibody expressed in CHO, targeting ERG. The Anti-ERG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ERG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990388
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CXADR Antibody is a humanized antibody expressed in CHO, targeting CXADR. The Anti-CXADR Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXADR Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P991248
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
TTX-080 is a humanized monoclonal antagonistic antibody targeting human leukocyte antigen G (HLA-G). TTX-080 exerts anti-tumor activity by relieving HLA-G-mediated immune suppression. TTX-080 is promising for research of solid tumors such as metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (mHNSCC) .
|
- HY-P991178
-
|
|
TNF Receptor
|
Cancer
|
|
BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
|
- HY-P990466
-
|
|
Mesothelin
|
Inflammation/Immunology
|
|
Anti-Mesothelin Antibody is a humanized antibody expressed in CHO that targets Mesothelin. The Anti-Mesothelin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-Mesothelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990431
-
|
|
Ser/Thr Protease
|
Inflammation/Immunology
|
|
Anti-HGFA Antibody is a humanized antibody expressed in CHO cells, targeting HGFA. The Anti-HGFA Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFA Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990564
-
|
BAY-103356; CDP-571
|
TNF Receptor
|
Inflammation/Immunology
|
|
Senlizumab is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. Senlizumab is composed of huIgG4SP heavy chains and huκ light chains, with a predicted molecular weight (MW) of 146.9 kDa. The isotype control for Senlizumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P991569
-
|
|
Wnt
|
Metabolic Disease
Endocrinology
|
|
PF-04840082 is a humanized IgG2 monoclonal antibody inhibitor targeting Dkk-1. PF-04840082 binds the physiological antagonist (Dkk-1) of the Wnt/LRP5 signal pathway and increases bone mass and bone mass density by activating osteoblasts. PF-04840082 can be used for osteoporosis research .
|
- HY-P991574
-
|
REG-101
|
ATGL
|
Cardiovascular Disease
|
|
MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonal antibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research .
|
- HY-P990549
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
ASK-8007 is a humanized antibody expressed by CHO, targeting Osteopontin. ASK-8007 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.02 kDa. The isotype control for ASK-8007 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990552A
-
|
MNPR-101
|
Integrin
|
Cancer
|
|
huATN-658 (MNPR-101) is a humanized monoclonal antibody inhibitor targeting urokinase-type plasminogen activator receptor (uPAR). huATN-658 blocks the interaction between uPAR and integrins, inhibiting the proliferation, invasion and migration of tumor cells. huATN-658 is promising for research of breast cancer (especially triple-negative breast cancer) .
|
- HY-P991517
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
BI-836858 is a fully humanized IgG1 anti-CD33 monoclonal antibody. BI-836858 is Fc-engineered for increased binding to FcγRIIIa (CD16). BI-836858 has antibody-dependent cellular cytotoxicity (ADCC) activities. BI-836858 can be used for the study of acute myeloid leukemia (AML) .
|
- HY-P990610
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
KHK-2898 is a humanized antibody expressed in CHO targeting CD98. KHK-2898 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for KHK-2898 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99163
-
|
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies .
|
- HY-P990675
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
VGX-100 is a humanized antibody expressed in CHO cells, targeting VEGFC. VGX-100 is composed of huIgG1 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for VGX-100 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990622
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
MB-311 is a humanized antibody expressed in CHO cells, targeting Lewis Y. MB-311 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MB-311 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990532
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-TPBG Antibody is a humanized antibody expressed in CHO cells, targeting TPBG. The Anti-TPBG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-TPBG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990006
-
|
TEV-48574
|
TNF Receptor
|
Inflammation/Immunology
|
|
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
|
- HY-P991197
-
|
LM-305 antibody; AZD-0305 antibody
|
CD3
|
Cancer
|
|
Anti-GPRC5D Antibody (LM-305 antibody) is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P9968A
-
|
|
EGFR
|
Cancer
|
|
Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody targeting EGFR with a KD value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
- HY-P990460
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
Anti-LAP Antibody is a humanized antibody expressed in CHO cells, targeting LAP. The Anti-LAP Antibody features a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-LAP Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990658
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
RG-7652 is a humanized antibody expressed in CHO cells, targeting PCSK9. RG-7652 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.88 kDa. The isotype control for RG-7652 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990544
-
|
AJW 200; AJvW 2
|
Integrin
|
Inflammation/Immunology
|
|
Anti-vWF Antibody is a humanized antibody expressed in CHO cells that targets vWF. The Anti-vWF Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.62 kDa. The isotype control for Anti-vWF Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990591
-
|
Aletekitug
|
Interleukin Related
|
Inflammation/Immunology
|
|
GSK-1070806 is a CHO-expressed humanized antibody that targets IL-18. GSK-1070806 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 147.38 kDa. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990570
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
CMAB008 is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. CMAB008 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CMAB008 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-164153
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
- HY-P990614
-
|
|
Myosin
|
Inflammation/Immunology
|
|
LK-1 is a humanized antibody expressed in CHO that targets S100A4. LK-1 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LK-1 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990465
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-Meflin Antibody is a humanized antibody expressed in CHO cells, targeting Meflin. The Anti-Meflin Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-Meflin Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990611
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
KRN-330 is a humanized antibody expressed in CHO cells, targeting GPA33. KRN-330 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for KRN-330 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99249
-
|
Pogalizumab; MOXR 0916
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .
|
- HY-P990550
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
ATH3G10 is a humanized antibody expressed in CHO that targets Phosphorylcholine. ATH3G10 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for ATH3G10 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991244
-
|
|
EGFR
|
Cancer
|
|
REGN-1400 is a humanized monoclonal antibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .
|
- HY-P991246
-
|
|
Virus Protease
HIV
|
Infection
|
|
VRC01LS is a humanized monoclonal antibody inhibitor targeting the CD4-binding site of HIV-1 envelope glycoprotein (Env). VRC01LS blocks the binding of HIV-1 to host cell CD4 receptor, inhibiting viral entry. VRC01LS is promising for research of HIV-1 infection .
|
- HY-P990374
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CLEC7A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC7A. The predicted molecular weight (MW) of Anti-CLEC7A Antibody is 150 kDa. The isotype control for Anti-CLEC7A Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990467
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
The Anti-MICB Antibody is a humanized antibody expressed in CHO cells, targeting MICB. The Anti-MICB Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for the Anti-MICB Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P991653
-
|
|
CCR
HIV
|
Infection
|
|
HGS004 is a humanized IgG4 monoclonal antibody inhibitor targeting CCR5. HGS004 has potent antivival activity against a diverse panel of CCR5-tropic HIV-1 and durg (such as Maraviroc (HY-13004))-resistant strains. HGS004 can be used for HIV-1 infections research .
|
- HY-P990668
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
TOL-101 is a humanized antibody expressed in CHO cells that targets TCR. TOL-101 is composed of huIgG2 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 125.6 kDa. The isotype control for TOL-101 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990589
-
|
BXL-1H5
|
Trk Receptor
|
Inflammation/Immunology
|
|
GBR-900 is a humanized antibody expressed in CHO that targets TrkA/NTRK1. GBR-900 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GBR-900 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990660
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
RGX-019 is a humanized antibody expressed in CHO cells, targeting MER/MERTK. RGX-019 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for RGX-019 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990632
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
MVT-5873 is a humanized antibody expressed in CHO cells, targeting Sialyl-Lewis A. MVT-5873 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for MVT-5873 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99761
-
|
XmAb5871
|
CD19
Apoptosis
|
Inflammation/Immunology
|
|
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .
|
- HY-P990620
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
LY3022856 is a humanized antibody expressed in CHO, targeting VEGFR3/FLT4. LY3022856 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.18 kDa. The isotype control for LY3022856 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990677
-
|
|
CCR
|
Inflammation/Immunology
|
|
VLST-002 is a humanized antibody expressed in CHO cells, targeting CCL5/RANTES. VLST-002 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99542
-
|
SAR-408701; HuMAb2-3-SPDB-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
|
- HY-P99101
-
|
AEX-4089; MGC026 antibody
|
ADC Antibody
|
Cancer
|
|
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
|
- HY-P990641
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
NTX-1088 is a CHO-expressed humanized antibody that targets PVR/CD155. NTX-1088 contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.86 kDa. The isotype control for NTX-1088 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99956
-
|
VLS-101; MK-2140
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer .
|
- HY-P990561
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
BT-063 is a humanized antibody expressed in CHO cells, targeting IL-10. BT-063 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for BT-063 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990474
-
|
AS2886401-00
|
Trk Receptor
|
Inflammation/Immunology
|
|
Anti-NGF/bNGF Antibody is a CHO-expressed humanized antibody that targets NGF/bNGF. Anti-NGF/bNGF Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.14 kDa. The isotype control for Anti-NGF/bNGF Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-163480
-
|
|
CXCR
|
Inflammation/Immunology
|
|
PF-06835375 is a humanized IgG1 antibody selective against CXCR5 expressed on B cells, Tfh cells, and circulating Tfh-like (cTfh) cells. PF-06835375 can be used for the study of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
- HY-P99464
-
|
IMMU-LL 2
|
CD22
|
Cancer
|
|
Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .
|
- HY-P99394
-
|
JNJ-64407564
|
CD3
|
Cancer
|
|
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .
|
- HY-P991655
-
|
|
IFNAR
HIV
|
Infection
Inflammation/Immunology
|
|
AGS-009 is a humanized monoclonal neutralising antibody targeting IFN-α. AGS-009 significantly reduces activated lymphocytes, such as CD4 + and CD8 + T cells as well as B cells in SIV infection rhesus macaque models. AGS-009 can be used for autoimmune diseases like systemic lupus erythematosus (SLE) and HIV infections research .
|
- HY-P990638
-
|
|
CXCR
|
Inflammation/Immunology
|
|
NI-0701 is a humanized antibody expressed in CHO cells that targets CCL5/RANTES. NI-0701 has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0701 can be referenced as Human IgG2 lambda, Isotype Control (HY-P991206).
|
- HY-P990581
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
ELB-031 is a humanized antibody expressed in CHO, targeting TYRO3. ELB-031 contains a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 143.64 kDa. The isotype control for ELB-031 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991240
-
|
|
EGFR
|
Cancer
|
|
CDX-3379 is a humanized monoclonal antibody inhibitor targeting ErbB3. CDX-3379 binds to ErbB3, blocking the dimerization of ErbB3 with other receptors, thereby inhibiting the phosphorylation of ErbB3. CDX-3379 can inhibit the growth and proliferation of tumor cells. CDX-3379 is promising for research of tumors expressing ErbB3 and NRG1, such as HNSCC .
|
- HY-P99382
-
|
JTX 2011; 37A10
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response .
|
- HY-P991651
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
MEDI4212 is a humanized IgG1λ monoclonal antibody inhibitor targeting IgE. MEDI4212 potently inhibits human IgE-mediated functional responses through its receptor FcεRI, such as calcium signaling, β-hexosaminidase release and phagocytosis. MEDI4212 prevents the binding of IgE to CD23 with an IC50 of 8 nM. MEDI4212 can be used severe asthma research .
|
- HY-P9918
-
|
Ticilimumab; CP-675206
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
|
- HY-P991149
-
|
|
TNF Receptor
|
Cancer
|
|
Nesfrotamig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2) and human tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Nesfrotamig is promising for research of cancers, especially in ERBB2-positive related tumor diseases, such as breast cancer and gastric cancer .
|
- HY-P990646
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-TPBG Antibody (PF-06263507) is a humanized antibody expressed in CHO cells that targets TPBG. PF-06263507 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for PF-06263507 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991180
-
|
|
TNF Receptor
|
Cancer
|
|
TRX-518 is a humanized agonist antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR). TRX-518 specifically targets GITR⁺ Tregs and CD45RA⁻Foxp3⁺ effector Tregs (eTregs) among regulatory T cells (Tregs), reducing the number of Tregs in circulation and within tumors. TRX-518 is promising for research of cancers .
|
- HY-P9929
-
|
BLA761046; MBL-CDB1; MDX-1388
|
Bacterial
|
Infection
|
|
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
|
- HY-P99414
-
|
AMG 557
|
Transmembrane Glycoprotein
Interleukin Related
|
Inflammation/Immunology
|
|
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
|
- HY-P990639
-
|
|
CXCR
|
Inflammation/Immunology
|
|
NI-0801 is a humanized antibody expressed in CHO, targeting CXCL10/IP-10. NI-0801 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0801 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-164152
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
- HY-P991620
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .
|
- HY-P990562
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CAT-2200 is a humanized antibody expressed in CHO, targeting CTLA-8/IL-17a. CAT-2200 is equipped with huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CAT-2200 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990585
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
ESBA-105 is a humanized antibody expressed in CHO cells, targeting TNFSF2/TNFa. ESBA-105 carries a huIgG1 heavy chain and a huκ light chain, with an anticipated molecular weight (MW) of 145.14 kDa. The isotype control for ESBA-105 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990524
-
|
|
Ser/Thr Protease
|
Inflammation/Immunology
|
|
The Anti-TMPRSS2 Antibody is a CHO-expressed humanized antibody that targets TMPRSS2. The Anti-TMPRSS2 Antibody features a huIgG1 heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. For the isotype control of the Anti-TMPRSS2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990352
-
|
Ona36
|
Scavenger Receptor Class B type I (SR-BI）
|
Inflammation/Immunology
|
|
Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990515
-
|
NKTT320
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-TCR Antibody (NKTT320) is a humanized antibody expressed in CHO, targeting TCR. Anti-TCR Antibody (NKTT320) features huIgG4 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TCR Antibody (NKTT320) can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990501
-
|
|
Wnt
β-catenin
|
Inflammation/Immunology
|
|
Anti-RSPO1 Antibody is a humanized antibody expressed in CHO that targets RSPO1. The Anti-RSPO1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-RSPO1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-164154
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
- HY-P991146
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
- HY-P991638
-
|
|
TNF Receptor
|
Cancer
|
|
XmAb-2513 is a humanized monoclonal antibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP). XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research .
|
- HY-P990347
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-CD151 Antibody is a CHO-expressed humanized antibody that targets CD151. The Anti-CD151 Antibody contains a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CD151 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99492
-
|
SB-408075; huC242-DM1
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1 (HY-19792)) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
- HY-P991534
-
|
|
Amyloid-β
|
Neurological Disease
|
|
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .
|
- HY-P990514
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-TAT226 Antibody is a CHO-expressed humanized antibody targeting TAT226. The Anti-TAT226 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-TAT226 Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990358
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CD7 Antibody is a humanized antibody expressed in CHO cells, targeting CD7. The Anti-CD7 Antibody is comprised of huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990586
-
|
FOR46
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
FG-3246 (FOR46) is a humanized antibody expressed in CHO cells that targets CD46. FG-3246 (FOR46) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for FG-3246 (FOR46) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990452
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-5 Antibody is a CHO-expressed humanized antibody that targets IL-5. The Anti-IL-5 Antibody is composed of huIgG4 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-5 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990672
-
U3-1784
2 Publications Verification
|
FGFR
|
Inflammation/Immunology
|
|
U3-1784 is a humanized antibody expressed in CHO that targets FGFR4/CD334. U3-1784 is equipped with a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for U3-1784 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990473
-
|
|
Trk Receptor
|
Inflammation/Immunology
|
|
Anti-MUSK Antibody is a humanized antibody expressed in CHO that targets MUSK. The Anti-MUSK Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 143.86 kDa. For the isotype control of Anti-MUSK Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
- HY-P991250
-
|
|
Integrin
|
Cancer
|
|
MSH-TP15e is a humanized monoclonal antibody inhibitor targeting intercellular adhesion molecule-1 (ICAM-1). MSH-TP15e recruits natural killer cells and significantly triggers antibody-dependent cell-mediated cytotoxicity (ADCC) to inhibit tumor cell growth. MSH-TP15e is promising for research of multiple myeloma (MM) .
|
- HY-P990645
-
|
|
Cadherin
|
Inflammation/Immunology
|
|
PF-03732010 is a humanized antibody expressed in CHO, targeting CDH3/P-cadherin. PF-03732010 has a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 142.7 kDa. The isotype control for PF-03732010 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-132260
-
|
IMGN529; Debio 1562
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Naratuximab emtansine (IMGN529) is a CD37-targeted ADC consisting of a humanized IgG1 mAb coupled to the microtubule disruptor DM1. Naratuximab emtansine has high affinity and specificity for CD37, allowing ADC internalization, processing and intracellular release of DM1. Due to its ability to disrupt microtubule assembly, DM1 can subsequently induce cell cycle arrest and apoptosis .
|
- HY-P990523
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-TMEFF2 Antibody is a humanized antibody expressed in CHO cells, targeting TMEFF2. The Anti-TMEFF2 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TMEFF2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990349
-
|
|
CD19
|
Inflammation/Immunology
|
|
The Anti-CD19 Antibody is a humanized antibody expressed in CHO cells, targeting CD19. The Anti-CD19 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990547
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
APX-007 is a CHO-expressed humanized antibody that targets IL-6Ra/CD126. APX-007 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for APX-007 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990670
-
|
Eltivutabart
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
TTX-030 is a humanized antibody expressed in CHO cells, targeting ENTPD1/CD39. TTX-030 contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for TTX-030 can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990434
-
|
|
Histone Methyltransferase
|
Inflammation/Immunology
|
|
The Anti-Histone H3 Antibody is a CHO-expressed humanized antibody that targets Histone H3. The Anti-Histone H3 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-Histone H3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990432
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-HGFR/c-Met Antibody is a humanized antibody expressed in CHO, targeting HGFR/c-Met. The Anti-HGFR/c-Met Antibody contains huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFR/c-Met Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990354
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-CD48 Antibody is a humanized antibody expressed in CHO cells that targets CD48. The Anti-CD48 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of the Anti-CD48 Antibody, you can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P99009
-
|
RVT-1401; HBM9161; IMVT-1401
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
|
- HY-P990647
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
PF-06342674 is a CHO-expressed humanized antibody that targets IL-7Ra/CD127. PF-06342674 carries a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.14 kDa. The isotype control for PF-06342674 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990419
-
|
|
Amino Acid Decarboxylase
|
Inflammation/Immunology
|
|
Anti-GAD65 Antibody is a humanized antibody expressed in CHO cells that targets GAD65. The Anti-GAD65 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.48 kDa. The isotype control for Anti-GAD65 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990359
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CD83 Antibody is a humanized antibody expressed in CHO cells that targets CD83. The Anti-CD83 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.8 kDa. The isotype control for Anti-CD83 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990463
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-MAGEA3 Antibody is a humanized antibody expressed in CHO cells that targets MAGEA3. The Anti-MAGEA3 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-MAGEA3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990478
-
|
|
CRAC Channel
|
Inflammation/Immunology
|
|
Anti-Orai1 Antibody is a humanized antibody expressed in CHO cells that targets Orai1. The Anti-Orai1 Antibody has a huIgG2 heavy chain and a huλ light chain, with an predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Orai1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P99391A
-
|
ABT-700 (powder)
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
|
- HY-P990338
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-ASIC1 Antibody is a humanized antibody expressed in CHO cells that targets ASIC1. The Anti-ASIC1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Anti-ASIC1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990439
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
The Anti-IFNAR1 Antibody is a humanized antibody expressed in CHO cells, targeting IFNAR1. The Anti-IFNAR1 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.92 kDa. The isotype control for the Anti-IFNAR1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990438
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-IFNa1 Antibody is a humanized antibody expressed in CHO cells that targets IFNa1. The Anti-IFNa1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.82 kDa. The isotype control for the Anti-IFNa1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990624
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
MEDI-2045 is a humanized antibody expressed in CHO cells that targets IL-4Ra/CD124. MEDI-2045 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MEDI-2045 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990360
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
The Anti-CD9 Antibody is a humanized antibody expressed in CHO, targeting CD9. The Anti-CD9 Antibody is equipped with huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990559
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
BMS-986178 is a humanized antibody expressed in CHO, targeting TNFRSF4/OX40/CD134. BMS-986178 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for BMS-986178 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990676
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
VIB-9600 is a humanized antibody expressed in CHO cells, targeting FcgR2a/CD32a. VIB-9600 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VIB-9600 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990517
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
Anti-TGFb1 Antibody is a humanized antibody expressed in CHO cells that targets TGFb1. The Anti-TGFb1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TGFb1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990372
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
|
|
The Anti-CLEC14A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC14A. The Anti-CLEC14A Antibody contains an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CLEC14A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-132253
-
|
|
Antibody-Drug Conjugates (ADCs)
Transmembrane Glycoprotein
|
Cancer
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
- HY-P990625
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
MEDI-3617 is a humanized antibody expressed in CHO cells, targeting Ang2/ANGPT2/Angiopoietin2. MEDI-3617 has a huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for MEDI-3617 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990449
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-IL-21 Antibody is a humanized antibody expressed in CHO cells that targets IL-21. The Anti-IL-21 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.32 kDa. The isotype control for Anti-IL-21 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990346
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CAPRIN1 Antibody is a humanized antibody expressed in CHO, targeting CAPRIN1. The Anti-CAPRIN1 Antibody comes with a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CAPRIN1 Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99115
-
|
ASC 22; KN 035
|
PD-1/PD-L1
|
Cancer
|
|
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .
|
- HY-P990462
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-LILRB4/ILT3/CD85k Antibody is a CHO-expressed humanized antibody that targets LILRB4/ILT3/CD85k. The predicted molecular weight (MW) of Anti-LILRB4/ILT3/CD85k Antibody is 144.36 kDa.
|
- HY-P990344
-
|
|
Bcl-2 Family
|
Inflammation/Immunology
|
|
The Anti-Bcl-2 Antibody is a humanized antibody expressed in CHO cells, targeting Bcl-2. The Anti-Bcl-2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Bcl-2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99683
-
|
SGN-LIV1A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .
|
- HY-P991654
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD of 0.43 nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research .
|
- HY-P990649
-
|
TRU-015
|
CD20
|
Inflammation/Immunology
|
|
PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 (TRU-015) is a single-chain Fv antibody, and its predicted molecular weight (MW) is 54.6 kDa. The isotype control for PF-5212374 (TRU-015) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990339
-
|
ORY012
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-AXL/UFO Antibody (ORY012) is a humanized antibody expressed in CHO cells, targeting AXL/UFO. Anti-AXL/UFO Antibody (ORY012) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.78 kDa. The isotype control for Anti-AXL/UFO Antibody (ORY012) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990430
-
|
TAK-701
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-HGF/SF Antibody (TAK-701) is a humanized antibody expressed in CHO, targeting HGF/SF. Anti-HGF/SF Antibody (TAK-701) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 153.8 kDa. The isotype control for Anti-HGF/SF Antibody (TAK-701) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990317
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
AGS-67E is a humanized antibody expressed by CHO, targeting TSPAN26/CD37. AGS-67E has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.44 kDa. The isotype control for AGS-67E can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990555
-
|
OSE-172
|
CD47
|
Inflammation/Immunology
|
|
BI-765063 (OSE-172) is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4-type heavy chain and a huκ-type light chain, with a predicted molecular weight (MW) of 146.3 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P991633
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
TQC2938 is a humanized IgG2 monoclonal antibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research .
|
- HY-P990643
-
|
|
Integrin
|
Inflammation/Immunology
|
|
OS-2966 is a humanized antibody expressed in CHO cells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99705
-
|
RG-7599; DNIB-0600A; NaPi2b-ADC
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Lifastuzumab vedotin (RG-7599; DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research .
|
- HY-P990332
-
|
CNTO 2125
|
Amyloid-β
|
Inflammation/Immunology
|
|
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHO cells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991609
-
|
|
MMP
|
Cancer
|
|
ABX-MA1 is a humanized IgG2 monoclonal antibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research .
|
- HY-P991555
-
|
|
TNF Receptor
Apoptosis
|
Cancer
|
|
XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonal antibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .
|
- HY-P991572
-
|
|
EGFR
|
Cancer
|
|
MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .
|
- HY-P990350
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CD20 Antibody is a humanized antibody expressed in CHO that targets CD20/MS4A1. The Anti-CD20 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD20 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990447
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-IL-20 Antibody is a Chinese hamster ovary (CHO) expressed humanized antibody that targets IL-20. The Anti-IL-20 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-20 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990512
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Sphingosine-1-phosphate Antibody is a humanized antibody expressed in CHO cells that targets Sphingosine-1-phosphate. Anti-Sphingosine-1-phosphate Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Sphingosine-1-phosphate Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991585
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
MORAb-028 is a humanized IgG1 monoclonal antibody inhibitor targeting GD2. MORAb-028 has a potent antitumor activity and kills GD2-expressing target cells via complement-mediated cytotoxicity (CDC). MORAb-028 significantly inhibits tumor growth in EL-4-luc xenograft mice model. MORAb-028 can be used for melanoma cancer research .
|
- HY-P99242
-
|
|
CD276/B7-H3
|
Cancer
|
|
Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .
|
- HY-P991720
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research .
|
- HY-P990353
-
|
TRX1
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD4 Antibody (TRX1) is a humanized antibody expressed in CHO cells that targets CD4. Anti-CD4 Antibody (TRX1) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD4 Antibody (TRX1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990380
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CRTAM/CD355 Antibody is a humanized antibody expressed in CHO cells, targeting CRTAM/CD355. The Anti-CRTAM/CD355 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CRTAM/CD355 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990403
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
The Anti-DSG3 Antibody is a humanized antibody expressed in CHO cells, targeting DSG3. The Anti-DSG3 Antibody has a huIgG1 type heavy chain and a huκ type light chain, and its predicted molecular weight (MW) is 146.54 kDa. The isotype control for the Anti-DSG3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990378
-
|
|
Complement System
|
Inflammation/Immunology
|
|
Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990321
-
|
MEDI 8968
|
Interleukin Related
|
Inflammation/Immunology
|
|
AMG-108 is a humanized antibody expressed in CHO cells, targeting IL-1R1/CD121a. AMG-108 is composed of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.62 kDa. The isotype control for AMG-108 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P991646
-
|
heMab
|
Transmembrane Glycoprotein
|
Cancer
|
|
ING-1 (heMab) is a high-affinity humanized monoclonal antibody against epithelial cell adhesion molecule (Ep-CAM). ING-1 is a transmembrane glycoprotein mediating Ca 2+. ING-1 binds to Ep-CAM on tumor cells and exhibits potent in vitro activity, targeting and inhibiting tumor growth and metastasis in mouse cancer models. ING-1 is useful in the research of breast, colorectal, and lung cancers, among other cancers .
|
- HY-P990902A
-
|
BMS-986012 (FUT8-KO)
|
Inhibitory Antibodies
|
Cancer
|
|
Atigotatug (FUT8-KO) is an anti-fuc-GM1 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out, and fucose deficiency enhances the ADCC effect of the antibody. Atigotatug (HY-P990902) is a Fucosyl ganglioside GM1 (fuc-GM1)-targeting IgG1κ type humanized antibody. Atigotatug can induce immune-mediated tumor cell death, such as small cell lung cancer .
|
- HY-P991611
-
|
|
iGluR
|
Inflammation/Immunology
|
|
ART5803 is a humanized IgG1 monoclonal antibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis .
|
- HY-P990443
-
|
H2L6
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-IL-13 Antibody (H2L6) is a humanized antibody expressed in CHO cells that targets IL-13. Anti-IL-13 Antibody (H2L6) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.16 kDa. The isotype control for Anti-IL-13 Antibody (H2L6) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991592
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
UB-221 is a humanized IgG1 monoclonal antibody inhibitor targeting IgE. UB-221 significantly decreases IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes and inhibits FcԑRI-mediated basophil activation and degranulation. UB-221 reduces IgE level in cynomolgus macaques and human IgE (ε, κ)-transgenic (hIGHE-knockin) mice. UB-221 can be used for asthma and chronic spontaneous urticaria (CSU) research .
|
- HY-P991082
-
|
SAR-428926 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonal antibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. Antibody Anti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990579
-
|
|
HCV
|
Inflammation/Immunology
|
|
Anti-CLDN6 Antibody (DS-9606A antibody) is a humanized antibody expressed in CHO cells, targeting CLDN6. Anti-CLDN6 Antibody features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for Anti-CLDN6 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990398
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Anti-DC-SIGN/CD209 Antibody is a CHO-expressed humanized antibody that targets DC-SIGN/CD209. Anti-DC-SIGN/CD209 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DC-SIGN/CD209 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991706
-
|
|
Phosphodiesterase (PDE)
CD3
|
Cancer
|
|
Nelvutamig is a humanized immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3) antibody targeting ENPP3/CD203c and CD3E. The corresponding isotype control is: Human immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3) .
|
- HY-P99612
-
|
MORAb-202
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
|
- HY-P990417
-
|
|
Antifolate
|
Inflammation/Immunology
|
|
Anti-FOLR1/FRA Antibody is a humanized antibody expressed in CHO cells, targeting FOLR1/FRA. The Anti-FOLR1/FRA Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.46 kDa. The isotype control for the Anti-FOLR1/FRA Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990426
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
The Anti-GREM1/Gremlin Antibody is a humanized antibody expressed in CHO that targets GREM1/Gremlin. The Anti-GREM1/Gremlin Antibody has a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GREM1/Gremlin Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990664
-
|
SC-005 antibody
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Melanotransferrin/CD228 Antibody (SC-005 antibody) is a humanized antibody expressed in CHO cells, targeting Melanotransferrin/CD228. Anti-Melanotransferrin/CD228 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.16 kDa. The isotype control for Anti-Melanotransferrin/CD228 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990605
-
|
IMGN-779 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CD33 Antibody (IMGN-779 antibody) is a CHO-expressed humanized antibody targeting Siglec-3/CD33. Anti-CD33 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.6 kDa. The isotype control for Anti-CD33 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991582
-
|
|
Fc Receptor (FcR)
|
Cancer
|
|
BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
|
- HY-P991570
-
|
AD5-10
|
TNF Receptor
Apoptosis
Caspase
Atg8/LC3
Akt
Beclin1
JNK
|
Cancer
|
|
Zaptuzumab (AD5-10) is a DR5-specific humanized monoclonal antibody that selectively binds to DR5 with high affinity. Zaptuzumab specifically induces cancer cell death by both caspase-apoptosis and autophagic cell death (ACD). Zaptuzumab activates both ADCC and CDC. Zaptuzumab induces ROS generation and GSH level reduction. Zaptuzumab shows a significant suppression of the tumor growth and good safety in various xenografts mice tumor models .
|
- HY-P99199
-
|
NI-0401
|
CD3
|
Inflammation/Immunology
|
|
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
|
- HY-P991610
-
|
Sym025
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
|
- HY-P990387
-
|
|
Ser/Thr Protease
|
Inflammation/Immunology
|
|
The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized antibody expressed in CHO cells, targeting CTSS/Cathepsin S. The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTSS/Cathepsin S Antibody (Fsn0503h) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990369
-
|
AB3-7
|
HCV
|
Inflammation/Immunology
|
|
Anti-CLDN6 Antibody (AB3-7) is a humanized antibody expressed in CHO targeting CLDN6. Anti-CLDN6 Antibody (AB3-7) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 78.02 kDa. The isotype control for Anti-CLDN6 Antibody (AB3-7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991511
-
|
|
PACAP Receptor
|
Neurological Disease
|
|
ALD1910 is a humanized monoclonal antibody against PACAP38 and PACAP27. ALD1910 blocks PACAP signaling through the pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a nonlinear epitope within PACAP and blocks its binding to the cell surface. ALD1910 can be used for the study of PACAP-mediated migraine .
|
- HY-P990319
-
|
|
NAMPT
|
Inflammation/Immunology
|
|
ALT-100 (Human IgG4) is a humanized antibody expressed in CHO, targeting NAMPT. ALT-100 (Human IgG4) consists of a huIgG1/huIgG4 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For inflammatory or fibrotic diseases, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990469
-
|
TA136
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-MPL/TPOR/CD110 Antibody (TA136) is a CHO-expressed humanized antibody that targets MPL/TPOR/CD110. The Anti-MPL/TPOR/CD110 Antibody (TA136) features a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-MPL/TPOR/CD110 Antibody (TA136) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991671
-
|
|
CD3
CD20
Transmembrane Glycoprotein
|
Cancer
|
|
Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research .
|
- HY-P990499
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-RHD/CD240d Antibody is a humanized antibody expressed in CHO cells that targets RHD/CD240d. The Anti-RHD/CD240d Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.4 kDa. The isotype control for Anti-RHD/CD240d Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991542
-
|
|
CD19
|
Cancer
|
|
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .
|
- HY-P991621
-
|
EOS-215
|
TREM receptor
|
Cancer
|
|
EOS006215 is a humanized monoclonal antibody inhibitor targeting TREM-2. EOS006215 reprograms TREM2 + macrophages, significantly blocks their pleiotropic pro-tumoral functions and overcomes resistance. EOS215 decreases metastasis burden in orthotopic 4T1 triple negative breast cancer mice model and significantly inhibits tumor growth in anti-PD-1 resistant mice model. EOS006215 can be used to study advanced malignant solid neoplasm, such as triple negative breast cancer (TNBC) .
|
- HY-P991515
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonal antibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) .
|
- HY-P99263
-
|
Anti-Human selectin P Recombinant Antibody
|
P-selectin
|
Cardiovascular Disease
|
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
|
- HY-P991599
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990531
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
The Anti-TNFSF9/4-1BBL Antibody is a CHO-expressed humanized antibody that targets TNFSF9/4-1BBL. The Anti-TNFSF9/4-1BBL Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-TNFSF9/4-1BBL Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990627
-
|
MEDI-547 antibody
|
Ephrin Receptor
|
Inflammation/Immunology
|
|
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is a humanized antibody expressed in CHO cells, targeting EphA2. Anti-EphA2 Antibody (1C1) contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 146.68 kDa. The isotype control for Anti-EphA2 Antibody (1C1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990470
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-MRC2/CD280 Antibody is a humanized antibody expressed in CHO cells, targeting MRC2/CD280. The Anti-MRC2/CD280 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.42 kDa. The isotype control for the Anti-MRC2/CD280 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990415
-
|
|
FGFR
|
Inflammation/Immunology
|
|
The Anti-FGFR1/CD331 Antibody is a humanized antibody expressed in CHO cells, targeting FGFR1/CD331. The Anti-FGFR1/CD331 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FGFR1/CD331 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990542
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Anti-VEGFR2/KDR/CD309 Antibody is a humanized antibody expressed in CHO, targeting VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody is equipped with muIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-VEGFR2/KDR/CD309 Antibody, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991217
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
EU-103 is a humanized monoclonal antibody targeting V-Set And Immunoglobulin Domain Containing 4 (VSIG4) with a KD value ranging from 10 −7 and 10 −9. EU-103 blocks the interaction between VSIG4 and CD8+ T cells, promotes the conversion of M2 macrophages into M1 macrophages, induces the proliferation of CD8+ T cells and the secretion of pro-inflammatory cytokines, thereby inhibiting tumor growth. EU-103 is promising for research of cancers, such as bladder cancer, breast cancer, and colon cancer .
|
- HY-P991565
-
|
|
c-Met/HGFR
|
Cancer
|
|
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
|
- HY-P991551
-
|
|
Dipeptidyl Peptidase
p38 MAPK
ERK
|
Infection
Cancer
|
|
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for researches on cancer or infection such as Malignant Mesothelioma and MERS .
|
- HY-P990659
-
|
RG-7841 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-LY6E Antibody (MLYE4489A) (RG-7841 antibody) is a humanized antibody expressed in CHO targeting Ly6E. Anti-LY6E Antibody (MLYE4489A) contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-LY6E Antibody (MLYE4489A) can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990537
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-VCAM1/CD106 Antibody is a humanized antibody expressed in CHO cells, targeting VCAM1/CD106. The Anti-VCAM1/CD106 Antibody has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 143.4 kDa. For the isotype control of the Anti-VCAM1/CD106 Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990494
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-PROM1/CD133 Antibody is a CHO-expressed humanized antibody targeting PROM1/CD133. The Anti-PROM1/CD133 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.64 kDa. The isotype control for the Anti-PROM1/CD133 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991294
-
|
|
ADC Antibody
|
Cancer
|
|
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
|
- HY-P991598
-
|
MOR12743; MOR03207
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .
|
- HY-P991047
-
|
JR-141 antibody (uncoupled from iduronate 2-sulfatase)
|
Transferrin Receptor
|
Neurological Disease
Cancer
|
|
Anti-CD71/TfR1 Antibody (JR-141 antibody (uncoupled from iduronate 2-sulfatase)) is a humanized anti-human transferrin receptor (CD71; TfR) antibody. Anti-CD71/TfR1 Antibody is the antibody part of the fusion protein Pabinafusp alfa (HY-P99797). The recommend isotype control of Anti-CD71/TfR1 Antibody: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991561
-
|
|
CD47
|
Cancer
|
|
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
|
- HY-P990397
-
|
FA19-1
|
VEGFR
|
Inflammation/Immunology
|
|
The Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized antibody expressed in CHO cells that targets DCBLD2/ESDN. The Anti-DCBLD2/ESDN Antibody (FA19-1) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-DCBLD2/ESDN Antibody (FA19-1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99016B
-
|
|
Antibody-Drug Conjugates (ADCs)
Nectin-4
|
Cancer
|
|
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
|
- HY-P991613
-
|
|
Orexin Receptor (OX Receptor)
NF-κB
|
Cancer
|
|
BGB-A445 is a humanized non-ligand-blocking agonistic OX40 monoclonal antibody with high affinity to OX40. BGB-A445 activates downstream NF-κB pathway to induce immune cell activation, proliferation, and survival. BGB-A445 dose-dependently and significantly depletes regulatory T cells via antibody-dependent cellular cytotoxicity (ADCC). BGB-A445 demonstrates robust and dose-dependent antitumor efficacy in the MC38 mice models. BGB-A445 can be used for the researches of cancer, such as colon adenocarcinoma .
|
- HY-P991563
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CEACAM5 Antibody (A5B7) is a humanized antibody expressed in CHO cells, targeting CEACAM5/CEA/CD66e. Anti-CEACAM5 Antibody (A5B7) consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CEACAM5 Antibody (A5B7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99744
-
|
TAK-573
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
|
- HY-P99555
-
|
OPN-305
|
Toll-like Receptor (TLR)
MyD88
NOD-like Receptor (NLR)
Tau Protein
Interleukin Related
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
|
- HY-P990472
-
|
H5B14
|
c-Met/HGFR
|
Inflammation/Immunology
|
|
Anti-MSPR/RON/CD136 Antibody (H5B14) is a humanized antibody expressed in CHO cells, targeting MSPR/RON/CD136. Anti-MSPR/RON/CD136 Antibody (H5B14) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 156.7 kDa. The isotype control for Anti-MSPR/RON/CD136 Antibody (H5B14) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99048
-
|
IBI308
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
- HY-P991634
-
|
|
CD73
TNF Receptor
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research .
|
- HY-P990385
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CTLA-4/CD152 Antibody is a humanized antibody expressed in CHO cells that targets CTLA-4/CD152. The Anti-CTLA-4/CD152 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CTLA-4/CD152 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991566
-
|
|
CTLA-4
|
Cancer
|
|
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
|
- HY-P990456
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Integrin b7/ITGB7 Antibody is a CHO-expressed humanized antibody that targets Integrin b7/ITGB7. Anti-Integrin b7/ITGB7 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Integrin b7/ITGB7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99056
-
|
PF 05082566
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
|
- HY-P990362
-
|
|
Cadherin
|
Inflammation/Immunology
|
|
Anti-CDH1/E-cadherin/CD324 Antibody is a humanized antibody expressed in CHO, targeting CDH1/E-cadherin/CD324. The Anti-CDH1/E-cadherin/CD324 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-CDH1/E-cadherin/CD324 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991656
-
|
|
CXCR
Apoptosis
p38 MAPK
Akt
|
Cancer
|
|
LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .
|
- HY-P991270
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy .
|
- HY-P991198
-
|
|
Tim3
|
Cancer
|
|
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
|
- HY-P991567
-
|
VX5/5261
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
VX5 is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration (EC50s for 105 and 253 nM for human tonsillar and pre-B-697-hCXCR5 cells, respectively). VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .
|
- HY-P991595
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990543
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990076
-
|
APN-301; hu14.18-IL2; EMD 273063
|
Inhibitory Antibodies
|
Cancer
|
|
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity .
|
- HY-P991584
-
|
|
FGFR
|
Cancer
|
|
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .
|
- HY-P990365
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-CEACAM5/CEA/CD66e Antibody is a humanized antibody expressed in CHO cells, targeting CEACAM5/CEA/CD66e. The Anti-CEACAM5/CEA/CD66e Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CEACAM5/CEA/CD66e Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990091
-
|
SAR 445088
|
Complement System
|
Inflammation/Immunology
|
|
Riliprubart (SAR 445088) is an anti-C1s humanized IgG4 monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a. Riliprubart can be used to study complement-mediated diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P99157
-
|
|
CD276/B7-H3
|
Cancer
|
|
Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
|
- HY-P990506
-
|
NCI m971
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Siglec-2/CD22 Antibody (NCI m971) is a humanized antibody expressed in CHO cells that targets Siglec-2/CD22. Anti-Siglec-2/CD22 Antibody (NCI m971) features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.64 kDa. The isotype control for Anti-Siglec-2/CD22 Antibody (NCI m971) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990507
-
|
NCI m972
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-Siglec-2/CD22 Antibody (NCI m972) is a humanized antibody expressed in CHO, targeting Siglec-2/CD22. The Anti-Siglec-2/CD22 Antibody (NCI m972) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.3 kDa. The isotype control for Anti-Siglec-2/CD22 Antibody (NCI m972) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990486
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Anti-PDCD1/PD-1/CD279 Antibody is a CHO-expressed humanized antibody that targets PDCD1/PD-1/CD279. Anti-PDCD1/PD-1/CD279 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PDCD1/PD-1/CD279 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990489
-
|
IMC-2C5
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-PDGFRB/CD140b Antibody (IMC-2C5) is a humanized antibody expressed in CHO cells that targets PDGFRB/CD140b. Anti-PDGFRB/CD140b Antibody (IMC-2C5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.54 kDa. The isotype control for Anti-PDGFRB/CD140b Antibody (IMC-2C5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99048A
-
|
IBI308 (Anti-PD-1)
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
- HY-P991223
-
|
|
Transmembrane Glycoprotein
TNF Receptor
|
Cancer
|
|
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
|
- HY-P990315
-
|
AGS-16C
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-ENPP3/CD203c Antibody (AGS-16C3F antibody) is a humanized antibody expressed in CHO cells, targeting ENPP3/CD203c. Anti-ENPP3/CD203c Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 154.04 kDa. The isotype control for Anti-ENPP3/CD203c Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P99929
-
|
HFB-30132A
|
SARS-CoV
|
Inflammation/Immunology
|
|
Enuzovimab (HFB-30132A) is a mAb against SARS-COV-2 Omicron. Enuzovimab binds to spike (S) protein with high affinity .
|
- HY-P99821
-
- HY-P99303
-
- HY-P99346
-
|
CT-P59
|
SARS-CoV
Angiotensin-converting Enzyme (ACE)
|
Infection
|
|
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
|
- HY-P99193
-
|
MEDI-528
|
Interleukin Related
|
Inflammation/Immunology
|
|
Enokizumab (MEDI-528) is a monoclonal antibody targeting to interleukin (IL)-9. IL-9 regulates the development of airway inflammation, mucus production, airway hyperresponsiveness, and airway fibrosis largely by increasing mast cell numbers and activity in the airways .
|
- HY-P9923
-
|
MEDI-563; BIW-8405; KHK4563
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
|
- HY-P99724
-
- HY-P99113
-
|
MEDI-551
|
ADC Antibody
CD19
|
Inflammation/Immunology
|
|
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .
|
- HY-P99816
-
|
|
PCSK9
|
Metabolic Disease
|
|
Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke .
|
- HY-P9991
-
|
TST001
|
Gap Junction Protein
|
Cancer
|
|
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
|
- HY-P99872
-
|
CSJ-117; NVP-CSJ117
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin (TSLP). Ecleralimab significantly attenuates allergen-induced airway responses and inflammation. Ecleralimab can be used for the study of inhaled asthma .
|
- HY-P990684
-
- HY-P990875
-
- HY-P990041
-
|
ADG-116
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer .
|
- HY-P99768
-
|
TTAC-0001
|
VEGFR
|
Cancer
|
|
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
|
- HY-P99954
-
|
|
Bacterial
|
Infection
|
|
Rivabazumab pegol is a PcrV protein antibody that can be used to study the phase II pegylated Fab of chronic Pseudomonas aeruginosa infection .
|
- HY-P99209
-
|
MEDI-524
|
RSV
|
Infection
|
|
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
|
- HY-P99842A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus .
|
- HY-P991063
-
|
BNT-313; Tixestobart
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
GEN-1053 (BNT-313) is a fully human IgG1 antibody that targets CD27. GEN-1053 binds to CD27 and forms a hexamer upon binding. The isotype control for GEN-1053 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
- HY-P99591
-
|
AS1402; huHMFG-1
|
Mucin
|
Cancer
|
|
Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer .
|
- HY-P9923A
-
|
MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
|
|
Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA)) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .
|
- HY-P99337
-
|
Ansuvimab-zyk; mAb114
|
Filovirus
|
Infection
|
|
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
|
- HY-P99788
-
|
|
ADC Antibody
ALCAM/CD166
|
Cancer
|
|
Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers .
|
- HY-P99160
-
|
hMN14
|
Transmembrane Glycoprotein
|
Cancer
|
|
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .
|
- HY-P990772
-
- HY-P99245
-
|
RG 7155; RO 5509554
|
c-Fms
|
Cancer
|
|
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .
|
- HY-P99756
-
|
MEDI8897
|
RSV
|
Infection
|
|
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
|
- HY-P990726
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P99222
-
|
MGA-031; PRV-031
|
CD3
|
Metabolic Disease
|
|
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
|
- HY-P990686
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ispectamab is an anti-TNFRSF17 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P9965
-
|
HuLuc 63; PDL 063; BMS 901608
|
Transmembrane Glycoprotein
|
Cancer
|
|
Elotuzumab (HuLuc 63) is an IgG1 monoclonal antibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating natural killer cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide (HY-A0003), Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma .
|
- HY-P99808
-
|
|
VEGFR
|
Cancer
|
|
Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers .
|
- HY-P99434
-
|
KY1005; SAR445229
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis .
|
- HY-P99631
-
|
CSL312
|
Factor Xa
|
Cardiovascular Disease
|
|
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
|
- HY-P990030
-
- HY-P99953
-
|
KB001
|
Bacterial
|
Infection
|
|
Rivabazumab is a recombinant antibody against Pseudomonas aeruginosa pcrV .
|
- HY-P99490
-
|
hzVSF-v13
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies .
|
- HY-P99550
-
|
MEDI-3506
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
|
- HY-P990697
-
|
ARX-788
|
EGFR
|
Inflammation/Immunology
|
|
Anvatabart is an anti-ERBB2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99693
-
|
GC1102
|
HBV
|
Infection
|
|
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection .
|
- HY-P99216
-
|
PF-04360365; RN 1219
|
EGFR
|
Neurological Disease
|
|
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease .
|
- HY-P99052
-
|
BGB-A317
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
|
- HY-P99042
-
|
|
Transmembrane Glycoprotein
ADC Antibody
|
Cancer
|
|
Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity .
|
- HY-P9971
-
|
SHR-1210; INCSHR1210
|
PD-1/PD-L1
|
Cancer
|
|
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
|
- HY-P990737
-
|
LY-3041658
|
CXCR
|
Inflammation/Immunology
|
|
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990770
-
- HY-P99253
-
|
KW-0761
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .
|
- HY-P99248
-
|
Risankizumab rzaa; BI 655066; ABBV-066
|
Interleukin Related
|
Inflammation/Immunology
|
|
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
|
- HY-P990046
-
|
Incagn-02385
|
LAG-3
|
Inflammation/Immunology
|
|
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .
|
- HY-P9984
-
|
rhuMAb Beta7; RG7413; PRO145223
|
Integrin
|
Cancer
|
|
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
|
- HY-P990764
-
|
SGN-B6A antibody
|
Integrin
|
Inflammation/Immunology
|
|
Sigvotatug is an anti-ITGB6 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990761
-
- HY-P99291
-
|
LM609; MEDI-522
|
Integrin
Apoptosis
Akt
|
Cancer
|
|
Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99730
-
|
TAK-079
|
CD38
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
|
- HY-P990981
-
|
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Clesitamig is a DLL3/CD3/CD137 trispecific T cell engager, consisting of two CD3/CD137 dual-specific antigen-binding fragments (Fabs) and one additional DLL3 antigen-binding fragment (Fab). Clesitamig exhibits potent antitumor activity and can be used in research on tumors such as small cell lung cancer .
|
- HY-P99049
-
|
APX005M; APX005M; EPI-0050
|
TNF Receptor
|
Inflammation/Immunology
|
|
Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .
|
- HY-P99356
-
|
BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)
|
α-synuclein
|
Neurological Disease
|
|
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease .
|
- HY-P990698
-
- HY-145645
-
|
NI-0101
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
Paridiprubart (NI-0101) is a humanised anti-TLR4 monoclonal antibody. Paridiprubar inhibits the production of pro-inflammatory cytokines by monocytes from rheumatoid arthritis specimen induced by rheumatoid arthritis synovial fluid (RASF). Paridiprubart can be used for the study of rheumatoid arthritis .
|
- HY-P990691
-
- HY-P99251
-
|
|
PCSK9
|
Others
|
|
Lodelcizumab is a monoclonal antibody targeting PCSK9. Lodelcizumab can be used for the research of hypercholesterolemia .
|
- HY-P9962
-
|
|
Fungal
|
Infection
|
|
Efungumab is a monoclonal antibody with antifungal activity. Efungumab binds to HSP 90, preventing a conformational change needed for fungal viability. Efungumab can be used for research on invasive candidiasis (IC) .
|
- HY-P99537
-
|
PBP1510
|
Inhibitory Antibodies
|
Cancer
|
|
Ulenistamab (PBP1510) is a first-in-class hunamised IgG1 monoclonal antibody targeting pancreatic adenocarcinoma upregulated factor (PAUF). Ulenistamab can be used for pancreatic cancer (PC) research .
|
- HY-P99632
-
|
REGN 2477
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
|
- HY-P99183
-
|
EMD 525797; DI17E6
|
Integrin
|
Cancer
|
|
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .
|
- HY-P990055
-
|
|
EGFR
|
Cancer
|
|
Nezutatug is an anti-HER3 antibody, and used for cancer research .
|
- HY-P99259
-
|
FPA 008; Anti-Human CSF1R Recombinant Antibody
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
|
- HY-P990753
-
- HY-P991042
-
|
|
IGF-1R
|
Cancer
|
|
Anti-IGFBP2 Antibody (M14) is an human anti-IGFBP2 monoclonal inhibitory antibody, which binds IGFBP2 with high affinity and blocks its binding with IGF1. Anti-IGFBP2 Antibody (M14) inhibits human endothelial cell recruitment, thus blocks the tumor progression of human metastatic cancer .
|
- HY-P99524
-
|
GBR500
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Vatelizumab (GBR500) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). Vatelizumab can be used for the research of multiple sclerosis .
|
- HY-P99186
-
|
|
Inhibitory Antibodies
|
Others
|
|
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis .
|
- HY-P99289
-
|
Antibody hLL 2; AMG-412
|
CD22
|
Inflammation/Immunology
Cancer
|
|
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
|
- HY-P990057
-
- HY-P99785
-
|
HLX20; HLX43 antibody
|
PD-1/PD-L1
|
Cancer
|
|
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
|
- HY-P99616
-
|
MOR-202
|
CD38
|
Cancer
|
|
Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research .
|
- HY-P990747
-
|
|
CD38
|
Inflammation/Immunology
|
|
Lumrotatug is an anti-CD38 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99850
-
- HY-P990702
-
|
LVGN-3616
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Pradusinstobart is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P99967
-
|
|
ADC Antibody
|
Cancer
|
|
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .
|
- HY-P990739
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99532
-
- HY-P99113A
-
|
|
CD19
|
Inflammation/Immunology
|
|
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica .
|
- HY-P99831
-
|
GB-221
|
EGFR
|
Others
Cancer
|
|
Coprelotamab (GB-221) is an IgG-κ monoclonal antibody targeting EGFR2. The commonly used expression system for Coprelotamab is CHO DG44 (Chinese Hamster Ovary) cells .
|
- HY-P990746
-
- HY-P990771
-
|
|
CD73
|
Inflammation/Immunology
|
|
Uprevstobart is an anti-NT5E human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99014
-
|
ARGX-110
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .
|
- HY-P990751
-
- HY-P99629
-
|
FHTR 2163; RG 6147; RO 7171009
|
Ser/Thr Protease
|
Neurological Disease
|
|
Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular degeneration (AMD) research .
|
- HY-P99213
-
|
GSK1223249
|
Inhibitory Antibodies
|
Neurological Disease
|
|
Ozanezumab (GSK1223249) is an anti-Nogo-A (neurite outgrowth inhibitor A) monoclonal antibody. Ozanezumab can be used in amyotrophic lateral sclerosis (ALS) and multiple sclerosis research .
|
- HY-P99258
-
|
OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody
|
Notch
|
Cancer
|
|
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .
|
- HY-P99171
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II) .
|
- HY-P99506
-
|
SC-003 mAb; SC-Mab003; SC34.28ss1
|
ADC Antibody
|
Cancer
|
|
Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research .
|
- HY-P99758
-
|
CS1003
|
PD-1/PD-L1
|
Cancer
|
|
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research .
|
- HY-P99367
-
- HY-P99701
-
|
BMS-986004
|
TNF Receptor
|
Inflammation/Immunology
|
|
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time .
|
- HY-P99246
-
|
MABp1
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Bermekimab (MABp1) is a human monoclonal antibody targeting interleukin-1α(IL-1α) . Bermekimab can prevent tumor-related inflammation. Bermekimab can be used in the research of atopic dermatitis .
|
- HY-P99498
-
|
CEA-IL2v; RG 7813; RO 6895882
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Cergutuzumab amunaleukin (CEA-IL2v) is a monomeric carcinoembryonic antigen (CEA)-targeted IL-2 variant-based immunocytokine. Cergutuzumab amunaleukin has immunostimulating and antineoplastic activities .
|
- HY-P990749
-
- HY-P99495
-
|
RWJ 49004
|
HIV
|
Inflammation/Immunology
|
|
Cedelizumab (RWJ 49004) is a IgG4 monoclonal antibody targeting CD4. Cedelizumab has immunosuppressant properties .
|
- HY-P990696
-
- HY-P99809
-
|
MK-1308
|
CTLA-4
|
Cancer
|
|
Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody .
|
- HY-P99865
-
|
AK-119
|
CD73
|
Others
|
|
Dresbuxelimab (AK-119) is an IgG-κ monoclonal antibody targeting CD73. The expression system is usually CHO (Chinese Hamster Ovary) cells .
|
- HY-P99673
-
|
REGN-3500; SAR-440340
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
|
- HY-P99594
-
|
ZKAB001; STI-1014; STI-A1014
|
PD-1/PD-L1
|
Cancer
|
|
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .
|
- HY-P99827
-
|
TSR-022; GSK4069889
|
Tim3
|
Cancer
|
|
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) .
|
- HY-P99010A
-
|
|
Interleukin Related
FGFR
|
Cancer
|
|
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
|
- HY-P99610
-
|
BI-754091
|
PD-1/PD-L1
|
Cancer
|
|
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .
|
- HY-P990762
-
- HY-P99237
-
- HY-P9973
-
|
DLX1008; ESBA 1008; RTH258
|
VEGFR
|
Cancer
|
|
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer .
|
- HY-P99280
-
|
Anti-Human IL17A/IL-17F Recombinant Antibody; CDP4940; UCB-4940
|
Interleukin Related
|
Inflammation/Immunology
|
|
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
|
- HY-P990767
-
- HY-P990687
-
- HY-P99378
-
|
ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab)
|
Apoptosis
|
Inflammation/Immunology
|
|
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .
|
- HY-P99969
-
|
CMAB-302; Cipterbin
|
EGFR
|
Cancer
|
|
Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities .
|
- HY-P990715
-
- HY-P99584
-
|
KD-247
|
HIV
|
Infection
|
|
Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection .
|
- HY-P99704
-
|
OCS-02
|
TNF Receptor
|
Inflammation/Immunology
|
|
Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation .
|
- HY-P99283
-
|
NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody
|
Factor Xa
|
Others
|
|
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .
|
- HY-P99196
-
|
|
c-Met/HGFR
|
Cancer
|
|
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
|
- HY-P99559
-
|
HexaBody-DR5/DR5; Hx-DR5-01/05
|
Inhibitory Antibodies
|
Cancer
|
|
Tilogotamab is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM) .
|
- HY-P99971
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990712
-
|
RZ-358; XOMA 358
|
Insulin Receptor
|
Inflammation/Immunology
|
|
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P99812
-
|
INCAGN-1876
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab binds to and activates GITR on T cells, which stimulates the immune system to enhance its anti-tumor activity. Ragifilimab can be used for advanced or metastatic solid tumors research .
|
- HY-P99733
-
|
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .
|
- HY-P99012
-
|
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .
|
- HY-P99922
-
|
|
LAG-3
|
Cancer
|
|
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .
|
- HY-P99261
-
|
OMP 21M18
|
Notch
|
Cancer
|
|
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .
|
- HY-P990735
-
- HY-P99779
-
- HY-P99187
-
|
PF-04950615; RN316
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .
|
- HY-P9987
-
|
hSel001; SEG101
|
P-selectin
|
Cardiovascular Disease
|
|
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease .
|
- HY-P990026
-
- HY-P99742
-
|
ADC-1013; JNJ-64457107
|
TNF Receptor
|
Cancer
|
|
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .
|
- HY-P99564
-
- HY-P99328
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
|
- HY-P99465
-
- HY-P990773
-
|
LY-3361237
|
CD28
|
Inflammation/Immunology
|
|
Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P99963
-
|
HS636
|
PD-1/PD-L1
|
Cancer
|
|
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .
|
- HY-P99047
-
|
AB 0024; GS 6624
|
Monoamine Oxidase
|
Inflammation/Immunology
Cancer
|
|
Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab can be used for the research of primary sclerosing cholangitis (PSC) .
|
- HY-P990775
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Vilastobart is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990324
-
|
3F6-9G5
|
Adenosine Receptor
|
Inflammation/Immunology
|
|
Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) is a humanized antibody expressed in CHO cells, targeting AA2AR/Adenosine A2aR. Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.66 kDa. The isotype control for Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99714
-
|
MGD019
|
PD-1/PD-L1
CTLA-4
|
Cancer
|
|
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
- HY-P99740
-
|
|
CD276/B7-H3
ADC Antibody
|
Cancer
|
|
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
|
- HY-P99407
-
|
VX 15/2503
|
Inhibitory Antibodies
|
Neurological Disease
Cancer
|
|
Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D .
|
- HY-P990730
-
- HY-P99419
-
|
GEN1046
|
PD-1/PD-L1
|
Cancer
|
|
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer .
|
- HY-P99640
-
|
ABBV-927
|
Inhibitory Antibodies
|
Cancer
|
|
Giloralimab (ABBV-927) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab has the potential for the research of cancer .
|
- HY-P99959
-
|
MT-3921; rH116A3
|
TGF-β Receptor
|
Neurological Disease
|
|
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .
|
- HY-P990716
-
- HY-P990013
-
|
Glutazumab; GMA-102; GMA-105
|
GCGR
|
Metabolic Disease
|
|
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .
|
- HY-P99330
-
|
Anti-Human VEGFA Recombinant Antibody; RO5520985
|
VEGFR
Tie
|
Cancer
|
|
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
|
- HY-P990012
-
|
EBI-031
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vamikibart (RG6179) is a monoclonal antibody targeting IL-6 that can be used to inhibit uveal macular edema (UME) and reduce retinal leakage. Vamikibart can reduce anterior chamber (AC) cell density, indicating a reduction in intraocular inflammation. Vamikibart can also be used to assess the leakage dynamics of ultra-wide-angle fluorescein angiography (UWFA) in the UME model to quantify changes in retinal leakage reflecting the effect of UME inhibition .
|
- HY-P99635
-
|
GZ-402668
|
NF-κB
|
Cancer
|
|
Gatralimab (GZ-402668) is an IgG1 anti-CD52 monoclonal antibody .
|
- HY-P99563
-
|
LY 3090106
|
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
|
|
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research .
|
- HY-P99437
-
|
KN-026
|
EGFR
|
Cancer
|
|
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .
|
- HY-P99852
-
|
ABT165; PR1283233
|
VEGFR
|
Cancer
|
|
Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.. Dilpacimab can be used in research of cancer .
|
- HY-P99715
-
|
|
EGFR
|
Cancer
|
|
Losatuxizumab is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .
|
- HY-P99619
-
|
SCT-I10A
|
PD-1/PD-L1
|
Cancer
|
|
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .
|
- HY-P99736
-
|
BI-754111
|
LAG-3
|
Cancer
|
|
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .
|
- HY-P99668
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
|
- HY-P99108
-
- HY-P99674
-
|
GEN-3009
|
Transmembrane Glycoprotein
|
Cancer
|
|
Ivicentamab (GEN-3009) is an IgG1κ-type bispecific antibody targeting different epitopes of CD37. Ivicentamab can be used for cancer research .
|
- HY-P9992
-
|
BAY-2315497; PSMA-TTC
|
PSMA
|
Inflammation/Immunology
|
|
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research .
|
- HY-P99393
-
|
MEDI 0562; Tavolimab
|
TNF Receptor
|
Cancer
|
|
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
|
- HY-P99618
-
|
IBI-315; BH2950
|
EGFR
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .
|
- HY-P9999
-
|
RG6102; RO-7126209
|
Amyloid-β
|
Neurological Disease
|
|
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .
|
- HY-P99454
-
|
ABBV-838
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .
|
- HY-P99453
-
|
|
ADC Antibody
|
Cancer
|
|
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
|
- HY-P99339
-
|
IMCgp100
|
Interleukin Related
TNF Receptor
|
Cancer
|
|
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .
|
- HY-P99011
-
|
|
CD3
|
Cancer
|
|
Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .
|
- HY-P99116
-
|
RG7716; RO-6867461
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
|
- HY-P99572
-
|
BNT-312; DuoBody-CD40x-4-1BB; GEN1042
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity .
|
- HY-P99694
-
|
JR-171
|
Transferrin Receptor
|
Neurological Disease
|
|
Lepunafusp alfa (JR-171) is a BBB-penetrable fusion protein consisting of J-Brain Cargo and IDUA (a lysosomal enzyme, α-L-iduronidase). Lepunafusp alfa can reduce concentration of heparan sulfate (HS) and dermatan sulfate (DS). Lepunafusp alfa can be used for research of mucopolysaccharidosis type I .
|
- HY-P99380
-
|
ZW 25
|
EGFR
|
Cancer
|
|
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .
|
- HY-P99623
-
|
MGD006; S80880
|
CD3
|
Cancer
|
|
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
|
- HY-P99470
-
|
GEN1029
|
TNF Receptor
Apoptosis
|
Cancer
|
|
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .
|
- HY-P99652
-
|
AK 111
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
|
- HY-P990722
-
- HY-P99455
-
|
EMB-01
|
EGFR
c-Met/HGFR
|
Cancer
|
|
Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity .
|
- HY-P99721
-
|
ABT-981
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis .
|
- HY-P99855
-
|
BCD-132
|
CD20
|
Inflammation/Immunology
|
|
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research .
|
- HY-P99671
-
|
M-6495
|
ADAMTS
|
Inflammation/Immunology
|
|
Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .
|
- HY-P99481
-
|
NEOD001
|
Amyloid-β
|
Neurological Disease
|
|
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
|
- HY-P99024
-
|
RO7082859; RG-6026
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
|
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .
|
- HY-P99941
-
|
INCMGA-00012; MGA-012
|
PD-1/PD-L1
|
Cancer
|
|
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
|
- HY-P99211
-
|
ChAglyCD3; TRX 4
|
CD3
|
Metabolic Disease
|
|
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .
|
- HY-P9940
-
|
ACE-910; RG6013
|
Factor VIII
|
Cardiovascular Disease
|
|
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .
|
- HY-P99903
-
|
IBI-322
|
PD-1/PD-L1
CD47
|
Inflammation/Immunology
Cancer
|
|
Simridarlimab (IBI-322) is a bispecific antibody targeting PD-L1 and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .
|
- HY-145626
-
|
BA302
|
ADC Antibody
ROR
|
Cancer
|
|
Ozuriftamab is a human IgG1 kappa antibody of ROR2. Ozuriftamab can be used to synthesize ADC such as Ozuriftamab vedotin (HY-145627). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99177
-
|
|
SARS-CoV
|
Infection
Cardiovascular Disease
|
|
Enibarcimab is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody, could be used for acute heart failure, COVID-19 infections and septic shock research .
|
- HY-P99708
-
|
ABBV-151; ARGX-115
|
TGF-beta/Smad
|
Cancer
|
|
Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors .
|
- HY-P990104
-
|
|
Notch
|
Inflammation/Immunology
Cancer
|
|
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.
|
- HY-P99803
-
|
VAL-1221
|
Glycosidase
|
Others
|
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
- HY-P99034
-
- HY-P99298
-
|
RG 7417; TNX 234; Anti-CFD Recombinant Antibody
|
Complement System
|
Inflammation/Immunology
|
|
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .
|
- HY-P99679
-
- HY-P99798
-
|
AMG 420; BI-836909
|
CD3
|
Cancer
|
|
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
|
- HY-P99676
-
|
SI-B001
|
EGFR
|
Cancer
|
|
Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
|
- HY-P99354
-
|
Anti-Human CTLA4xLAG3
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
|
- HY-P99896
-
|
BTRC-4017A; RG-6194
|
EGFR
CD3
|
Cancer
|
|
Runimotamab (RG-6194) is a HER2 and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99776
-
|
XmAb-13676
|
CD20
CD3
|
Cancer
|
|
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
|
- HY-P99575
-
|
AMG-757
|
Notch
|
Inflammation/Immunology
Cancer
|
|
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
|
- HY-P99675
-
|
AK112
|
PD-1/PD-L1
VEGFR
|
Cancer
|
|
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .
|
- HY-P99802
-
|
BAY 2010112; AMG 212; MT112
|
CD3
|
Cancer
|
|
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
- HY-P99814
-
|
AMG-701
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
|
- HY-P99523
-
|
AMG 199
|
CD3
|
Cancer
|
|
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
